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T h e  G e n e t i c s  o f  Su s c e p t ib il it y  t o  L e p r o s y
ABSTRACT
There is strong evidence that genetic hictors play a role in susceptibility to leprosy. 
Although the major histocompatibihty complex is known to play a part, it does not 
account for the whole picture. Recent advances in genetic technology have made it 
possible to identify loci involved in complex traits. In this thesis I discuss two contrasting 
approaches: a genome-wide search for the detection of major genes, and candidate gene 
association studies capable of detecting smaller genetic effects.
242 affected sibling pairs with leprosy were identified in Tamil Nadu in South India. 
DNA extracted from their blood was used to perform a two-stage genome wide search. 
Initially 92 families were screened using 293 polymorphic microsateUite marieurs. A 
further 96 families were then used to rescreen the markers that showed lod scores 
suggestive of linkage. Markers on chromosomes 2, 6, 10, 16 and 17 showed increased 
sharing which could be consistent with the presence of minor genes. These r^ o n s  
indude some interesting candidate genes that warrant further investigation.
Association studies were performed on 5 candidate gaies using cases and controls 
from South India, Bengal, and Mali: Intedeukins-4 and —10, tumour necrosis factor 
(INF), vitamin D receptor, and the natural resistance associated macrophage protein 1 
(NRAMPl). An association was found between the NRAMPl 1729+55del4 
polymorphism and leprosy type in a population from Mali, mutant homozygotes being 
susceptible to paudbadllary leprosy whilst heterozygotes were susceptible to 
multdbadllary leprosy (y} =8.88, p=0.00288 OR=5.79{CI 1.46-24.61}). These findings 
persisted after logistic r^ession  to allow for region and ethnicity. This association was 
not observed in the South TtiihaTi cases and controls. A borderline association was found
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between the TNF — 238 polymorphism and susceptibility to leprosy in a South Tndiau 
population, cases having an excess of the common allele compared to controls (2x2 —
4.12, p=0.042 OR=1.68{CI 0.98-2.87}).
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CHAPTER 1
1 INTRODUCTION
1.1 BACKGROUND TO GENETICS AND INFECTIOUS DISEASES
It is likely that infectious diseases have played a major role in the natural selection of
humans over the last 5000 years or so (Haldane 1949). With the advent of antibiotics 
and vaccines it finally seemed possible that we might be able to defeat microbes. 
However, it was not long before it became apparent that the war was &r from over 
(Ridley 1993). The ever growing problem of multi-resistant bacteria, the resurgence of 
old infectious diseases such as tuberculosis, and the presence of newly emerging 
infectious diseases such as AIDS, make it imperative that we use alternative approaches 
to combat these diseases (Garrett 1995). Even in the presence of rapid advances in 
molecular biology and vaccine technology, pathogens continue to have the upper hand. 
At present much hope is pinned on understanding the genetic mechanisms underlying 
host susceptibility to infection. Once the basic biological processes are known, we may 
be able to man^ulate the host response in such a way that pathology is avoided.
Genetic polymorphisms have been found in various host genes. Both infectious 
diseases and starvation are likely to have played a major role in determining the 
fcequency of a number of genetic polymorphisms. The differential distribution of 
polymorphic variations of a gene in a population may give us clues as to the adaptive 
value of a trait It has been su^ested that in cases where the rarest polymorphism of a 
gene reaches a frequency of more than 1-2%, this may represent the end result of some
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fonn of selective advantage for the carrier (Motulsky 1960). As well as advantageous 
effects, polymorphisms may have deleterious effects, which may influence the final 
frequency of the tmit Both sickle cell disease and ^stic fibrosis are examples of such 
“balanced polymorphisms”. Polymorphisn^ that are beneficial in some diseases may 
confer susceptibility to other diseases.
There are now numerous pieces of evidence for host factors in susceptibihty to 
infectious disease. There is an extensive list of polymorphisms that control disease 
severity and outcome for malaria alone. Sickle cell disease and the thalassaemias have 
reached high frequencies in a number of populations as a result of falciparum malaria. 
The Duffy blood group, ghicose-6-phosphate deficiency, ovalocytosis and the human 
leucocyte antigen, HLA B53, are just a few other factors found to affect the ability of the 
malaria parasite to survive in the host (Hill 1996).
In a Brazilian population linkage analysis su^ested that 5q31-33 was involved in the 
intensity of infection with Schistosoma mansonii. A further study on a Senegalese 
population confirmed this linkage (Marquet et al 1996) and (Muller Myhsok et al 1997). 
This region includes several cytokine genes as well as genes involved in determining T 
lymphocyte differentiation (Marsh et al. 1994).
Mutations have been identified in the interferon gamma receptor 1 gene that cause 
susc^tibility to  atypical m ycobacterial m fcctiuus (Newport et a l  1996) and (Jouanguy et 
al 1996). Polymorph^ms in the human natural resistance associated macrophage protein, 
NRAMPl, has been found to influence susceptibility to tuberculosis (IB) (Bellamy et al 
1998) and HLA DR2 plays a role in susceptibility to both TB and leprosy (Rajalingam et
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aL 1996) (Todd et aL 1990) (Roy et al 1997). The —308 polymoiphism of the tumour 
necrosis factor promoter region has been found to influence susceptibility to a number 
of diseases, including malaria, l^rosy and lAishmamaAiA (McGuitc ei al 1994), (Roy et al 
1997) and (Cabrera et al 1995). Identification of a 32 base pair deletion (A32) in the CC- 
chemokine receptor (CCR5) provides protection ftom infection with the macrophage 
trophic form of the HIV virus (Fauci 1996).
It is unlikely that leprosy has played a major role in determining our present day 
genetic ms^-up as it is a non-fatal d^ease (dthough it could be argued that fertility may 
have been reduced in the affected population, resulting in an excess of leprosy resistance 
genes in the population). However, it is possible that leprosy susceptibihty genes are 
shared with a number of other infectious diseases e g. tuberculosis, another intracellular 
mycobacterium. The chronic nature of leprosy makes it an ideal infectious disease to 
study by the affected sibling pair approach (see section 4.3) as both siblings are likely to 
be alive, as will many of the parents.
Leprosy is an immunological disease, affected individuals falling into different 
positions of the Thl/Th2 spectrum (see section 1.5.1). Studies of the genetics of leprosy 
can give answers r^arding susceptibihty to leprosy type as weU as leprosy per se. If we 
can unravel the genetic mechanisms determining someone’s position on the leprosy 
spectrum, we may get new insights into a large number of other conditions, espedaUy 
those of an immunological nature. By understanding the basic biological mechanisms of 
the disease process, avenues towards new therapeutic measures may be opened.
In the remainder of this chapter I will give a brief clinical outlme of leprosy.
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paying particular attention to the evidence for genetic components to susceptibility, and 
then discuss the approaches that can be used to study the genetics of complex diseases.
1.2 HISTORY OF LEPROSY
Leprosy has been one of the most feared diseases since Biblical times though
many of the diseases referred to as leprosy in the Bible may be the result of an error of 
translation (McDougall 1996) or misdiagnosis. The first written reference to leprosy was 
in about 600 B.C in the Sushrata Samhita, an ancient Indian medical treatise. The disease 
is thought to have spread to China and Japan firom, other parts of Asia, and was probably 
introduced into Europe by Greek soldiers returning £tom Asia in the fourth century B.C. 
Leprosy was at its most prevalent in Europe between the 10* and 15* centuries A.D., 
numerous Iqirosaria being established by wealthy families (McDougall 1996). Sufferers 
were stigmatised having to warn other people of their approach by tinging a bell or 
blowing a trumpet Many people believed that it was a disease cast on people as a result 
of sin, particularly that of a sexual nature (Brody 1974). The isolation suffered by lepers 
may have contributed to the gradual decline in cases of disease in Europe, though tiie 
Black Death, famines and socioeconomic factors may also have played a role. Despite 
this speculation, the decline in leprosy remains unexplained
Leprosy was still prevalent in Norway at the end of the last century and it is from 
this country that much of the early authoritative scientific literature on this disease 
comes. In 1873 Gerhard Henrik Armauer Hansen confirmed his suspicions that leprosy 
was a communicable disease when he discovered the leprosy bacillus. His faither in law, 
Daniel Dannielson, was a strong proponent of the hereditary nature of leprosy but
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further work by Hansen emphasised the infectious nature of the disease and the genetic 
theories were largely dismissed and forgotten about (Fine 1981). It has only been over 
the last three decades or so that strong evidence for genetic factors m  susceptibihty to 
this disease have re-emerged (see section 1.7).
1.3 EPIDEMIOLOGY OF LEPROSY
1.3.1 PREVALENCE
From estimates of 10-12 million cases of leprosy worldwide in the 1980s, levels have
fallen progressively from 5.5 million in 1991, 3.1 in 1993 and 1.8 in 1995, to 1.15 million 
in 1997. Over half a million new cases were registered in 1996 of whom 16% were 
children, and almost 1/3 were multibadllary cases (WHO 1997). 73% of new cases were 
from India, where the prevalence at the beginning of 1997 was 5.9 per 10,000 and the 
case detection rate was 44 per 100,000. Much of the change in prevalence is related to an 
alteration in the definition of a leprosy case that followed the introduction of multidrug 
therapy (MDT) in the 1980’s. Consequently, interpretation of the data is very difficult, 
but it does appear that incidence rates remain remarkably constant (WHO 1997). In 
virgin populations prevalence rates as high as 250/1000 have been recorded (Wade and 
Ledowsky 1952).
1.3.2 GEOGRAPHICAL DISTRIBUTION
Fig. 1.1 shows the geographical distribution of leprosy at the current time. Although
leprosy is generally considered to be a tropical disease, it was prevalent in Europe during 
the Middle Ages, and there were still a laige number of sufferers in Norway at the end of
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Leprosy in the World, 1998
Prevalence rates per 10,000
□ 5-15□ 3-5m 1-3□ 0.1-1□ 0
Fi .^ 1.1 Geographical distribution of Ijepro^ in 1997 (WHO)
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the last centiuy. The proportion of lepromatous to tuberculoid cases is very varied with a 
tendency for there to be a small percentage of lepromatous cases amongst Afdcans (4- 
18%) whereas in Central and South America up to 63 % of cases ate Icpiumatous 
(Bechelli and Martinez Dominguez 1972). Various complications of leprosy are also 
frequently regional e.g. leprotic alopecia in Japan and the Ludo phenomenon in South 
America (Hastings 1994).
1.3.3 AGE d ist r ib u t io n
The age distribution of leprosy follows a bimodal pattern with peaks at 10-14 years
and a further peak at 35-44, which then plateaus (de Vries and Perry 1985). Leprosy can 
occur at any age and in virgin populations exposed to leprosy for the first time, leprosy 
seems to affect all age groups in more or less equal proportions, whereas in populations 
where leprosy is dying out it tends to affect older adults only (Wade and Ledowsky 
1952). Lepromatous leprosy tends to have a later onset than tuberculoid lq)rosy (Irgens 
and Slqaerven 1985).
1.3.4 SEX d ist r ib u t io n
Males tend to have a higher inddence of leprosy than females once adulthood is
reached although there are parts of the world where it is equal or even reversed. This sex 
difference is more marked in lepromatous leprosy and is also observed in the rate of 
complications (de Vries and Perry 1985).
1.3.5 OTHER FACTORS INFLUENCING LEPROSY OCCURRENCE
It has frequently been noted that the type and severity of disease differs between two
ethnic groups living in the same environment e g. greater severity of disease in
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Europeans noted in both India and South Africa (Spickett 1962). In fact, susceptibility to 
leprosy appears to be greatest in Caucasians, followed by East Asians, Indians, then 
Blacks (Bryceson and Platzgraff 1990). Housing, schooling, caste, nutdtiuiiai status, 
climate and numerous other factors have been considered to play a role in susceptibility 
to disease (Fine et aL 1997).
1.4 THE BACTERIOLOGY AND TRANSMISSION OF LEPROSY
1.4.1 b a c t e r io l o g y
Leprosy is caused by the add fast gram positive rod-shaped Myœhactmum leprae. It is
an obligate intracellular anaerobe with an optimum temperature for In vivo growth of 27- 
30°C (Shepherd 1965). The bacterium remains viable for at least 9 days outside the host 
(Desikan 1977). M. leprae was the first bacterium to be identified, yet it remains elusive in 
that it cannot be cultured In vitro. It has only been in fairly recent years that it could even 
be cultured experimentally In vivo^  firstly in the mouse footpad and nude mice, and 
subsequently in nine-banded armadillos and various primates. Thanks to this we now 
know that the generation time for M. leprae is 11-13 days, the slowest growing bacteria 
known, and studies on drug sensitivities together with various other characteristics have 
been possible (Hastings 1994).
Over the last few years the ultrastructure of M. leprae has been more dearly defined 
and the genome sequenced in part (Fsihi and Cole 1995). Because of the difficulties in 
investigating M. leprae we still do not know how it enters the body, what the infecting 
dose is and whether it is this or host aspects that determine the nature of disease 
subsequently developing. How many people have a subclinical infection that dears
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before it becomes manifest is also unclear. A proportion of people who develop clinically 
evident disease will self-cure over time. Pathogenicity of M  kprcu results from its ability 
to survive intracellularly and to stimulate the host immune system, rather than from the 
release of toxins.
Unlike other mycobacteria that are found exclusively in macrophages, M. leprae is also 
found in muscle cells, epithelial cells and Schwann cells. The binding protein for entry 
into Schwann cells is laminin-0C2, which is present on the basal lamina (Rambukkana et 
al. 1997). Fibfonectin has also been found to enhance mycobacterial invasion into 
epithelial and Schwann cells (Schorey et aL 1995). Complement, especially the C2a 
component, and mannose receptors are involved in entry into macrophages (Schorey et 
aL 1997).
1.4.2 TRANSMISSION
It seems most likely that bacteria are spread from the respiratory tract of infected
individuals. Apart from exceptional circumstances, such as the two cases of leprosy that 
occurred in tattoos (Porritt and Olsen 1947), it is usually impossible to be certain as to 
when an infection was acquired. Proposed routes of infection include the respiratory 
mucosa, the skin (either directly or, more probably, via injuries or bites), transplacental 
spread and via the gut in the case of breastmilk. Animal models have been used to test 
hypotheses, but the most important portal of entry in man remains elusive. Since the 
bacilli survive for at least 9 days in tropical environments (Desikan 1977) it may be that 
fomites play a role in transmission. Other non-human reservoirs of infection have not 
been completely ruled out e.g. it has been shown that mosquitoes can act as passive
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transmitters of M. leprae though their role in the transmission of disease in humans is 
uncertain (Narayanan et al 1977).
1.4.3 INCUBATION PERIOD
It has been very difficult to determine the incubation period for leprosy in endemic
situations since tests to determine whether infection has occurred are inadequate and the 
onset of disease is so insidious. The earliest cases recorded were in two children of three 
weeks of age neither of whose parents had evidence of leprosy though there was a strong 
family history of the disease in one case (Montestmc and Berdonneau 1954). In this 
paper they also mention two other cases with extremely short histories of exposure to 
leprosy and short incubation periods. The longest known incubation period quoted is 40 
years (Bryceson and Platzgraff 1990). NCDC data fcom U.S. war veterans whose 
exposure to disease was limited to a short period, found incubation periods firom 2.9 to
5.3 years for mberculoid leprosy, and 9.3 to 11.6 years for lepromatous disease (NCDC 
USA 1970 data quoted in (Hastings 1994)).
Subclinical infection is well recognised. More than 50% of individuals with 
occupational contact with leprosy for over one year had positive lymphocyte 
transformation tests in one study (Godal and Negassi 1973)
1.5 TH E IMMUNOLOGY OF LEPROSY
The manifestations of leprosy depend upon an interaction between the infecting
organisms and the host’s immune response to the bacilli The rliniral spectrum of the
disease mirrors the immunological response. In lepromatous leprosy, where numerous
bacilli are present, there is suppression or absence of a cell-mediated response. The large
10
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antigen load evokes a strong, but often non-specific, antibody response, which is 
ineffective at clearing the infection. In tuberculoid leprosy there is a very marked T-cell- 
medialcd tc sp u u sc  which keeps the bacterial concentrations low but can in itself lead to 
serious tissue damage. The stronger the cell-mediated response in tuberculoid lesions, the 
more profound and rapid the onset of anaesthesia and autonomic changes, such as hair 
loss and loss of sweating. Antibody levels are very low or absent at the tuberculoid end 
of the spectrum. In between these two extremes the borderline forms of leprosy reflect 
an intermediate level of cell-mediated immunity and antibody response corresponding to 
their position in the spectrum. This intermediate state is unstable and is liable to up- or 
down-grading resulting in inflammation that may lead to pathology including sudden 
neurological deficits (Ridley and Jopling 1966) and (Hastings 1994).
Sieling et aL have suggested that it may be the lipoarabinomannam (LAM), a 
heteropolysaccharide in the cell wall of M. leprae and M. tuberculosis that results in the 
monocyte mediated immunosuppression seen in lepromatous leprosy (Sieling et aL
1993). LAM inhibits antigen processing, macrophage activation and the release of toxic 
oxygen free radicals. Phenolic ^ycolipid-1 (PGL-1) may also be a T-ceU suppressor 
(Mehra et aL 1984).
1.5.1 THl VERSUS TH2 RESPONSE
T helper cells can be divided into two distinct populations of CD4 cells, Thl and
Th2, according to their function and to the cytokines that they produce. A third category 
of CD4 cells, ThO cells, release a mixture of Thl typical and Th2 typical cytokines. Thl 
cells activate cellular immunity and are particularly effective in combating diseases caused
11
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by viruses, intracellular bacteria and parasites. The predominant Thl cytokines are 
interferon-y, interleukin-2, TNF and interleukin-12. Th2 cells enhance the humoral 
immune response, stimulating B cells to produce antibodies, especially IgE, IgA and 
IgGl. This type of response is more effective at dealing with fcee-hving bacteria and 
other extracellular organisms such as helminths. The Th2 cytokines are interleukins 4, 5, 
6, 10 and 13. IL-4 and IL-10 have marked T-suppressor activity. IL-4 and 5 regulate B 
cells, eosinophils and mast cells. Thl cells downregulate Th2 cells and vice versa, as a 
result of which there tends to be a polarisation of the final response (Powrie 1993). Ai. 
leprae reactive T cells from mberculoid patients are mainly of the Thl type, whereas Th2 
cells predominate in lepromatous lesions. When lepromatous leprosy lesions are injected 
with Thl like cytokines there are clear signs of increased cell-mediated immunity and 
evidence of bacterial degradation (Kaplan 1994).
1.6 CLINICAL ASPECTS OF LEPROSY
1.6.1 THE CLASSIFICATION OF LEPROSY
Leprosy has the most varied clinical manifestations of any infectious disease. Over
the years numerous classifications have been established in an attempt to make
descriptions easier. These have been based on morphological features, bacteriological,
immunological and histopathological findings. The most frequently used classification is
the Ridley-Jopling classification which is based on all of the above findings (Ridley and
Jopling 1966). This classification divides leprosy into TT (polar tuberculoic^, BT
(borderline mberculoid), BB (borderline borderline), BL (borderline lepromatous), and
LL ^olar Iqiromatous). Indeterminate leprosy and pure neuritic leprosy are two other
12
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types of leprosy that do not fit neatly into the above spectrum. In the majority of field 
situations the resources for accurate classification by the Ridley-Jopling method are 
unavailable. For the putposcs of treatment, the WHO have classified leprosy as 
multibadllary (MB, which encompasses LL, BL and BB) and paudbadllary (PB, which 
includes TT, BT, Indeterminate and pure neuritic).
1.6.2 CLINICAL sig ns
The cardinal features of leprosy are anaesthetic skin lesions, thickened nerves and the
presence of mycobacteria in slit-skin smears and biopsies. Although there are differential 
diagnoses for the former two criteria, their presence in a leprosy endemic region is 
invariably due to leprosy. In the majority of people exposed to M. leprae there is either no 
invasion, or there is sub-clinical infection which resolves spontaneously (Lara and 
Nolasco 1956). In cases where the disease is not contained, clinical signs and symptoms 
may not develop for some years and may be akin to post-primary mberculosis.
The most frequent early finding is of indeterminate leprosy, characterised by poorly 
defined hypopigmented macules with no diagnostic features. Early tuberculoid lesions 
appear as hypopigmented or slightly erythematous macules with hypoanaesthesia and 
typically the involvement of one nearby nerve trunk (see fig. 1.2). Early lepromatous 
lesions are often numerous but difficult to see until the skin becomes infiltrated when 
there is a diffuse shininess to the skin, or papules start to appear. Patients may present 
with anaesthesia or sudden loss of motor function or weakness. More unusual 
presentations include tenosynovitis, iridocychtis, nasal stuffiness, oedema, neuritic pain 
or symptoms of a reaction. The borderline fo rms o f  leprosy display characteristics inter-
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Fig. 1.2 Photograph of a patient with tubemloid lepro^.
This shows a depigmented patch of skin ju st behind the ear, which was anaesthetic on examination. 
More clearly seen is a grossly thickened greater auricular nerve.
14
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mediate between TT and LL (Ridley and Jopling 1966).
1.6.3 THE COURSE OF THE DISEASE
Early tuberculoid and indeterminate lesions frequently resolve spontaneously.
Continuation o f the disease may lead to serious nerve damage in tuberculoid leprosy and 
to chronicity and long-term complications in lepromatous disease. Lepromatous patients 
are also prone to develop Type 2 reactions (see section 1.6.4). Patients in the borderline 
regions are unstable and will tend to up- or down-grade with an acute Type 1 reaction 
and the onset o f neurological deficit may be insidious over a number o f years.
Lepromatous disease may be virtually imperceptible due to diffuse infiltration, but in 
advanced cases patients may have leonine facies, destruction of the facial bones, nodules 
and ulcers, unpleasant smelling nasal discharge, blindness, and deformity from nerve 
damage and trauma (fig. 1.3). These factors aU contribute to stigmatisation. The bacilli 
can invade internal organs although they do not seem to cause direct damage in these 
sites. In the long-term amyloidosis and glomerulonephritis may lead to premature death 
in these patients.
1.6.4 LEPROSY REACTIONS
Reactions constitute some o f the major complications o f leprosy, particularly now
that leprosy is treatable. They can be classified into Type 1 and Type 2 reactions. The 
former occur in borderline cases o f leprosy, the latter in lepromatous and borderline 
lepromatous cases. Pregnancy, vaccination, acute illness or stress may precipitate both 
Type 1 and Type 2 reactions.
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Fig. 1.3 Photograph of a patient with lepromatous leproy.
% / y  z j w a x y  o r  W  ^ a A f r /  o / ' / &  zir
/^ zj/)a/zf«/. Hf z/ofj w , Wfz^z; ,^az^  //,zo,èfzzz/% o/" /& a ^wwozz Wzzri of
lepromatous leproy
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Type 1 reactions, whether they are due to up- or down- grading, are characterised by 
increased inflammation in a pre-existing lesion and progression towards one or other end 
o f the leprosy spectrum. Crops o f new lesions may appear and nerves become tender and 
swollen with accompanying neurological signs or symptoms. These reactions can occur 
in people anywhere along the leprosy spectrum, but most frequently in unstable 
borderline cases. The underlying basis for the reaction appears to be a sudden increase in 
cell mediated immunity against M. leprae antigens, though what precipitates this remains 
uncertain. Histologically, there is inflammation with an influx o f CD4 cells expressing 
and producing Thl type cytokines (Yamamura et al. 1992). It is the production o f  
cytokines that can lead to the rapid onset o f nerve damage. As many as 50% of  
borderline patients will develop a Type 1 reaction during the first 12 months o f treatment 
(Hastings 1994). Roche et al. found that PGL-1 seropositivity and, to a lesser extent, 
lepromin reactivity were independently associated with increased risk o f type 1 reactions 
(p<0.0005 and p<0.005 respectively) (Roche et al. 1997).
Type 2 reactions occur in lepromatous and borderline lepromatous cases, the most 
common clinical manifestation being erythema nodosum leprosum (ENL). This is 
characterised by multiple erythematous subcutaneous tender nodules, papules and 
pustules accompanied by fever and constitutional symptoms. These resolve, passing 
through the discolouration characteristic o f bruising, but may leave severe scarring (fig. 
1.4). Episodes typically last between a few days and a few weeks but are frequently 
recurrent and associated with other systemic manifestations, such as fever, malaise, arthr-
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Figure 1.4 Photograph of a man who has had Erythema Nodosum Leprosum on numerous occasions.
Note the scarring on his face and arms from recurrent lesions, the moon facies secondary to high dose 
steroid therapy, and the evidence of neurological damage in both hands with a scar from decompression 
surgery on the left forearm
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algia, iridocyclitis, orchitis, periostitis and tenosynovitis. Treatment with multi-drug 
therapy is a frequent trigger o f type 2 reactions, probably due to the large load o f dead 
bacilli. More than 50% o f LL, and about 25% o f BL, patients will get a type 2 reaction, 
although these figures are thought to be declining since the introduction o f multi drug 
therapy (Hastings 1994) and (Becx-Bleumink and Berhe 1992).
The pathogenesis o f ENL is thought to be an acute immune complex mediated 
reactional episode (type III Arthus reaction) due to deposition o f antigen-antibody com­
plexes which activate complement resulting in neutrophil chemotaxis (Ridley and Ridley 
1983). The toxic products released by the neutrophils result in tissue damage (Naafs 
1994). Histologically there is acute inflammation with dilated capillaries, oedema, 
vasculitis, neutrophil infiltration and fibrinoid necrosis. Histiocytes containing 
fragmented bacteria are frequently seen (Rao and Rao 1987). Immunoglobulins and 
complement are found in the lesions on appropriate staining and circulating immune 
complexes and degradative products o f the complement pathway can be detected in the 
blood.
Traditionally, ENL has been thought o f as demonstrating a predominantly Th2 type 
response (Ottenhoff 1994) and (Yamamura et al. 1992). However, it now appears that 
the acute episodes may actually represent transient Thl type responses. Such reactions 
are accompanied by an increase in cell mediated immunity with an increase in the ratio o f  
T helper to T suppressor cells and a transient increase in responsiveness o f peripheral 
blood lymphocytes to phytohaemagglutinin and mycobacterial antigens (Rao and 
Raol987). Once the acute reaction is over the cytokine profile returns to a lepromatous 
pattern. FiUey et al. demonstrated high circulating levels o f IL-2 receptors during ENL
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and increased levels o f agalalactosyl IgG, both o f which suggest increased T cell activity. 
They also demonstrated an effect on B cell regulatory events (Filley et al. 1989). Levels o f  
agalalactosyl IgG are also raised during TB, Crohn’s disease and rheumatoid arthritis, but 
not in the non-reactional state o f lepromatous leprosy or sarcoidosis. This suggests that 
ENL may be triggered by an acute phase response on a background o f chronic T cell 
mediated inflammation (Filley et al. 1989).
1.7 EVIDENCE FOR GENETIC FACTORS IN  SUSCEPTIBILITY TO LEPROSY
For centuries people have noted that leprosy tends to run in families. In the latter
half o f the last century there was much dispute as to whether leprosy was a genetic or 
environmental disease. When Hansen discovered the leprosy bacillus in 1873, aU the 
previous theories o f a hereditary cause for leprosy appeared to be redundant (Fine 1981). 
It has only been in the last few decades that the possibihty o f a genetic component in 
susceptibility to leprosy has resurfaced. The evidence now available shows that both the 
“germ theorists” and the “hereditarians” were correct. Evidence comes from twin 
studies, family and community studies, segregation analysis, marker studies and recendy 
candidate gene studies, and anecdotal evidence. Some o f these are elaborated below.
1.7.1 ANECDOTAL
There are numerous reports and observations o f multiple cases o f leprosy within 
members o f the same family (Aredath 1983) and (Anon. B.C.). Racial differences have 
also been noted, suggesting possible host genetic differences. For example, in Malaya it 
was noted that one third o f leprosy cases in Chinese were tuberculoid whereas three 
quarters o f  those in Indians were o f this type (Spickett 1962). These racial differences
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have since been supported by findings on differential macrophage function in vitro 
between different racial groups (Crowle and Elkins 1990).
1.7.2 TWIN s t u d i e s
Twin studies are a useful method for dissecting the degree to which environmental
and genetic factors play a role. Monozygotic (MZ) twins share the same genes, whereas 
dizygotic (DZ) twins share only half their genes on average. It is assumed that MZ and 
DZ share their environments to roughly the same extent if they have been brought up 
together. If a disease has a strong genetic component, MZ twins would be expected to be 
more concordant for the disease in question than DZ twins. In a relatively large study of 
twins with leprosy performed in Bengal, concordance rates for leprosy were 60% in 
monozygotic (MZ) twins and 20% in dizygotic (DZ) twins. It is o f interest that although 
concordance for leprosy type was similar for both MZ and DZ twins (see Table 1.1), 
there were 5 out o f 37 monozygous sets o f twins where the type o f leprosy differed. This 
suggests that host genetic factors are not the only determinants o f leprosy type 
(Chakravartti and Vogel 1973 referred to in Fine 1981). Very similar results were found 
in a smaller study in South India (Mohammed Ali and Ramanujam 1966). Ascertainment 
bias is a possibihty in both these studies as there were an excess o f monozygous over 
dizygous twins.
1.7.3 SEGREGATION STUDIES
Segregation analysis is a method in which the pattern o f inheritance observed in large
pedigrees is fitted to a variety o f models o f inheritance. The model that provides the 
closest fit is felt to be the most probable explanation for the inheritance pattern. Abel
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62 MZ Cases Leprosy Type 40 DZ Cases Leprosy Type
Concordant for 
disease
37 (60%) 8(20%)
Concordant for 
type
32 (86%) 34%LL,
59%TT,
6%Borderline
6(75%) 33%LL,
67% TT
1 affected 25 24%LL,
72%TT,
4%B orderline
32 25%LL,
63%TT,
13%Borderline
Table 1.1 Results of Chakravartti and VogeTs Twin study in '^rosy
MZ = monozygous twins 
DZ = dizygous twins 
LL — lepromatous leprosy 
TT = tuberculoid leprosy 
Borderline = borderline leprosy
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and Demenais performed a study on 27 multigenerational pedigrees from Desirade, an 
island where the incidence of leprosy was particularly high as everyone from the 
surrounding islands who succuinbcd to the disease was deported there from 1728 
onwards. The results of this study were consistent with an autosomal recessive or 
codominant major gene controlling susceptibility to leprosy per se and to non- 
lepromatous leprosy respectively. In this population, assuming a recessive inheritance, 
the risk of developing leprosy was 62% by the age of 68 in those homozygous for the 
recessive alleles. They also calculated that the proportion of leprosy cases due to non- 
genetic factors was 23% in this population (Abel and Demenais 1988). Several other 
groups have performed segregation analyses and found that susceptibility would be 
consistent with a recessive model of inheritance e.g. (Haile et al. 1985). It was this 
evidence of a major gene effect in leprosy that lent support to the performance of a 
genome screen.
1.7.4 FAMILIAL CLUSTERING
Family clustering has frequently been observed in leprosy, but one of the most
difficult aspects in the interpretation of this type of data is differentiating between the 
shared environmental and the shared genetic factors. Bias can be introduced due to lack 
of standardisation for fiimily size, different age distributions, household clustering rather 
than family clustering, and social factors e.g. lepers marry lepers, or stay at home (Fine 
1981).
Shields et aL performed a fascinating study on the Karimui of Papua New Guinea, 
which overcame some of these problems. The social .unit of this tribe is the co m m unity
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rather than the family and polygamy is common. Children spend very little time with 
their fathers, yet their risk of developing leprosy was increased if they were from a 
strongly affected kindred, irrespective o f  whether this w as on  the m other's or father's 
side (Shields et aL 1987).
1.7.5 GENETIC MARKERS
The most frequently tested genetic markers are those of the major histocompatibility
complex. It is likely that the present diversity of the HLA system has been shaped by
selective pressure from infectious diseases as shown by Hill et al’s findings of HLA types
and malaria (Hill et aL 1991). The cellular immune system is likely to be more important
in protecting the host from intracellular infections than the humoral immune, system. It is
therefore not surprising that numerous studies have been performed on HLA in leprosy.
The smdies have generated a large number of differing findings (summarised by Todd et
aL 1990). Some have shown association between leprosy type and different HLA groups,
some with leprosy per se, and others have shown no association whatsoever. The most
consistent association has been with HLA DR2 and DQwl and susceptibility to leprosy
per se. Comparisons of these studies are hampered by variations in the classification of
leprosy fcom study to study, frequently small numbers, and poorly matched controls. In
the early days typing methods varied enormously.
Todd et aL pooled the data of their own study in Louisiana widi othef population 
studies and found that DR2 and DQwl were significantly associated with leprosy with 
relative risks of 2.65 and 2.73 respectively, and p values of IxlCL® and 3.6x10"®. When 
they looked at studies on polar forms of leprosy versus controls they found that both of
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the above HLA types were associated with both forms of leprosy. DRw53, DR4 and A24 
were also associated in the pooled data even after correction (Todd et aL 1990).
The fact that different associations have been found in different populations would 
suggest that linkage disequilibrium may be playing a role, and that a gene in close 
proximity to the HLA region is in fact the leprosy susceptibility locus rather than HLA 
itself. In favour of a direct role of various HLA types, recent work looking at epitopes 
fcom heat shock proteins has shown that although they are recognised by a diverse range 
of HLA alleles, DR2 is the most efficient restriction element in both tuberculoid and 
lepromatous disease (Mitra et al. 1997). Risch looked at leprosy data collected by Haile et 
aL and calculated that the increased risk to siblings over the general population risk for 
tuberculoid leprosy was 2.38, 1.49 of this being attributable to HLA (Risch 1987) and 
(Haile et al. 1985). In other words, HLA is insufficient to account for the total genetic 
component of leprosy susceptibility. This su^ ests that there are likely to be other genes 
outside this region that are contributing to the genetic risk.
 ^ Numerous genetic markers have been studied for association with leprosy, e.g. ABO 
blood groups, ghicose-6-phosphate dehydrogenase deficiency, dermatoglyphics (Gupta 
and Tutakne 1986), (Beiguelman 1967) and (Blackwell et al. 1997). Of the other markers 
studied, results have been varied and inconsistent, reflecting genetic heterogeneity, 
inappropriate significance levels or poor control groups. Interestingly, colour blindness 
has been noted to be more prevalent in leprosy patients than in controls in two 
independent studies (Shwe 1992) and (Ghei et al. personal communication). Shwe 
examined 697 leprosy patients and 292 healthy controls fcom Myanmar for colour 
blindness using Ishihara plates. 7.88% of male tuberculoid leprosy patients and 12.18%
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of male lepromatous leprosy patients were red-green or totally colour blind. Only 0.67% 
of male controls fell into this category and only 1 out of 220 females examined had this 
problem (an LL case).
1.7.6 GENE id e n t if ic a t io n
Recendy a number of candidate genes have been studied for association with leprosy
type and leprosy per se. Roy et aL have looked at the tumour necrosis factor (TNF), 
vitamm D receptor (VDR), the natural resistance associated macrophage protein 
(NRAMPl) microsatellite, and mannose binding protein (MBP) in leprosy patients fcom 
Calcutta. The —308 TNF polymorphism and the VDR Taq 1 polymorphism genotype are 
associated with leprosy type in this population. No association was found for either the 
NRAMPl microsatellite or mannose binding protein (S. Roy - personal communication 
and Roy et al. 1997). A transporter associated with antigen-processing (TAP2-B) 
polymorphism has been found to be associated with tuberculoid leprosy in North India 
(Rajalingam et aL 1997).
1.7.7 LINKAGE STUDIES
A number of studies have been performed to look for linkage between HLA and
leprosy. In family studies the question is whether the affected siblings share their HLA 
haplotypes more often than would be expected by chance. Non-random segregation of 
HLA haplo^pes was demonstrated amongst siblings with tuberculoid and borderline 
leprosy fcom Surinam (de Vries et aL 1976). This segregation was also seen amongst 
those siblings who both suffered fcom tuberculoid leprosy, but not in those who had 
different forms of the disease. Another study by the same group demonstrated
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segregation of HLA-DR2 alleles with tuberculoid leprosy (van Eden et aL 1980). Haile et 
aL demonstrated evidence of linkage of tuberculoid leprosy and HLA in a Soufh Indian 
population (Haile ct aL 1985). Abel et aL, on the other hand, failed to demonstrate 
linkage of leprosy with 5 markers, which included HLA and ABO blood group, in their 
families from Desirade (Abel et aL 1989). More recently, Blackwell et aL have looked at 
linkage of a number of markers to leprosy in Brazilian families. They demonstrated that 
HLA is both linked to, and assocdated with, leprosy per se (Blachwell et al. 1997).
1.7.8 ANIMAL STUDIES
Animal studies have the advantage of the possibihty of specific matings with a rapid
turnover, and fewer ethical problems than in humans. Results need to be extrapolated
from animals to humans. With the increasing knowledge of genetic sequences, areas of
homology between the species can be identified, m aking some of these assumptions
more plausible. The natural resistance associated protein, Nrampl, of mice has been
found to affect susceptibihty to infechons with a number of intracellular organisms
including M. lepmemurium (see chapter 6).
,1.7.9 ADOPTION STUDY
Adoption studies can be particularly useful in assessing the degree to which a chsease
is influenced by genetic frcitors. These stuches cen be combined with twin stuches (where
numbers allow) to provide particnilarly interesting results. Their main drawback is that
they require large numbers and reliable mechcel records. There are no studies on leprosy
in adoptees, but Sorensen et aL performed a fascinating study on infectious chseases as a
whole in Danish adoptees. They found that the risk of a child dying from an infectious
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disease was increased more than 5 fold if one of their biological parents had died of an 
infectious disease before the age of 50, whereas the risk was dose to unity if the adoptive 
parcmts did so. T h e reverse was true for cancer. This suggests that susceptibility to 
infectious diseases has a major genetic component (Sorensen et aL 1988).
1.7.10 SEX RATIO
The excess of males affected by leprosy in most populations may be due to 
ascertainment bias. However, it is interesting to note that similar findings have been 
found in tuberculosis (MRC 1992) and anecdotally in other infectious diseases. 
Furthermore, Bellamy et al. have recently found a possible linkage to the X chromosome 
in a genome wide search for tuberculosis susceptibility genes in the Gambia and South 
Afdca (R. Bellamy - personal communication).
1.7.11 OTHER FACTORS DETERMINING CLINICAL EXPRESSION OF DISEASE
It is likely that the majority of people exposed to M. leprae mount an adequate
immune response so that the disease is never manifest (Godal and Negassi 1973). 
However some people will get infected and the degree to which their immune system 
controls the infection will determine the manifestations of the disease. The bacillus is not 
very toxic and large numbers of bacteria can be tolerated with very few sequelae, most of 
the pathology being due to the host’s own immunological response. A large number of 
factors have been implicated in determining the host response to infection.
Various host factors play a role in determining the response to infection. Nutritional 
status at the time of infection may be important Zinc deficiency results in a switch from 
a Thl to a Th2 type response ^prietsma 1997) and a number of vitamin deficiencies
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have been associated with leprosy (Foster et aL 1988). Mitra et aL have evidence that 
suggests that the MHC phenotype can modulate the Thl vs. Th2 profile that the patient 
develops against leprosy (Mitra et aL 1997). Interactions with genes other than the MHC 
may play a role. Specific epitopes may push the response to one end of the spectrum or 
the other e g. Liew et al found that a specific 10-mer epitope resulted in a Th2 response 
to Leishmania major in mice (Liew et aL 1990).
The hormonal environment at the time of infection may be important in determining 
the clinical picture. Certainly, there is an increased rate of comphcations and relapses 
during pregnancy, and there are changes in the epidemiological pattern seen at puberty as 
compared to childhood (de Vries and Perry 1985). Both age at exposure to the bacillus 
and birth order have been implicated in determining the form of disease that develops. It 
has been su^ested that earlier infection may predispose to the mberculoid form of 
disease (Koumantaki et aL 1987). Although the evidence is weak, this theory is supported 
by the higher incidence of tuberculoid disease in highly endemic areas than in non­
endemic areas (Fine 1982).
Parasite factors including infecting dose and antigenic load, may determine the host 
response (Howe et aL 1995). Bancroft et aL found that Balb/K mice, that are usually 
resistant to nematode infections, become infected if the initial infecting dose was less 
than 40 eggs (Bancroft et aL 1994). This may be because a Thl response is induced by a 
low antigenic load (Hosken et aL 1995). Lipoarabinomannam has been proposed as a 
virulence factor in mycobacterial disease (Chan et aL 1991). It appears to downregulate 
macrophage effector function and inhibits the release of toxic oxygen free radicals 
(Kaplan et aL 1987). PGL-1 of M. leprae may also trigger T cell suppressor cells (Mehra et
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aL 1984). Nitric oxide (NO) is a potent effector of macrophage stasis/ddal activity. 
Prostaglandins and transforming growth factor P inhibit NO production. Both interferon 
gamma and tumour necrosis factor enhance macrophage phagocytic capacity and 
possibly mycobacterial killing in vivo (Bermudez 1988). There may be other mechanisms 
that influence the production and effectiveness of reactive intermediates.
Recent, co-existing or superimposed infections may alter the host im m une  response. 
Parronchi found that the presence of concurrent atopic allergy affected cytokine 
production by M. tuberculosis infected specific clones of macrophages parronchi et al. 
1991). Previous exposure to other mycobacteria and to BCG may affect the host 
response to infection (Rook et aL 1981). Antigen-antibody complexes promote a Th2 
type response, though they will enhance a Thl response as long as they lack the ability to 
crosslink Fey receptors on the cell surface (Berger et aL 1996).
The route of infection and the infection type may determine whether there is 
predominantly a Thl or a Th2 response. For example, the intradermal route of infection 
in the mouse footpad sensitises the mouse to M. lepraemuriumy whereas the intravenous 
route tolerises the mouse (Shepherd et aL 1982).
It has been found that there is diumal variation in the interferon- gamma (EFN-)): 
IL-10 ratio with a high ratio in the morning corresponding to the cortisol dip and the 
peak in plasma melatonin levels. Administration of 25mg of cortisone produced > 70% 
decrease in the ratio. Because of the opposing effects of IFN-y and IL-10 on the im m une  
system the timing of infection may determine the subsequent im m une response that
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develops (Petrovsky and Harrison 1997).
Host genetic factors may affect infection in various ways. Differences in expression 
of cell receptors to which bacteria or viruses may attach may affect host susceptibihty e g. 
M. iubmubsis gains access to macrophages by binding to C3 and Fc receptors on the cell 
surface prior to phagocytosis (Walker and Lowrie 1981). M. leprae ran evade various host 
defence mechanisms e.g. the production of NH4 increases resistance to phagosome 
acidification and there are m echanism s by which phagosome maturation and the fusion 
of phagosomes with lysosomes are prevented (Schlesinger and Horwitz 1990), (Clemens 
and Horwitz 1995) and (D'Arcy Hart and Young 1991).
1.7.12 HOST SUSCEPTIBILrrY TO LEPROSY
When considering susceptibihty to leprosy, there are a number of stages to the
infection that need to be considered and may provide clues as to the genetic m echanism s 
involved. These are outlined below. Assuming exposure, the inirial acquisition of 
infection may involve ceU receptors as widi CCR5 in HIV infections. In leprosy C3 and 
Fc receptors on macrophages are used for attachment prior to phagocytosis. Genetic 
polymorphisms in these could well affect susceptibiUly to infection.
The next hurdle for the organism is establishing infection. Primed macrophages may 
rapidly destroy bacteria that enter the cell e g. Nrampl in beg' mice seems to be active in 
rapid priming of the macrophages, such that bacteria entering the cells are rapidly 
destroyed. Nitric oxide synthase is important in controlling the intracellular growth of M. 
ieprae (Adams et aL 1991). There are known polymorphisms in ÎNOS that would be 
worthwhile considering as candidate alleles for leprosy susceptibility (D.Burgner —
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personal communication). Both interferon gamma and tumour necrosis factor enhance 
macrophage phagocytic capacity and possibly mycobacterial killing in vivo (Bermudez 
1988).
In leprosy, disease is more closely related to host response than to mycobacterial 
virulence. Thus it is the bacteria's ability to survive in host cells and to activate the 
immune system rather than direct cellular damage that contributes to pathology. 
Infection may be progressive or quiescent The cytokine response is probably particularly 
important at this stage, Thl responses favouring clearance of the organism, Th2 
responses allowing excessive growth of bacteria (see section 1.5.1).
Various host factors may keep the disease quiescent as occurs in tuberculosis 
infections. When conditions alter e g. the host becomes immunosuppressed, the disease 
may become active again. Resistance to reinfection may depend on the initial 
immunological response mounted by the individual and the rapidity with which memory 
cells mount a response. Previous infection with similar organisms may mean that such a 
response can be mounted on first exposure to the organism, which may be sufficient to 
prevent infection. Various environmental mycobacteria and vaccines such as BCG may 
share sufficient epitopes that the host can keep an infection with leprosy at bay if they 
have had previous closure  to these factors.
1.8 STRATEGIES FOR MAPPING INFECTIOUS DISEASE SUSCEPTIBILITY 
GENES
In this study I used a two-pronged approach to detect leprosy susceptibihty genes: a 
genome wide search to look for major susceptibihty loci, and some candidate gene
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association studies in the hope of detecting some smaller effect genes. Below I give a 
brief outline of these two methods along with 2 other approaches that have not been 
applied in the current work.
1.8.1 a s s o c i a t i o n  s t u d i e s
Association, or case control, studies can be used to compare the frequencies of 
polymorphic alleles between unrelated affected and unaffected individuals from a 
population. Candidate genes are genes that are suspected to play a role in susceptibihty to 
a given disease because of an <7 priori knowledge of their function. An allele A of a 
candidate gene is said to be associated with the trait if it occurs at a significantly higher 
frequency in the affected individuals than in the controls. Analysis of alleles is performed 
using sl2 X 2 test, and analysis of genotypes using a  3 x  2 5^2 test. The most important 
aspect of this type of study is to have a weU-matched control population. It is a powerful 
method provided the marker is close to the disease aUele and a large enough population 
is cAainincd. A major lim itation is that studies can only be performed for genes that have 
already been identified and in which polymorphisms are known. Candidate genes are 
chosen on a best-guess basis, but there are frequently a large number of potential 
candidate genes for any given trait, of which very few may prove to be associated.
An association may be true and the allele may be the actual cause for the disease or 
may be in linkage dis^uilibrium with the dkease causing allele. Linkage disequilibrium is 
the term applied when haplotypic combinations of alleles at different loci occur more 
frequently than would be expected by random association. This will occur in situations 
where most people who possess the trait share a common ancestor from whom they
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have inherited the mutation alongside the susceptibihty gene. This could be due to a 
population bottleneck, population admixture where allele frequencies in the populations 
were different, genetic drift, a new mutation, or selective advantage of one of the alleles 
(Weeks and Lathrop 1995). If the marker is tightly linked to the disease causing allele, the 
association will be strong and will persist over many generations. Because the marker 
allele is close enough to the true disease allele, there has been insufficient time for 
recombination events to erode the association, so the two are inherited together in the 
majority of cases. For two loci with recombination fraction 0, the initial linkage 
disequihbrium is reduced by (1- 0 )° after n generations. It has been estimated that 
carriers of an allele that coalesced 60 generations ago share 5cM of DNA. This explains 
the common occurrence of shared genomic areas around a rare mutated allele (van der 
Meulen and te - Meerman 1997). The particular allele in linkage disequilibrium may vary 
from one population to another. A third reason for finding an association between an 
allele and a disease is population artefact due to non-homogeneity of the population 
(Lander and Shork 1994) e g. Pima Indians and the Gm locus (Knowler et al. 1988).
The power of association methods depends upon a number of factors. These include 
the degree of linkage disequilibrium between the marker and the disease locus, and the 
recombination fraction between the two. Other factors include the frequency of the 
mutation, the increase in risk due to the allele, and the penetrance of the different 
genotypes (Weeks and Lathrop 1995). An advantage of case control studies over 
genome-wide screens is the speed with which they can be performed and analysed, and 
the relatively low cost They can detect disease loci that would be missed by linkage 
analysis (Greenberg 1993).
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There are two approaches that can overcome the problems of population 
stratification that occur in case control studies:
i) Haplotype relative Risk Method (HRR)
The problems associated with having to find a well matched control that are 
encountered in association studies, are overcome in the HRR method by using an 
internal control Nuclear families are used and the “control” is derived firom the non- 
inherited parental alleles (fig. 1.5). This is a non-parametric method. A 3 x 2 table can be 
constructed of the presence or absence of the allele in question in cases versus “controls” 
and a test performed. Various statistical tests are applicable (Schaid and Sommer 
1994). The ratio of discordant pairs provides an estimate of the relative risk (Khoury
1994). It may be obvious looking at the results that a disease is dominant or recessive, 
and it may even be possible to see the effects of imprinting by examining whether the 
alleles originate fix>m the mother or father (Schaid and Sommer 1994).
AB CD
I I
AD The non inherited genotype is
BC
Fig. 1.5 Demonstration of '^ virtual control” used in the Ficplotype Relative RJsk Method
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There are two main disadvantages to this method. Firstly, because two parents need 
typing there is 50% more work involved than in a traditional case control study. 
Secondly, in any disease in which the onset is late there may be problems recruiting 
parents. The HRR method has been used successfully in establishing an association 
between attention-deficit hyperactivity disorder and the dopamine transporter locus (Gill 
etaI 1997).
ii) Transmission Disequihbrium Test
This is a powerful test that has been successfully apphed, for example, in the study of 
diabetes susceptibihty loci (Copeman et aL 1995). Parents heterozygous for the aUele of 
interest are considered and the frequency of transmission of the two alleles to their 
affected offspring is examined. If there is no association, the transmission of each aUele 
would be expected to be 50%. If there is a significant deviation from this, there is 
evidence of association. It is a useful test to apply in cases where linkage has not been 
detected, but an association has been found as it directly tests for linkage and is 
unaffected by population stratification (Spielman et al. 1993). The advantage of this 
method is that it is unaffected by population stratification, yet it is simpler to perform 
than linkage studies as multiple affected family members are not required. The 
disadvantage is that linkage can only be detected if there is association due to linkage 
disequihbrium between the marker and the locus. Significant results may be artefactual 
due to meiotic segregation distortion, which would occur in both affected and unaffected 
children. Provided unaffected children are available this can be excluded.
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1.8.2 g e n o m e -w id e  SEARCHES
It is likely that susceptibility to leprosy is a complex trait with several susceptibility
loci that interact with one another and with the environment to determine disease 
outcome. The evidence from segr^ation analyses lends support to a major gene effect It 
has only recently become feasible to attempt to look at the genetics of this type of 
disease in a systematic way.
In this approach the entire genome is systematically screened for linkage of major 
susceptibility loci to regularly spaced markers. It is an expensive and labour intensive 
method, but, provided the markers are suitably spaced (up to 20cM), it will identify major 
genes (Terwilliger 1995). It has less power than the candidate gene approach, but is more 
systematic and has been used effectively in identifying type 1 insulin dependent diabetes 
loci (Davies et al. 1994). Traditionally, and in our study, people have genotyped both 
parents and at least two affected siblings. Various approaches have been used in order to 
try to increase efficiency. Hauser suggested initially screening the affected siblings alone, 
halving the initial number of genotypes that need to be performed. This is followed by 
typing additional family members for the markers that produce lod scores of more than 
1, together with nearby surrounding markers (Hauser et aL 1996). A simulation study was 
performed for a disease where the Xs of the locus was 2.5. This found that the power of a 
genome screen to detect a lod score equal to or greater than 2.3, was 99.9% if 96 families 
were examined for 273 markets at an average spacing of 20cM (Davies et al. 1994).
1.8.3 ANIMAL MODEL HOMOLOGUES
Animals can be bred much more easily than humans and backcross experiments 
performed so that known genotypes can easily be produced and studied. The animals can
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be kept in conditions that maximise the importance of the underlying genetic factors. 
Because genetic heterogeneity can be eliminated, frr more complex traits can be studied 
in animals than humans. This may help in establishing the physiulugieal and b iochem ical 
basis for various mammalian diseases. Dense maps are now available for mice and rats. 
Numerous diseases have being investigated using quantitative trait locus mapping, some 
of which have direct human parallels. For example, the finding of linkage of 
hypertension in rats to the angiotensin converting enzyme led to the establishment of the 
role of angiotensinogen in human disease (Crabbe et al 1994) (Tanksley 1993). Using 
knockout mice, it should be possible to gradually dissect out polygenic causes of 
different traits.
Unfortunately it is not always possible to extrapolate findings in one species to 
another. Another problem is that defects are often noted in inbred strains of mice that 
are in sterile environments. It is possible that if they were in the wild, these strains would 
never have survived, so the likelihood of a human homologue is very small. Examples of 
human homologues of mice genes are the IDDMl and EDDM7 genes causing 
susceptibihty to insulin dependent diabetes (Copeman et aL 1995) and (Todd et al. 1987). 
After many years of speculation, the human homologue of the mouse natural resistance 
macrophage associated protein, NRAMPl, is now coming iq) trumps in a number of 
diseases (see chapter 6).
1.8.4 POPULATION AND FAMILY STUDIES
Population studies and family studies can be used to investigate the effects of genetic
polymorphisms on susceptibihty to various diseases. Family studies have the advantage
38
T h e  G e n e t i c s  o f  Su s c e p t ib il it y  t o  L e p r o s y
of eliminating artefacts of population heterogeneity and linkage disequilibrium. They also 
give extra information about the inheritance, penetrance and frequency of disease 
susceptibility genes. The disadvantage of selected multicase families is that they may be 
non-representative of the patient population.
1.9 OUTLINE OF WORK PERFORMED IN  THIS THESIS
In view of the strong evidence for genetic factors in leprosy, in particular that
from segregation studies pointing towards a major gene effect, we decided to perform a
genome-wide search in leprosy -affected sibling pairs. We also performed a few
association studies on candidate genes in order to see if they had any role in the disease.
The collection of samples, techniques employed, rationale for testing the candidate
genes, results and conclusions are discussed in the following chapters.
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CHAPTER 2
2 m a t e r i a l s  AND M ETH O D S
2.1 OVERVIEW OF METHODS USED
Two methods were used in the work for this thesis. Firstly a two-staged genome-
wide search for major leprosy susceptibility loci was performed. Families were identified
in which there were at least 2 siblings with a history of proven leprosy. Blood was
collected feom the siblings and their parents and DNA Œtracted. In the first instance 92
families were screened using 293 fluorescentiy labelled microsatellite markers. The
microsatellites were amplified by the polymerase chain reaction (PGR), pooled into sets
of non-overlapping size ranges, and run with a size marker through polyacrylamide gels
on 373 ABI sequencers. The products were sized to within 1 base pair using the
programmes Genescan Analysis™ and Genotyper™. Final analysis of the families was
performed using GAS™ and Sib-Pair™, computer programmes that perform %^ -tests and 
calculate lod scores based upon the observed and expected allele sharing patterns. Multi­
point analysis was also performed using Mapmaker Sib™. Markers with lod scores or p-
values suggestive of possible linkage were screened in the second stage of the study using 
a further 96 families.
Secondly, case-control studies of candidate gene polymorphisms were 
undertaken. The region of interest was amplified by PGR, the product was blotted onto 
nylon filters, and the filter probed for the different alleles with sequence-specific 
oligonucleotides (SSÜ). The SSO's were pre-labeUed with digoxigenin (DIG) (produced
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by Boehtmget Mannheim). Following treatment with an anti-DIG antibody attached to a 
phosphatase enzyme (anti-DIG-AP), CSPD was added to the filters. CSPD is a 
chemiluminescent agent that is a substrate for the phosphatase. If the DIG labelled 
probe had attached to the filter, chemiluminescence was produced following incubation 
with CSPD. This was easily detected by exposing the filters to X-ray film, after which 
scoring of the samples could be performed.
2.2 GENERAL METHODS
(see scctiou2.4  for ilt^tails o f  solutions usecQ
2.2.1 DNA EXTRACTION FROM WHOLE BLOOD
5-9 ml of blood was collected in EDTA tubes and DNA was extracted on the
same day using Nucleon II ™ kits (Scodab). Red ceU lysis was performed by adding
Nucleon Reagent A (at a volume 4 times that of the blood) to the blood and mixing the
solution for 4 minutes at room temperature. The solution was then centrifuged for 4
minutes at 1300g and the supernatant discarded into Virkon. 2ml of Nucleon Reagent B
was added to the white cell pellet, admixture and lysis being encouraged by briefly
vortexing the tube. The solution was transferred to a 15ml tube and deproteinisation
performed by adding 500[xl of 5M sodium perchlorate solution and mixing the tube for
15 minutes at room temperature. The tube was then placed in a water bath at 65*'C and
shaken for 25 minutes. DNA was extracted by adding 2ml of chloroform that had been
stored at minus 20°C, and mixing the tube for 10 minutes. 300 pi of Nucleon silica
suspension (provided in the kit) was added and the solution centrifuged at 1300g for 3
minutes. This produced a biphasic solution separated by a thin layer of silica solution.
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with a lower organic phase, and an upper DNA containing phase. The upper phase was 
carefully transferred to another tube. If some of the silica solution had also been 
transferred, it was re-centrifu^d and the supernatant tmnsferred to a new tube. The 
DNA was then precipitated by adding it to approximately twice the volume (usually 7m^ 
of 100% ethanol at 4°C. The DNA was transferred to an eppendorf tube, allowed to ait 
dry, and then dissolved in 10 x TE buffer. Following extraction, samples were stored 
at 4**C or -20**C depending on the availabihty of frdhties, and transportation back to the 
UK was performed on ice. Samples to be used in the genome screen were diluted further 
in 10 X TE buffer to reach a roughly uniform concentration of 170-230ng/ p i Some of 
this was further diluted with distilled water to reach a concentration of approximately 
lOng/ [il and stored in 96 well deep — well plates at 4®C in a set format for convenience 
of use. The other samples were stored at -20^C once back in the UK at concentrations 
ranging between 200 — lOOOng/pL
During the second visit to India, the prolonged mixing steps at the sodium 
perchlorate and chloroform stages were replaced by fully inverting the tubes a minimum 
of 7 times, and the water-bath incubation step was omitted.
2.2.2 MEASUREMENT OF DNA CONCENTRATIONS
DNA concentrations were measured using a Hoefer fhiorimeter. The method is
based on the binding of a fluorescent dye (Hoescht 33258) to DNA. Calf thymus DNA
at a concentration of lOOOng/ml was used to calibrate the fluorimeter. This allowed
accurate measurement of DNA concentrations between 100-2000ng/ml. Each sample
was then checked in turn. If the concentration was greater than 2000ng/ ml, it was
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diluted until it was within the tan^.
2.2.3 POLYMERASE CHAIN REACTION FOR AMPLIFICATION OF DNA
The Polymerase Chain Reaction (PCR) method was used to amplify the
deoxyribonucleic add (DNA). Regions lying between two primers were amplified in an
exponential way, by repeated cycles of temperature changes that allowed dénaturation,
extension and annealing of the DNA strands in the presence of appropriate reagents.
The primers were chosen according to the area of interest, their estimated melting
temperatures, Tm,, their length, a lack of secondary structure and a lack of
complementarity of the 3* ends dther between or within individual primers. Computer
programs are now widely available to aid in the selection of specific primers, although in
most cases other groups had already identified suitable primers.
Initially Hybaid PCR machines were used for thermal cycling in this project M[ 
machines gradually became more readily available during the course of the project, which 
speedW up the process. The annealing tempemture varied with the reaction (generally 
between 49-61®C), but dénaturation temperatures of 94 — 95®C, and extension 
temperatures of 72°C were used.
A thermostable DNA polymerase Taq (Thermus aquaticus) was used to drive the 
reaction. In general a standard buffer solution was used with a standard concentration of 
dNTPs (deoxynudeotide phosphate) and primers. The magnesium concentration was 
varied between 0.5 — 5 mM in order to optimise the PCR product The annealing 
temperature chosen was usually a few degrees below the calculated Tm of the primers, 
after which optimisations were performed at a variety of temperatures and magnesium 
concentrations. If the PCR did not work with the standard buffer, further experiments
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were performed using the Stratagqie™ set of buffers, in order to find the most suitable 
conditions. Occasionally glycerol or DMSG was added to improve the specificity of the 
product, 25(d reactions were used for the case-control studies involving sequence- 
specific oligonucleotides, and lOpl reactions for microsatellite studies. 96 well 
polycarbonate plates were used and the reaction solutions covered with 1 drop of 
mineral oil
The success of reactions was assessed on 1-1.5% agarose gels. Once a PCR had been 
successfully optimised using a small number of samples, large-scale amplification was 
performed. Reaction conditions for the candidate genes studied are listed in tables 2.1 to 
2.5.
2.2.4 AGAROSE GEL ELECTROPHORESIS
1-1.5% agarose gels were used to check the successful amplifioition of DNA by
PCR. Small gels (60 sample capacity including marker ^ e ) were made from 100ml of 
TBE (TAE used from mid 1997) with 1 — 1.5g of agarose. This was heated in a 
microwave oven for 3 minutes until the solution was clear. It was cooled to about 60°C 
under running tap water after which 5 pi of ethidium bromide was added. This was 
mixed in thoroughly by swiriing the bottle and the solution was then poured into a pre­
prepared gel-tray and allowed to set at room temperature for about 20 minutes before 
use. Larger gels with capacity for 3 x 96 well plates plus markers were made using four 
times the above amounts.
3 pi of loading dye (0.25% bromphenol blue) was added to 5 pi of DNA product and 
loaded onto the gel 3 pi of a 0X174 molecular weight marker (Pharmacia) with
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Gene Primers PCR Conditions Probes
temp)
(stringency
IL-4 5'ACTAGG 
CCT CAC 
CTGATA 
CG-3’
S’GTT GTA 
ATG GAG 
TCC TCC TG- 
3’
25pl reaction: 1 x Ammonium 
Buffer, 4.5mM MgCk, 0.2mM 
dNTPs, 1 pM primers, 0.5mM 
spermidine, 3%DMSO, 1 unit 
AmpliTaq 
Hybaid cycler :
Hot start 95°Cx300s, 38x{94°C 
x60s,57°C x45s,72°C x600s}
5'-GAACATTGT 
CCC CCA GTG-3’ 
(52°C)
5’- GAA CAT TGT 
TCC CCA GTG-3’ 
(51°C)
IL-10-
592
5’ CTG GCT 
CCC CTT 
ACC TTC 
TAC ACA 3’ 
5TGG GCT 
AAA TAT 
CCT CAA 
AGT TCC 3’
25 pi reaction: 1 x KCl Buffer, 
2mM MgClz, 0.2 mM dNTPs,
2 pM primers, 1 unit of Taq 
gold
^  cycler:
94°Cx 14 mins.
35x{94°C X 10s, 58°C x 20s, 
72°C X 30s} then 72°C x 2 
mins.
5’-CGC CTG TCC 
TGTAGG-3’ (43°C) 
5’-CGC CTG TAG 
TGT AGG-3’ (57°C)
Table 2. 1 PCR conditions used in case-control studies
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Gene Primers PCR Conditions Probes
temp)
(stringency
IL-10-
1082
As for IL-10- 
592
As for IL-10-592 5’-TTT GGG AGG 
GGG AAG-3’ (48°C) 
5*-TTT GGG AAG 
GGG AAG-3’ (42°C)
IL-10
microsat­
ellite
5’-GTC CTT 
CGC GAG 
GTA GAG 
CAA CAC 
TCC -3’ FAM 
5’-CTC CCA 
AAG AAG 
CCT TAG 
TAG TGT T- 
3’
15pl reaction: Ix KCl Buffer, 
ImM MgCb, 0.2 mM dNTPs, 
6pM primers, 0.5 units of Taq 
gold
cycler 94®C x 15 mins. 
38x{95°C X Is, 53°C x 20s, 
72°C X 5s} then 72°C x 2 mins.
N/A
Diluted lin 40 before 
loading onto ABI gel
NRAMP
Intron4
5*-TCT CTG 
GCT GAA 
GGC TCT 
CC-3’
5’-TGT GCT 
ATC AGT 
TGA GCC 
TC-3’
25pl reaction: Ix KCl Buffer, 
ImM MgCL 0.2 mM dNTPs, 
2 |JM primers, 1 unit of Taq 
gold
cycler 94°C x 15mins, 
38x{94°C X 15s, 58®C x 30s, 
72°C X 45s}, then 72°C for 2
m in s.
3*-TTG GGG GGC 
CTG GAC-5* (53®C, 
SSC)
3’-TTG GGG GCC 
CTG GAC-5* (48®C, 
SSC)
Tcû)k 2.2 PCR conditions used in case-control studks (continued)
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Gene Primers PCR Conditions Probes
temp)
(stringency
NRAMP
TGTG
5’ GCATCT 
CGC CAA 
TTC ATG 
GT-3’
5'AAC TGT 
CCC ACT 
CTATCCTG- 
3’
25pl reaction: Ix KCl Buffer, 
ImM MgCb, 0.2 mM dNTPs,
2 pM primers, 10% glycerol, 1 
unit of Taq gold
cycler 94°C x 14mins, 
5x{94®C X 15s, 58°C x 30s, 
72®C X 30s} then 32 x {94°C x 
15s, 53°C X 30s, 72®C x 30s), 
then 72°C x 2m ins
5’-CTG GAT GTG 
GAG GGG-3’ (51°C) 
5’-TGC TGG AGA 
GGG GGC-3’ (48°C)
NRAMP
microsat­
ellite
5*-TTC CGC 
ATTAGG 
GCAACG 
AG-3’
5’-TTC TGT 
GCC TCC 
CAAGTT 
AGC-3’-TET
15pl reaction: Ix KCl Buffer, 
2mM MgCk, 0.2 mM dNTPs, 
6)lM primers, 0.5 units of Taq 
gold
cycler 94°C x 15 mins. 
38x{95°C X 15s, 55°C x 20s, 
72®C X 5s}, then 72°C x 2
m in s.
N/A
Diluted lin 40 before 
loading onto ABI gel
Tahk 2.3 PCR conditions used in case-control studies (continued)
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Gene Primers PCR Conditions Probes (stringency 
temp)
TNF-238 5’ CAAACA 25pl reaction: 1 x KCl Buffer, 5’- CTG CTC CGA
CAGGCC 2.5mM MgCh, 0.32 mM TTC CGA G-3’(56°Q
TCA GGA dNTPs, 5’ CCT CGGAAT
CTC- 3’ 1.6 pM primers, 1 unit of Taq CAGAGC AGGG-3’
5’ AGG GAG gold (58®C)
CGTCTG cycler
CTG GCT G-3’ 94°Cx 14 mins.
35x{95°C X 10s, 60°C x 20s, 
72°C X 30s} then 72°C x 2
mins.
T N F - As for TNF — As for TN F-238 5’ AGG GGC ATG
308 238 GGGACG G G -y 
(61.5®C)
5’ AGG GGC ATG 
AGGACG G G -y 
(61.5°C)
Tahk 2.4 PCR condiHons used in case-control studies (continued)
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Gene Primers PCR Conditions Probes
temp)
(stringency
VDR 5'CAGAGC 
ATG GAC 
AGG GAG 
CAA G-3’ 
5’-GGT GGC 
GGCAGC 
GGATGTA-3’
Ix Ammonium Buffer, 2mM 
MgCb, 0.2 mM dNTPs, 1 pM 
primers, 10% glycerol, lunit of 
Taq gold 
cycler 
94°C X 14 mins.
35x{94°C X 30s, 49°C x30s,
72°C x45s}
5’-GCG CTG ATT 
GAG GCC ATC-3’ 
(65.5°C)
5’-GCG CTG ATC 
GAG GCC ATC-3’ 
(63.5°C)
Table 2.5 PCR conditions used in case-control studies (continued)
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fragment sizes of 72, 118, 194, 234, 271, 310, 603, 872, 1078 and 1353 base pairs was 
always run in at least one well per row of products. Electrophoresis of the gel took place 
in a tank filled with TBE solution (TAE from mid 1997) with a current of 100 volts for 
approximately 20 m inu tes. The presence of a single product band of the correct size 
could then be confirmed by exam in in g  the gel under ultraviolet light (Eagle Eye, 
Stratagene).
2.3 METHODS SPECIFIC TO SEQUENCE SPECIFIC OLIGONUCLEOTIDE 
PROBING
2.3.1 TRANSFER OF AMPLIFIED DNA TO NYLON FILTER USING DOT BLOTTING
Once amplification of the samples for candidate gene studies (except those of
microsatellites) had been successfully performed, the product was transferred to a nylon
membrane for probing. Initially 10 pi of the product was rendered single stranded by
adding it to 100 pi of a denaturing solution incubated on ice. The denaturing solution
was made of 86 pi of TE, 6 pi of O.SmM EDTA at pH 8.0, and 8 pi of freshly made 6M
NaOH. After 10 minutes incubation, the reaction was neutralised with 100 pi of 2M
ammonium acetate. A positively charged nylon membrane was placed in a Hybridot
manifold on top of 2 moistened pieces of Whatmann paper, and moistened with distilled
water. The lid of the manifold was screwed finger-right, the suction turned on, and 100
pi of IM ammonium acetate solution was put into each well. Once this had been
completely sucked through the filter, the denatured PCR products were transferred to
the filter, followed by 200 pi of IM am m on iu m  acetate. The product was fixed to the
filter by UV crosslihking followed by baking at 80IC for 2 hours in an oven.
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23.2 LABELLING OF OLIGONUCLEOTIDE PROBES WITH DIGOXIGENIN
Digoxigenin kits (Boelmnget Mannheim) were used to label oligonucleotides. This
was done using the following components:
4 [il Tailing buffer 
4 [il 25mM cobalt chloride 
1 [il of oligonucleotide (O.lmM)
1 [ilDIG-dUTP 
9 [il milli-Q water
Finally 1 pi of terminal transferase was added and the mixture incubated at 37°C. 
After 15 minutes the tube was put on ice and made up to a volume of 100 pi with milli- 
Q water. 25 pi of this was used for probing the filters in one Hybaid bottle.
2.3.3 HYBRIDISATION OF DIG-LABELLED PROBE AND STRINGENCY WASHING
(O riginally all probes were s tandardised  u sin g  the T M A C  hybridisation solution.
However, this is a toxic and e3q>ensive agent, so in some methods SSC hybridisation
solution was used instead)
This procedure was performed in Hybaid botdes rotating in a Hybaid rôtisserie oven 
at the temperatures mentioned. Up to 2 blotted and fixed nylon filters were placed in 
each Hybaid bottle so that the side with the single stranded DNA was facing internally 
and the filters were non-overlapping. The filters were blocked for 20 minutes using 10ml 
of blocking reagent at room temperature. This solution was then discarded and the filters 
prepared for hybridisation by adding 10ml of hybridisation solution and incubating them 
at 5**C below the stringency temperature for 20 minutes. 25 pi of digoxigenin-labelled
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probe was then added to each tube and hybridisation performed for at least 1 hour at the 
same temperature as the pre-hybridisation. The filters were rinsed for 20 minutes at room 
temperature with Wash Buffer. The stringency wash was then performed by incubating 
the filters with 10ml of TMAC hybridisation solution (TMAC methoc^ or 10ml of 0.5 x 
Wash buffer (SSC metho^ at the stringency temperature for 15 minutes in order to leave 
just specifically bound probe attached to the DNA on the filter. (An estimation of the 
stringency temperature was made using the formula Tm (“C) = 4(G + C) + 2(A + 1).
2.3.4 DIG DETECTION
The filters were rinsed with Buffer 1, then blocked with 10ml of Buffer 2 at room
temperature. After 20 minutes Ipl of anti-dig-AP was added to the buffer 2 and
incubated for a further 30 minutes. The solution was then discarded and the filters
washed with Washing Buffer at room temperature for 20 minutes. The filters were rinsed
in buffer 3 for 3 minutes, drained well, and then incubated with 5ml of CSPD solution
for 3, 5 or 8 minutes, depending on how many times the solution had been used
previously. The filters were then wrapped in saran wrap, incubated at 37®C for 15
minutes, and exposed to X-Ray film for an average of 15 minutes. A decision was madp,
as to whether the stringency wash needed repeating at a higher temperature ^  which
case the method was restarted at the stringency wash step), or the filters needed re-
probing at a lower temperature Qn which case the method was started firom the
beginning).
2.3.5 STRIPPING DIG-LABELLED OLIGONUCLEOTIDES FROM HYBRIDISED NYLON
FILTERS
If the filters were scorable and an alternative allele was to be probed for, the filters
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had to be stripped before reprobing. To start with the filters were incubated with 10ml of 
Stripping Buffer 1 at 65°C for 30 minutes. The solution was discarded and replaced with 
10ml of Stripping Buffer 2 for 20 minutes at room temperature. Finally the filters were 
incubated with 10ml of Stripping Buffer 3 at 37**C for 30 minutes.
2.3.6 STATISTICAL METHODS USED FOR CASE-CONTROL STUDIES
SPSS was used to analyse the data firom the case control studies. The Statcalc
programme in EPI INFO was used for 3 x 2 (2 degrees of freedom {d.f.}) and 2x2 (1
d.f.) values, and calculation of odds ratios. Logistic regression was used to control for
the confounding effects of ethnic and regional groups, age and sex in the Mali study
using SPSS.
2.4 STOCK SOLUTIONS
2.4.1 SOLUTIONS USED FOR DNA EXTRACTION
Nucleon Reagent A -lOmM Tris-HCl, 320mM Sucrose, 5mM MgCb, 1% Triton-X, 
adjusted to pHS.O using 40% NaOH and autoclaved.
Nucleon Reagent B - 400mM Tris-HCl, 60mM EDTA, 150mM NaCl, 1% SDS (added 
after autoclavin^, adjusted to pH8.0 using 40% NaOH and autoclaved.
10 X TE buffer - lOmM Tris-HCl, O.lmM EDTA, adjusted to pH8.0 using 40%
NaOH and autoclaved.
5M sodium perchlorate - supplied with kit 
Nucleon siUca suspension - supplied with kit
2.4.2 GENERAL STOCK SOLUTIONS
SOOMm EDTA - 186.1g NazEDTA, made to pH 8.0 with NaOH
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10% SDS - lOOg sodium kuryl su^hate
20 X SSC -175.3g NaCl, 88.2g Na citrate, made to pH 7.0 with NaOH 
20 X SSPE -175.3g NaCl, 31.2g NaH2? 0 4 .H2 0 ,7.4g EDTA made to pH 7.4 with NaOH 
50 X TAE buffer - 242g Tris base, 57.1ml glacial acetic add, 37.2g Na2EDTA.2H20 
10 X TBE buffer -108g Tris base, 55g boric add, 40ml 0.5M EDTA, pH 8.0 
TE buffer -lOmM Tris.Cl, ImM EDTA made to pH 8.0 with NaOH
2.4.3 PCR BUFFERS
10 X KCl Buffer - lOOmM Tris HCl pH8.3,15mM MgCb, 250mM KCl
10 X Ammonium Buffer - 160mM (NHi)2S04,670mM TrisHCl ^ H  8.8), 0.1% Tween20
2.4.4 REAGENTS USED FOR SEQUENCE SPECIFIC OLIGONUCLEOTIDE PROBING 
DNA denaturing mix (100 pl/lOpl of DNA)- 6|il 0.5M EDTA (pH 8.0), 86pl TE buffer
(pH 8.0), 8pl 6M NaOH (fresh)
Blocking Solution - 4 x SSPE, 1% Blocking reagent stock (supphed by Boehringer 
Mannheim), 0.1% lauxyl sarcosine
TMAC Hybridisation solution - 3M TMAC, 50mM Tris (pH 8.0), 0.1% SDS, 2mM 
EDTA
SSC Hybridisation solution- 5x SSC, 1% blocking reagent, 0.1% lauryl sarcosine, 0.02% 
SDS
lOx Buffer 1- 1.5M NaCl, IM maldc add, made to pH 7.5 with NaOH (approx. 80g)
Wash buffer - 2 x SSPE, 0.1% SDS
Washing buffer -1 x Buffer 1,0.3% Tween20
Buffer 2 -1 X Buffer 1,1% Blocking reagent stock (kept at 4°C)
Buffer 3 - lOOmM Tris (pH 9.0), lOOmM NaCl, 20mM h%Cb
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CSPD - (supplied by Boehringer Mannheim) 1% in Buffer 3 (can be used 3 rimes within
48hrs. provided stored in light-proof container at 4®Q
Stripping buffcrl - SOmM EDTA (pH 8.0), 2 x SSC
Stripping buffer 2 -2 x SSC, 0.1% SDS
Stripping buffer 3 - 0.2M NaOH, 0.1% SDS
2.5 SUMMARY OF TH E METHOD USED FOR GENOME SCREENING
2.5.1 in t r o d u c t io n
Now that numerous miorosatellito marker lod are available (Dib et al. 1996), and
there is the technology to accurately size them, whole genome linkage mapping of
complex diseases has become possible. Sets of up to 8 markers that have non
overlapping allele sizes can be run in the same gel lane together with an internal size
standard. By labelling primers with one of three fluorescent markers that emit different
wavelengths (Ziegle et aL 1992), 3 markers with overlapping size ranges can be run in the
same lane together with a size marker labelled with a fourth dye, and each can be
distinguished (fig 2.1). As a result, up to 24 microsateUite markers firom one individual
can be run in one lane (see appendix for marker sets) (Schwengel et al. 1994). This means
that, in theory, 96 nudear families could be screened for 288 markers by loading just 144
polyacrylamide gels.
The ABI machines have a laser that continuously scans the gel detects the fluorescent 
labels as they pass through the gel under the influence of the electric current 
Sophisticated software can be used to calculate the allele sizes by comparing them with 
the size standard, and the table produced can be analysed by any of the numerous linkage
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Fh£. 2.1 Gel picture produced by Genescan Analysis^^.
Each vertical line represents one lane and contains the pooled products of microsatellite per reactions from 
one set of markers in one individual The red marks are produced by the Tamra labelled si;(e standard. 
The yellow, green and blue marks are producedfrom the Hex, Tet and Fam labelled primers that have 
been incorporated into the products during per amplification.
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programs now available. With the possibilities of mult^lexing PCRs, robotic devices, and 
even better software, the whole process is likely to become even faster in the future.
2.5.2 LARGE SCALE DNA AMPLIFICATION
92 families with adequate amounts of DNA, and in whom the parents were as
distantly related as possible, were designated to be used in the first round of the genome 
screen. A further 96 families were chosen for the second round. The DNA was diluted to 
a concentration of between 170 — 230 ng/ml using 10^ TE buffer, and then further 
diluted to lOng/ml with milli-Q water. This stock was placed in four 96-well deep-well 
plates (Beckmann), with the samples arranged in a predetermined fashion. This allowed 
easy dispensing of the DNA into polypropylene plates (Costar) for PGR using multi­
channel, multi-dispensing pipettes.
PGR optimisations of the microsatellite markers belonging to one set were 
performed using spare DNA samples, by the standard techniques described above. A 
control sample containing water rather than DNA was always run, and the size of the 
products checked against a marker (OX 174). Once optimised, stock sufficient for all 4 
plates was made up, Taq being added last Using m ultich an n el pipettes, the stock could 
be dispensed rapidly into ready prepared 96 well polypropylene plates (Gostar) containing 
the correct amount of DNA and m ineral oil The plates were centrifuged briefly at 
lOOOrpm before the PGR was performed. Four to six wells ftom each plate were checked 
for success of the reaction by running the product on agarose gels as described above. 
The basic 15pl reaction mix was as follows:
5 jil of DNA at lOng/pl
57
T h e  G e n e t ic s  o f  Su s c e p t ib il it y  t o  L e p r o s y  
1 X KCL buffer 
1 — 4mM 
200pM dNTPs 
4 pM of each primer
0.2 units of Taq initially AmpUtaq, but changed to TAQ gold in January 1997)
1 drop of mineral oil
PCR cycles used in the genome screen are shown in Table 2.6 and conditions for the 
different primers are summarised in appendix 2.
2.5.3 POOLING OF PCR PRODUCTS
Once all the PCRs ftom one set had been successfully performed on all the families,
the products were pooled as follows. 5 pi of the products of all the markers labelled with 
one particular dye were aliquoted into a ftesh 96-weU plate. In this way a pool of Hex, 
Tet and Fam was created corresponding to each of the four 96-well deep-well plates. 
Pools of the pools were then made so that the ratio of product was 4 Hex : 2 Fam : 1 
Tet An equal volume of milli-Q water was added to each pool, and the trays were 
centrifuged briefly at 1000 rpm.
2.5.4 PREPARATION OF THE SAMPLES FOR GEL LOADING
A 1; 5 solution of loading dye: formamide was made and 3.2 pi of the resulting 
solution was added to 0.8 pi of the Tamra labelled marker dye, for every sample to be 
loaded. QThe Tamra marker had firagments of the fbllo^Mug sizes: 50,75,100,139,150,
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Standard Loflg(L) Extra Long (XL)
94°C X 14 mins 94®C X 14 mins 94°C X 14 mins
95®C X 1 s } 
49-61®C X 20 s}x 38 
72*’C X 5 s }
95®C X 1 s } 
49-61°Cx20s}x38 
72®C X 10 s }
95°C X 1 s } 
49-61®Cx20s}x40 
72°C X 10 s }
72®C X 1 min 72®C X 1 mifi 72°C X 1 min
(Conditions are given in the appendix)
59
T h e  G e n e t ic s  o f  Su s c e p t ib il it y  t o  L e p r o s y
160, 200, 250, 300, 340, 350, 400, 450, 490 and 500 base pairs). 4pl of this solution was 
added to 3 pi of each pool of pool sample in a clean Costar plate. Just prior to loading 
the gel, these samples were denatured at 95°C for 2 minutes, then put on iee. 3.5 pi of 
each sample was loaded into the wells of the acrylamide gel once it had been fully 
prepared (see below).
2.5.5 SETTING UP POLYACRYLAMIDE GELS
6% acrylamide/7M urea (Severn Biotech) 36 well gels were prepared for use by
the cote facility. They were allowed to set for at least 2 hours before use. The ^ass plates 
were then thoroughly cleaned under distilled tap water and dried clean so that there was 
no smearing. The comb was carefully removed and the gel placed in position in the 373A 
ABI sequencer. A plate-check was performed to ensure that there were no significant 
peaks on the trace that would subsequently interfere with the output The voltage was 
adjusted so that the y co-ordinate of the trace lay between 800 — 1000. The wells were 
flushed with TBE buffer, the gel loaded in a predetermined order, and the run begun. 
Runs were performed using “Filter set B” for an average of 5 hours, or until the peak of 
the Tamra marker dye just larger than the largest expected allele size, had passed the 
laser.
2.5.6 GENESCAN ANALYSIS
The resulting gel files were transferred to Macintosh computers and analysed
using Genescan Analysis™ as per instruction booklet Default sample sheets (based 
upon the layout of the deep-well 96 well DNA plates) were entered onto the computer 
and saved. The gel file was then opened, the lanes tracked manually and the appropriate
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ABI gel tnatfiy and sample sheet imported. The Local Southern method was used for 
size-calling. Analysis was then initiated having defined red as the size standard colour and 
having entered the fiagment sizes corresponding to the red peaks. Sample files were 
produced and saved.
2.5.7 GENOTYPING
Using the Genotyper™ software, templates were constructed for each marker
set. Data concerning the marker name, expected size range, and fluorescent label were 
incorporated, and the templates saved A macro was constructed so that the two highest 
peaks would be labelled, a fable of the results produced, and the table rewritten after 
corrections had been made by the person checking the analysis.
Once a template had been produced, sample files firom Genescan Analysis™ 
were imported and analysis proceeded Genotyper™ works by correlating the fluorescent 
intensity of the labelled fragment with the size information and marker loci information. 
Because the allele railing by Genotyper™ is not 100% reliable, all results were checked 
manually. This also allowed the detection of cases of non-parentage. Allele size data were 
e3q>orted and stored as Excel files.
2.5.8 PREPARATION FOR FURTHER ANALYSIS OF DATA
We used the MRC set of microsatellite markers used by Todd et al in their screen for
type 1 diabetes genes, plus a number of gap fillers and rq)lacanent markers, which took 
the total to 293 markers (Todd et aL 1990). The mean density of the markers was 
11.7cM. Initially the markers were divided into 14 sets, but because of marker failures 
and gap fillers this was expanded to 20 sets. One primer for each microsatellite was
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labelled with one of the following fluorescent dyes: Fam (blue), Hex (yellow) or Tet 
(green) (see appendix for details). Products were pooled, a Tamra labelled size standard 
added, and aliquots of this were loaded into 36 well polyacrylamide ^Is m 373A Applied 
Biosystems Sequencers.
A laser scanned the gel during electropheresis, picking up the different fluorescent 
signals ftom the DNA fragments (fig.2.1). This method can distinguish fragments within 
1 base pair size difference. The gels were analysed u sin g  Genescan A nalys is™  and 
Genotyper™ to produce peaks representing the different alleles (fig.2.2). Although 
polymerase slippage occurs in th is method, resulting in stutter bands, the stutter peaks 
are not as tall as the true peaks, and interpretation of true peaks is generally 
straightforward. As a result, the problems that used to be encountered in interpreting 
autoradiographs with multiple bands have been overcome. Despite this, the labelling of 
peaks by the computer was always c o n firm ed  manually, as was inheritance. Global 
binning of alleles was performed using the GAS™ programme. Statistical sib pair 
analysis was performed using GAS™ initially, but then Sibpair™ and Mapmaker Sib™, 
as they were found to be more reliable programs (Young 1995) and (Davis and Weeks 
1997).
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230 232 234 236 238 240 242 244 246 248 250 252 254 256 258 260 262
17*29.1 -F ATHER 17 Green 29.1-F ATHER
-300
-200
-100
1240.58
18*29.2-MOTHER 18 Green 29.2-MOTHER
-100
-50
238.57 1246.62
19*29.3-DAUGHTER 19 Green 29.3-DAUGHTER
-200
-100
1246.62240.62
20 Green 29.4-SON20*29.4-SON
r200
-100
-50
238.60
m
Ft£. 2.2 AJlele peaks produced ly Genotyper^ for one microsatelUte marker on one nuclear family. 
Note that the father is homorg^us, so if is impossible to know néetherthe children are JBD or Just IBS 
for the 240 allele
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CHAPTER 3
3 s a m p l e  c o l l e c t i o n  a n d  c h a r a c t e r i s t i c s
3.1 SAMPLE COLLECTION
Samples for this thesis came from a number of different sources. In this chapter I
discuss some of the details behind the sample collection. Table 3.1 summarises the 
origins of the specimens used in different studies.
3.1.1 SAMPLE COLLECTION IN TAMIL NADU, SOUTH INDIA
India is the country with over half the world’s leprosy, with an estimated 680,000
cases in 1997 (WHO 1997). There are some excellent leprosy control programmes in 
place with experienced staff surveying large populations. We collaborated with two such 
programmes in Tamil Nadu, South India, with the help of Professor R.M. Pitchappan 
from Madurai Kamaraj University. The leprosy projects were in Kumbakonam and in 
Sakthi Nagar (fig 3.1).
KUMBAKONAM
Kumbakonam is a small market town firmed for its numerous temples. Over 90% of 
the population are rural, their main occupations being farming, silk weaving and 
labouring. Dr. T. Sitaraman and other members of the Lion’s Club established the 
leprosy project in Kumbakonam in 1981. The aim of the project has been to detect new 
cases of leposy at an early stage, and to monitor the prevalence and incidence of the 
disease since the introduction of multidrug therapy.
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Place Country Sib-Pairs
4-parents
Additional
Cases
Controls Collected
and
extracted
by:
Kumbakonam and 
Sakthi Nagar, 
Tamil Nadu
India 242 132 201 S.Me & K.B.
Vishakapatnam India 100 0 0 S.G. & team 
(minimal 
help from 
S.Me)
Bamako Mali,
West Africa
0 279 210 S.Mu & G.W 
(Co and Ex) 
S.Me (Ex)
Calcutta India 0 227 165 S.R.
Table 3.1 Details of samples collectedfor genome scnen and case control studies described in this thesis 
K.B. =K.Balakrishnan S.G.= Satish Ghei S.Me = Sarah Meisner
S.Mu = Stuart Mucklow S.R. = Suschismita Roy G.W. = Giles Warner
Co = collected by Ex = extracted by
65
T h e  G e n e t i c s  o f  S u s c e p t i b i l i t y  t o  L e p r o s y
P A K I S T A N
ICO 300 MILES
I M A C  
m D E S H
C H IN A
vr
/ ahunaczhal 
» F RADESt t i
T I B E T
S I KKI
U T >T W R B H U T A N
LANDRwJ A&T HwN
(^ANGLA ^^ MANi^ UR
I I T R I P UW E S TBENGAL
I Vishakapatnam
A R A B IAN 
SEA
BAY 
OF 
BENGAL
Sakthi Nagar
MMD CHERR’
T \
U  BURMA 
%
LAKBHti
D H EE F
Kumbakonam
I N D I A N f  S R I \|IANKAS| o c e a n
A N ['I» IA M
A N DHICCeSR:liLrtCt
Fig. 3.1 Map of India showing Kumbakonam, Sakthi Nagar and Vishakapatnam
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The headquarters are at the Hindu Mission Hospital in the town, but the 53 field 
workers go out to the villages and cover a population of more than 1.2 million in an area 
of 1892 square kilometres. There are three main administrative divisions each with a non­
medical supervisor (NM^. The areas are divided into between 12 and 17 subdivisions, a 
field worker with a basic training in the diagnosis of leprosy being allocated to each 
subdivision (Sitaraman 1997). AU school children are nvaminftd annually and the 
remainder of the population at least once every four years.
Whenever a field worker identifies a suspected case of leprosy, their non-medical 
supervisor (MMS) reviews the individual and their immediate family. If the NMS agrees 
with the diagnosis then any affected individuals are referred to the doctors, who hold 
clinics at local health centres and in Kumbakonam. If the NMS agrees with the diagnosis, 
the patient is referred to one of the mobile clinics where a doctor with specific training in 
leprosy makes a final decision on the diagnosis. AU cases confirmed by the doctors are 
treated as per WHO regime, 6 months of Rifunpidn and Dapsone for PB cases, and 2 
years of Rifampidn, Clofazimine and Dapsone for MB cases.
There is no monetary incentive for staff to diagnose cases. SpUt skin smears are taken 
on aU cases and a random selection of slides is checked annually at the Schiffiien Leprosy 
Research Centre at Karigiri and to GREMALTES in Madras. W.H.O. consultants visit 
once every foiir months. Patients are foUowed up during treatment and are referred to 
the Sacred Heart Leprosy Hospital in Kumbakonam if there are any complications. 
In i997, 532,359 individuals were screened for leprosy by the Hindu Mission Hospital 
staff. 621 of those screened had leprosy ^e. an annual rate of 1.17/1000 population
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F/ .^ 3.2 A  Bar Chart of the number of newfy diaffiosed cases per year in Kumbakonam since 1988
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Fig 3,3 A  Bar Chart of the number of nemfy diagnosed cases per 100,000 of the population examined 
per y  ear in Kumbakonam since 1988
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screene<^.88.7% of these cases were paudbacdllary. 63.6% were male. Only 1 of the 
7 Omultibacillary cases occurred in an individual under 15 years of age, whereas 71% of 
the p au d b ad lla iy  cases w ere in this age group. In addition to the new patients there are 
6423 patients currently under surveillance. Figures 3.2 and 3.3 show the distribution of 
new cases and new cases per 100,000 of the population in the surveillance area from 
1988 to 1997.
sa k th i NAGAR
Sakthi Nagar is a sugar factory in a rural area of Tamil Nadu about 20 miles from 
Erode. There is no town as such. The local population pursue similar professions to 
those in Kumbakonam, only a minority actually being directly employed by the factory. 
The factory managers established a hospital, and the Leprosy Project at Sakthi Nagar is 
an offshoot of this. Dr. N .K Shanker Narayan currently runs i t  The project is arranged 
in a similar way to that in Kumbakonam, with field-workers, non-medical supervisors 
and doctors. I have been unable to get up to date ruformation o u  the cuircut prevalence  
and incidence of leprosy in the area.
SAMPLE COLLECTION IN TAMIL NADU
I went on 2 field trips to India in order to collect samples for the genome screen. The 
first trç  took place from July to October 1995, the second from October 1996 to 
January 1997. Blood was collected ftom a total of 220 families consisting of 2 parents 
and at least 2 siblings, both of whom had a previous diagnosis of leprosy. There are also 
22 incomplete families. All famihes were ftom T amil Nadu in South India, 182 of the 
families being from the Kumbakonam region, the remainder from Sakthi Nagar.
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In addition to the families, I collected blood ftom a total of 201 controls matched for 
caste and, as frequently as possible, for area. The majority of the controls were 
neighbours of the families and none of them had any first-degree relatives with leprosy. 
Most were over 20 years of age. Finally, I collected blood from 100 patients with a past 
history of erythema nodosum leprosum (ENL), 44 lepromatous leprosy patients who had 
had no episodes of ENL over at least two years (referred to as ‘TX controls” in this 
thesis), and 16 patients who had suffered type 1 leprosy reactions. AU of these patients 
were under the care of Dr. S. Thomson at the Sacred Heart Leprosy Mission at 
Kumbakonam This hospital specialises in the care of leprosy patients from as far as 200 
miles away including any complicated cases detected by the Hindu Mission Hospital 
Details of the families coUected are shown in the tables 3.2 to 3.5.
In the vast majority of families blood was sampled firom a nuclear family comprising 
two affected siblings and their parents. In 11 families there were three affected siblings, 
and 1 family had 4 affected children (table 3.2). This latter family was the only one in 
which the individuals were not fuUy Tamil, the mother originating from Malaysia. Most 
of the siblings had been affected by tuberculoid leprosy, but in 13 families, one sibling 
had suffered from lepromatous leprosy. There were no families in which both siblings 
had had lepromatous leprosy (table 3.3). In 61 families one or other parent had been 
affected by leprosy at some stage, whilst both parents had been infected in 13 families 
(table 3.4). There is a large amount of consanguinuity in South TnHia^  cousin and uncle/ 
niece marriages being encouraged rather than stigmatised. Although 57% of the parents 
claimed to be unrelated, 20% of parents were first cousins and 7% uncle/ niece 
marriages (table 3.5).
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Sib paifs in Incomplete 
family/insuff­
icient DNA
2 siblings 3 siblings 4 siblings
No. of 
Families
33 201 11 1
Tabk 3.2 Breakdonm ofkproyfamilies coUectedfrom Tamil Nadu fir  sib-pair study
Case mix of 
families
Both sibs
paiicibacillaiy
leprosy
1 sib paucibacillaiy 
1 sib multibaciUaty
Both sibs 
multibaciUaty
No. of Families 221 13 0
Table 3.3 Breakdown of leprosy type observed in leproy affected sibpairsfrom Tamil Nadu (in families 
with just 2 affected siblings)
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Patents afiFected Neithet patent 
affected (or 
infotmation on 1 
patent only)
1 patent affected Both patents 
affected
No. of funilies 172 (70%) 61 (25%)
(26 mothers, 35 
fathers )
13 (5%)
Tabk 3.4 Ijprosy cases in parents offamikes with 2 or more affected siblingsfrom Tamil Nadu
Relationship of patents Percentage of Families
Untelated 57%
Distantly telated 11%
Fitst cousitis 20%
U ncle/Niece marriage 7%
Unknown 5%
Tabk 3.5 BilaUonshp of parents in families colkctedfrom Tamil Nadufor genome screen
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s a m p l e s  f o r  v is h a k a p a t n a m
100 sets of affected sib-pairs and their parents were collected by Dr. Satish Ghei and 
his team from the Japanese leprosy Mission Agra QALMA). The samples were collected 
in Vishakapatnam in Andhra Pradesh, South India. JALMA has strong links with 
GREMALTES, a large leprosy screening programme similar to those in Tamil Nadu. 
Vishakapatnam is a large port town, people living in relatively poor urban conditions, but 
not slums.
CALCUTTA LEPROSY SAMPLES
Dr. Suschismita Roy collected these sanq>les between 1992-1995 as part of her PhD 
at Cambridge. Cases and controls were recruited from the Leprosy clinic at the School of 
Tropical Medicine in Calcutta. The diagnosis was made by experienced physicians and 
reviewed by a panel of 3 leprologists following further investigations. Controls were 
blood donors from the Swasti Blood Bank in Calcutta. There were 121 patients with 
leptomatous lepiosy (median age 33 years) ^ d  107 with tuberculoid leprosy (median age 
30 years) plus 160 controls (median age 34 years). There were 6 women in the 
tuberculoid leprosy group and 10 in the lepromatous leprosy group, none amongst the 
controls. Cases and controls were well matched for ethnic group and caste.
3.1.2 AFRICAN LEPROSY SAMPLES
Africa is the continait with the second laigest lq>rosy problem after Asia with an
estimated 140,000 cases in 1997. Mali, in West Africa, had 1581 new and 3248 registered
cases of leprosy in 1997 (WHO 1997) (see Fig.3.4). The Institut Marchoux is the national
leprology centre for Mah and also the leprosy reference centre. In addition to leprosy the
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Fig.3.4 Map of Mali
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Institut also specialises in dermatology. It has a busy outpatient department as well as a 
30 bedded leprosy ward.
Samples were collected by Stuart Mucklow and Giles Warner with the co-operation 
of the Institut Marchoux in Mali. The cases recruited were out-patients, in-patients and 
ex-patients from the leprology unit Details were taken of age, sex, ethnic group, form 
and type of leprosy, stage of treatment and BCG status. Controls were recruited from 
those attending the phlebotomy department, staff members, unaffected family members 
of leprosy cases and non-leprosy patients attending the general medical or infectious 
diseases out-patient clinics at the Institut Marchoux. All controls were questioned and 
examined to exclude the possibility of them having leprosy.
The cases were of aU clinical types, about 2/3 being multibadllary, 3/4 of whom had 
polar lepromatous leprosy (tables 3.6 and 3.7). There was a higher proportion of men 
amongst the cases than the controls, and controls had a lower mean age than the cases. 
Just over 50% of the cases collected had experienced leprosy reactions at some stage, the 
large proportion reflecting the fact that samples were collected from a tertiary referral 
centre(Table 3.8). Over 70% of the reactions were type 2 in nature, the excess number 
mirroring the excess number of lepromatous cases. 55% of people with type 1 reactions 
had multibadllary leprosy, 45% paudbadllary again reflecting the skew in lepromatous 
cases collected.
Over 44% of the participants originated from around Bamako (Table 3.9). Cases 
were significantly under-represented amongst this group ^<0.001), which is not 
surprising given the nature of refeirds to this hospital, some leprosy patients travelling
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great distances for expert advice. The reverse pattern is seen in people from 
administrative districts V and VII ^<0.001). The four largest ethnic groups were the 
Bambara (40%), the Peulh/Foulah (20%), the Malinke (14%) and the Sarakoli (10%) 
(Table 3.10). There were an excess of cases compared to controls amongst the Bambara 
and the Peulh/Foulah (p=0.005), whereas in the other two groups the differences were 
less marked and were in the opposite direction.
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Leprosy Type No. of females No. of males Total No. 
samples
of Mean
Age(years)
MB 53(28.6% of MB 
cases)
132(71.4% 
MB cases)
of 185(66.3%
cases)
of 45.7
(s.d.14.4)
PB 31(33.0% of PB 
cases)
63(67.0% of PB 
cases)
94(33.7%
cases)
of 44.9
(s.d.14.9)
Total No. of 
Cases (MB+PB)
84(30.1% of 
cases)
195(69.9%
cases)
of 279 45.4
(s.d.14.6)
Controls 133(63.3% of 
controls)
77(36.7%
controls)
of 210 32.5
(s.d.13.0)
Table 3.6 Age, Sex and Case distribution of samples from Mah (MB — muMbaciUary, PB = 
paudbadllary lepro  ^cases)
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Leprosy Type No. of Cases
Indeterminate 2 (0.7%)
TT 46 (16.5%)
BT 49 (17.6%)
BB 5 (1.8%)
BL 46 (16.5%)
LL 131 (47.0%)
Tabk 3.7 Frequencies of different types of kprosy in casesfrom Mali
(IT = tuberculoid, BT = borderline tuberculoid, BB = borderline borderline,
BL = borderline lepromatous, LL = lepromatous leprosy)
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Reaction Type No. with reaction %MB %PB
No reaction 130 (46.6%) 42.3 57.7
Type 1 reaction 42 (15.1%) 54.8 45.2
Type 2 reaction 107 (38.4%) 100 0
Tabk 3.8 Frequtncy of kprosy reactions in kprosy patientsfrom Mali 
(MB = multibadllary, PB = paudbadllary)
80
T h e  G e n e t ic s  o f  Su s c e p t ib il it y  t o  L e p r o s y
Region* MB
(% of total 
cases & 
controls in 
the region)
PB
(% of total 
cases & 
controls in 
the region)
Total
Cases
(% of totaQ
Controls
(% of tota^
Total
(% of total)
I 27 (71'%) 11 (29%) 38 (14%) 26 (12%) 64 (13.1%)
II(Bamako/
Koulikoto)
64 (69%) 29 (31%) 93 (33%) 123 (59%) 216(44.2%)
III 12 (57%) 9 (43%) 21 (8%) 15 (7%) 36 (7.4%)
IV 30 (75%) 10 (25%) 40 (14%) 23 (11%) 63 (12.9%)
V 28 (57%) 21 (43%) 49 (18%) 8 (4%) 57 (11.7%)
VI 11 (61%) 7 (39%) 18 (6%) 11 (5%) 29 (5.9%)
v n 2 (40%) 3 (60%) 5 (2%) 0 5 (1.0%)
v n i 0 0 0 (0%) 1 (1%) 1 (0.2%)
Other West
African
countries
11 (73%) 4 (27%) 15 (5%) 3 (1%) 18 (3.7%)
Total 185 (66%) 94 (34%) 279 210 489
Tabk 3.9 Regnal distribution of cases and controls from MaU (MB =muüibacilla ,^ PB 
paucibacillar^ )
* The numbers refer to the administrative subdivisions of Mali
81
T h e  G e n e t i c s  o f  Su s c e p t ib il it y  t o  L e p r o s y
Ethnic Group MB (%
cases fui
ethnic
group)
PB (%
cases for
ethnic
group)
Total no. of 
Cases (% of
total cases 
for ethnic 
group)
Controls
(% of total 
cases for 
ethnic 
group)
Total
Bambara 79 (67%) 39 (33%) 118 (43%) 71 (35%) 189 (40%)
Bobo 1 1 2 1 3
Bozo/Somono 5 1 6 3 9
Dogon 7 2 9 2 11
Forgeron 1 0 1 3 4
Kassouke 2 1 3 2 5
Kissie 0 0 0 1 1
Malinke 16 (59%) 11 (41%) 27 (10%) 37 (18%) 64 (14%)
Minianka 0 0 0 5 5
Moor 3 0 3 1 4
Ouolof 1 0 1 1 2
Peulh/Foulah 36 (59%) 25 (41%) 61 (22%) 35 (17%) 96 (20%)
Sarakole 18 (72%) 7 (28%) 25 (9%) 24 (12%) 49 (10%)
Senoufo 0 1 1 5 6
Song/rhai 9 4 13 9 22
Sonike 3 0 3 0 3
Touareg 0 0 0 1 1
Total 181 (66%) 92 (34%) 273 201 474
Table 3.10 ’Ethnic gjvip distribution 
(MB = multibadllaty cases, PB =
of cases and controlsfrom Mali 
: paucibacillaiy cases)
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CHAPTER 4
4 GENOME SCREEN
4.1 INTRODUCTION
As discussed in chapter 1, it is clear that susceptibility to leprosy has a genetic
component (Fine 1981) and the evidence from segregation analyses points towards the 
possibility of a major gene effect (Abel and Demenais 1988). There are two main 
approaches to finding genes in complex diseases: linkage studies and association studies. 
Association studies are discussed in section 1.8.1. In the linkage approach the entire 
genome is systematically screened for linkage of major susceptibility loci to regularly 
spaced markers. It is an expensive and labour intensive method, but provided the 
markers are suitably spaced it will identify major genes. It has been used successfully in a 
number of complex disorders where there are several genes that interact with the 
environment e.g. types 1 and 2 diabetes and asthma (Davies et aL 1994), (Daniels et al 
1996). Because families are needed, there can be problems when studying diseases that 
have a late onset as parents will be unavailable. Identity by state methods can overcome 
this problem by making a number of assumptions.
The chronicity of leprosy and the fact that it hequently affects relatively young 
individuals makes it an ideal disease to study by this m ethod, especially com pared to  
most other infectious diseases. In this chapter I will discuss the genome wide search 
approach that we used to search for leprosy susceptibility ^nes.
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4.1.1 c o m p l e x  DISEASE
Any multifactoml disease that deviates from classical Mendelian rules is said to be
complex. This may be because there are several genes controlling that particular 
phenotype. Le. genetic heterogeneity, or there may be “phenocopies”, where a phenotype 
is produced by environmental rather than genetic causes. Interactions with other genes 
and with the environment may result in a given genotype producing a number of 
different phenotypes. Penetrance of a genetic disease ran vary for reasons not yet 
understood, or may be age or sex related as in the case of the BRCAl gene (Newman et 
aL 1998). In some cases several m utatiuus need  to  b e  inherited at a num ber of loci before  
a disease will manifest itself. Le. there is polygenic inheritance as occurs in some forms of 
Hirschsprung’s disease (Israel and Dunant 1998). Other complicating factors include a 
high frequency of disease causing alleles in the general population, imprinting, 
anticipation and mitochondrial inheritance (Lander and Shork 1994).
4.2 LINKAGE ANALYSIS
4.2.1 BACKGROUND TO LINKAGE ANAYSIS
The term “linkage” was first coined in the early years of this century. It refers to the
tendency of genes to be inherited together as a result of their close location on the same 
chromosome, thus deviating from the predictions of Mendel’s law of independent 
assortment The percentage recombination between two loci is a measure of the degree 
of linkage and, over short distances, can be rou^ily correlated with physical distance 
between the locL Linkage analysis involves proposing a model to explain the inheritance 
patterns observed in a pedigree. The objective of linkage analysis is to identify the map 
location of disease genes where the biochemical mechanism is unknown. Genes may be
84
T h e  G e n e t i c s  o f  Su s c e p t ib il it y  t o  L e p r o s y
detected despite genetic heterogeneity, incomplete penetrance, variable age of onset, and 
the presence of families with non-genetic causes. By identifying the gene and its 
molecular sequence, the biochemical mechanism may be determined, and cures for the 
disease established
Originally a paucity of markers hampered progress in genetic mapping, blood group 
antigens being one of the few polymorphic alleles that could be used. During the 1980’s 
methods became available to locate genes responsible for simple Mendelian genetic traits 
(Botstein et aL 1980). With the advent of dense genetic maps (Dib et aL 1996), 
automated sequencers, advanced computer software, and even robots, the possibility of 
dissecting the genetics of complex multifactorial diseases is now a reality. Genome 
screening was first used successfully in animal models e.g. NOD mice, but since then 
numerous studies have been performed on polygenic human diseases, such as diabetes 
(Davies et aL 1994) and asthma (Daniels et aL 1996).
Linkage studies can either be parametric or non-parametric. In the former a mode of 
inheritance is postulated and the theory tested using lod scores (see section 4.2.5). When 
the mode of inheritance is known this method is statistically efficient, gives an idea of the 
location of the gene and allows both linkage detection and exclusion. Non-parametric 
methods are a more appropriate method for linkage detection in complex diseases where 
the mode of inheritance is unknown. Maximum likelihood interval mapping is used to 
analyse markers spaced at 10-20cM intervals on affected relative pairs (Hauser et aL 
1996).
Factors that may disturb the usual inverse relationship between linkage 
disequilibrium and genetic distance include mutation, genetic drift, population admixture.
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genetic selection and variance of the sample. In addition, recombination events are more 
frequent in telomeric regions than elsewhere on the chromosome, and in certain genes 
e.g. human immunoglobulin genes there is a high recombination mte in somatic events, 
but not in meiosis (Watkins et aL 1994). Gene localisation by linkage methods is limited 
to an approximately l-2cM region since the number of meioses required to detect 
recombinants becomes very large as the distance becomes smaller.
Linkage disequilibrium is the non-random segregation of alleles linked to a locus. It 
relies on the fret that the closer two alleles are on a chromosome, the more likely they 
are to be inherited together. Descendants, who inherited a disease allele from an 
ancestor, are also likely to share the ancestral haplotype in the region of the disease locus. 
The size of this region depends upon the recombination rate and the age of the 
mutation. I linkage disequilibrium methods are useful in reducing the size of the region 
detected by linkage methods and have been used successfully in localising several genes 
e.g. the cystic fibrosis gene (Terwilliger 1995).
4.2.2 MICROSATELLITE MARKERS
Microsatellites are tandem repeats of nucleotides (most commonly (CA) repeats) that
are interspersed throughout the genome, and probably arose due to polymerase slippage
during evolution (Schlotterer and Tautz 1992). These markers are inherited in a
Mendelian fashion and are polymorphic with a relatively low mutation rate (Dib et aL
1996). Botstein suggested that a map of 150 markers that were sufficiently polymorphic,
with spacing of approximately 20cM, was adequate to detect linkage to any given locus
(Botstein et aL 1980). One su^ested screening method that could reduce the workload
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and expense of a genome screen is to only screen those markers in GC rich regions of 
the genome (Antonarakis 1994).
Various groups have worked on the production of sets of microsatellite markers that 
can be run in one gel lane concurrently, thus reducing the number of gels that need 
loading (Schwengel et al. 1994). Using fluorescently labelled markers it is possible to run 
large numbers of products in the same gel lane without producing overlapping bands. 
Markers are chosen based on their polymorphic information content (PIC), map 
position, and whether they amplify well on PGR and produce clear bands on the 
Genotyper™ programme.
4.2.3 RISK OF DEVELOPING DISEASE TO RELATIVES OF AN AFFECTED INDIVIDUAL 
The concept of Xr , the risk to a relative, R, of an affected individual compared to the
risk  in  th e  genera l p o p u la tio n , is a  u sefu l m easu re  o f  th e  genetic  risk  - th e  larger Xr, th e
greater the genetic effect (Risch 1990a). In insulin dependent diabetes, Xs, the risk to a
sibling, S, compared to the population, is 15, whereas in cystic fibrosis it is 500 (Davies et
aL 1994). Risch estimated the Xs in tuberculoid leprosy to be 2.38 (Risch 1987). When
genes are identified, the contribution of the gene to the Xs can be calculated, so that an
estimate of the number of major genes remaining can be made though the interaction of
the genes may be additive or multiplicative (Cordell and Todd 1995).
4.2.4 IBD VS IBS
Any two copies of an allele A at a locus are said to be identical by state (IBS). 
However, they are only identical by descent (IBD) if they are both inherited firom a 
common ancestor. Two alleles that are EBD are also IBS, but the converse does not
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necessarily follow. It has been argued that provided a marker is sufficiently polymorphic, 
IBS status will approximate to IBD status (Weeks and Lange 1988).
4.2.5 LOD SCORES
The lod score is the “logarithm of the odds” ratio of having the observed result at a 
given recombination fiaction, 0 (where O<0<O.5), compared to the result eq>ected if the 
null hypothesis were true. It represents a measure of the evidence for linkage versus the 
absence of linkage. By convention in classical parametric linkage studies, a lod score of 
more than 3 is taken as being highly suggestive of linkage, which corresponds to an odds 
ratio of 1000:1. There has been a great deal of discussion over the appropriate threshold 
that should be applied to genome screens. The main problem is that every case will differ 
in terms of the genetic model, the markers screened and their heterozygosity and 
informativeness (Lander and K ru^ak  1995). It has been su^^ ted  that simulation 
models be performed to calculate appropriate thresholds (Lander and Shork 1994).
To calculate the expected  lo d  score o n e  needs to know aU the possible phenotypic 
constellations for that family type and their probability of occurrence. At a given 
recombination firaction, 6, the expected lod score is the weighted average of the Zi(6) 
over all possible outcomes, where zi is the probability of an affected sib-pair sharing i 
alleles identical by descent The m axim um  lod score (ML^ is firequendy quoted and 
represents the maximum score reached after varying die parameters, e.g. 0, allele 
frequencies, penetrance and phenotypic variance.
4.2.6 THE POSSIBLE SHARING TRIANGLE
When multiple calculations of the lod score are performed at different recombination
fractions, implausible results may occur if the possible sharing triangle is not taken into
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account The following restrictions have been found to hold:
21 > 0
20 +  Zl +  22 =  1
21 = 2zo
This leads to a triangle bound by zo = 0, zi =0.5, and zi =2zo. When this method is 
applied, the MLS is the m axim um  lod score satisfying the above conditions (H olm ans 
1993).
4.2.7 EXCLUSION MAPPING
Exclusion mapping is a parametric method used to identify chromosomal r^ o n s
that are unlikely to be linked to a disease. Lod scores are calculated as a function of 6 and
X, such that areas of the genome producing a sufficiently low lod score can be excluded
from containing the gene of interest at the specified value of X. Assumptions have to be
made concerning the mode of inheritance, the number of disease lod and/or the X«
(Hauser et al. 1996). Lod scores of - 2 are g^erally taken to mean that that particular
region has been exduded from linkage. This is probably the most powerful application of
multilocus mapping (Edwards 1987).
4.3 AFFECTED SIB-PAIR METHOD
The affected sib-pair method is a non-parametric method of linkage analysis. It
requires no prior assumptions as to the mode of inheritance, making it more robust than 
parametric methods. If the disease model is known correcdy then parametric methods 
are more powerful, but if not, the sib-pair method is useful as it is less susceptible to 
modelling errors. It has greatest power when the disease is recessive. By focusing only on
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affected children, problems of incomplete penetrance are circumvented and the need to 
control for environmental frctors is eliminated. Complex diseases with g^etic and 
aetiological heterogeneity and polygenic inheritance can be studied. An advantage over 
other types of linkage study is that nuclear families are ^nerally easier to collect than 
large multiplex families. They are also more likely to represent the common form of the 
disease or trait
In the affected sib-pair method one is testing for cosegregation of a marker allele 
with a disease-predisposing allele. Given traditional Mendelian rules of inheritance, 2 
affected siblings have a 25% chance of sharing 2 alleles ibd at a particular locus, a 50% 
chance of sharing 1 allele ibd, and a 25% chance of sharing neither allele (see fig.4.1), 
thus the expected 2:1:0 sharing ratio is 1:2:1. An alternative way of looking at this is to
AB CD
AC AC - both alleles shared
AD -1 allele shared 
BC - 1 allele shared 
BD - no alleles shared
Ft£.4.1 Sharing of alieles in nhUngs
consider the inheritance of alleles from one parent. Le. 1:0 sharing. Randomly selected 
siblings have a 50% chance of sharing an allele ibd. If siblings are selected that both 
suffer from the same genetically determined disease, there is a high probability that they 
will share the segment of chromosome that carries the disease susceptibility gene. As a
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result of this, the percentage sharing of closely linked marker alleles will be greater than 
expected (Ott 1991).
Two or more siblings affected by a disease are typed for polymorphic markers such 
as microsatellite markers. If thek parents are also typed, the interpretation of whether 
alleles are ibd or ibs is much easier and cases of non-patemity can be recognised and 
excluded. The percentage sharing of alleles identical by descent in a number of siblings is 
compared with that predicted by random segregation, the null hypothesis being that a 
given marker is unlinked to disease. The results are analysed by a Chi-squared test, 
comparing the number of shared alleles to the number that would be expected if the null 
hypothesis were true. A p-value of less than 0.05 is taken as an indicator of possible 
linkage. Lod scores can also be calculated. In the case of microsatellite markers, where 
perhaps 300 analyses are performed per family, a p-value of 0.05 is likely to occur 15 
times by chance alone. One way of allowing for this is to divide the p-value by the 
nmnber of tests to be performed or apply a correction, which allows for multiple testing 
e.g. the Bonferroni correction:
ai =  1-(1- an)^/“
where ai is the significance level for each individual test and On is the overall significance 
level after n tests e.g. for a significance level of 0.05 over 300 tests, ai is 1.7x10^ (Weeks 
et aL 1997). This correction assumes that the tests are mutually independent If too low a 
significance level is chosen then a type II error may occur. An alternative approach is to 
perform the genome screen in two stages. In the first stage all the markers at the chosen 
spacing are examined. Those markers that appear to be linked in the first round are re­
examined in a second screen on a further set of families. Once linkages have been
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confirmed, fine mapping can be performed or candidate genes in the region can be 
investigated using case control studies.
Unfortunately, not all meioses are informative even when both parents are available 
for typing. In the case of intercross parents who are both heterozygous for the same 
alleles, it is inq)ossible to tell whether two children with the genotype AB share 0,1 or 2 
alleles identical by descent A similar scenario occurs in the case of a parent being 
homozygous at a locus (fig. 4.2). Multi point methods of analysis, e.g. Mapmaker Sibs™, 
use information firom nearby markers to estimate the sharing in cases such as these.
AB AB
AA AB AB BB
AA BC
AB AC AB AC
Fig. 4.2 Pedignes demonstrating ambigdty seen during inUrvross matings and in cases of homov^ÿisity 
in one of the parents
If the parents are unavailable, other family members can be used to increase the 
power. However, typing both parents is more informative than having one parent, which 
is more informative than having additional siblings. Risch found that the type of relative- 
pair best suited for a particular linkage study was dependent on the X.r, 0, and
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polymorphic information content (PIC) of the markers. For large values of A,r  and PIC, 
he found it worthwhile typing more distant relative pairs, whereas, in cases where the A,r 
was small and the PIC less than 0.7, siblings were preferred (Risch 1990b). Hauser 
suggested using affected sibling pairs without their parents in initial screening. Although 
less information is available and assumptions are made in calculating maximum 
likelihoods, twice as many pairs can be typed for the same amount of lab work. This 
increase in information may lead to increases in the lod score of between 17-46% as well 
as decreasing the workload and expenditure of the genome screen (Hauser et aL 1996).
The power of a test is the probability of rejecting the null hypothesis when the null 
hypothesis is false. In linkage studies this depends upon the recombination fraction, the 
amount of data available, the spacing of the markers, and the X, value for that locus. In 
most cases the values for 0 and X will be unknown. Brown et aL suggested that 20cM 
intervals were a good compromise between power and workload in initial screens 
(Brown et aL 1994). On further screening higher density mapping can be performed on 
selected regions. Based on simulation studies, if 96 sib-pairs are investigated using 
microsateUite markers at 20 cM intervals, there is a 99.9% chance of detecting a lod score 
of 2.3 or more for a locus where the Xg is 2.5 (Davies et al. 1994). Various formulae are 
available to calculate the number of families required to detect a significant linkage 
(Elandt Johnson 1971).
4.3.1 ADJUSTMENTS FOR FAMILIES WITH MULTIPLE AFFECTED SIBLINGS
In cases where there are more than 2 affected siblings from one fam ily the number of
sibling pairs cannot simply be calculated from {(n-1) + (n-2) + (n-3) + .....0}, as might
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be expected, because the pairs are not mutually independent of one another (Hodge 
1984). Knowledge of the allele sharing of two pairs of siblings in a family with 3 affected 
siblings, frequently allows deduction of the sharing in the thitd pair. In order to 
overcome this, a weighting function may be incorporated (Suarez and Van Eerdewegh 
1984). Different computer programs use different methods. The GAS™ programme 
incorporates Hodge weighting:
W=4(2n-3+ri/2W l
3n(n-l)
Other programmes, such as Sibpair™ and Mapmaker Sibs™, treat each set of 
siblings independently.
4.3.2 ANALYSIS OF AFFECTED SIB-PAIR METHODS
Numerous programs are now available for the analysis of affected sib-pair (ASP)
studies. Although they are aU essentially based on looking at whether ASPs share more
than the expected 50% of their alleles at a disease susceptibility locus, they apply many
methods. Some look at IBS sharing rather than EBD sharing. The power of the test
depends not only on this aspect, but also on the true mode of inheritance, whether
single- or multipoint analysis is used, how many parents are typed, and various correction
factors that are incorporated (Davis and Weeks 1997). A lot of the programmes use the
maximised lod score method, some applying Holman’s method of “maximising within
the possible tnangle” in order to eliminate implausible results. Different programmes
deal with greater than two affected siblings in different ways. Some use a weighting
function, whilst others allow the user to select whether just one pair is used, one sibling is
94
T h e  G e n e t ic s  o f  Su s c e p t ib il it y  t o  L e p r o s y  
chosen and paired with all other affected siblings in turn, or all possible pairs are used.
Analysis can be performed in two main ways: single-point or multi-point analysis. 
In the former, one marker is analysed at a time. Because of recombination effects, the 
further away the marker is from the gene, the less likelihood there is of detecting linkage. 
As a result some degree of misclassification ran occur. In multi point analysis, because 
several markers are investigated at once, recombination events can be compensated for. 
Multipoint methods allow exclusion mapping to be performed in addition to maximum- 
likelihood mapping (Kruglyak and Lander 1995).
GAS™
GAS™ is a single-point method of linkage analysis. It only analyses families in which 
data are available from both sets of parents. Hodge weighting is applied to families with 
multiple affected siblings and H olman’s maximum sharing triangle is applied in 
calculating the maximum lod scores. A two-sided chi-squared test is used to detect 
deviations from the expected 2:1:0 ibd allele sharing of affected sib-pairs. This decreases 
the power of this method compared to a lot of other methods. A one sided binomial test 
is used for looking at 1:0 sharing. When simulation studies were performed by Davis and 
Weeks, GAS™ was found to hâve a false positive rate of more than 6% (Davis and 
Weeks 1997).
THE SIBPAIR™ PROGRAM
This program can be used to estimate ibd allele sharing based on population allele
frequencies. It uses a likelihood based test that calculates the lod score for nuclear
families by assuming that the parents are heterozygous at the disease predisposing allele
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and that affected sibs are homozygous (Knapp et al 1994). It treats affected siblings 
independently e.g.trios are treated as two sib-pairs, and sib quads as 3 sib-pairs. The 
average number of shared and unshared alleles is computed for each sibling and a given 
proband. The average is calculated from the results of all sibs that could be considered 
probands. If a parental genotype is unavailable, the program computes the likelihood of 
each possible genotype for the untyped parents, and calculates the number of alleles 
shared identical by descent in the. affected siblings as an average of all the possible 
parental genotypes. Data from homozygous parents is omitted. A chi-squared test is then 
performed on the number of sib-pairs sharing 2 alleles ibd with the number sharing 0 
alleles ibd (Trust 1996). This method was used successfully by Julier et al in defining the 
insulin IGF2 region (fulier et al 1991).
MAPMAKER-SmS
This is a multi point method of fnaximnm-likelihnnd mapping. Information is used 
from aU available siblings and parents to infer the IBD distribution at each point along 
the genome. This means that additional power is gained from analysing the same number 
of famdies as single-point analysis. The method is particularly useful in cases where 
families are incomplete. The programme can analyse multiply affected siblings in 
different ways. Holman’s possible triangje method is applied during MLS calculation 
(Holmans 1993). The program can be used to give mavimnm-likp.lihood data in 
qualitative traits, exclusion maps, quantitative trait mapping and information content 
mapping (Kruglyak and lender 1995).
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4.4 RESULTS
The genome screen was performed in two stages. In the first instance 92 families 
firom South India were screened for 293 markers, of which 14 failed to amplify. The 
markers had a mean sex-averaged interval of ll.TcM (range 0.2-40.2). 39 markers had 
intervals greater than 20cM. The overall length covered was 3415cM. A second screen 
was performed on aU markers firom the first round that showed p-values or maximum 
likelihood estimates that were su^estive of possible linkage, in the hope of replicating 
any true linkages.
Evidence for linkage was evaluated in two ways — a chi-squared statistic was 
calculated by comparing the observed and expected allele sharing identical by descent 
and two-point linkage methods were used to calculate maximum likelihood estimates of 
the odds ratio. Initially GAS™ was used in the analysis, but due to the discovery that it 
had been found to be unreliable, we changed to Sib-Pair™ during the second round of 
the analysis, re-analysing all previous data at that point (Davis and Weeks 1997). 
Multipoint analysis was also performed using hfrpmaker Sib™ for all the first round 
results.
Ninety-six nuclear families firom South India were used in the second round. They 
were screened for markers where the MLS was greater than 1 or the p value less than 
0.10 on Sib-Pair™ (or on GAS™ in cases where Sib-Pair™ analysis had not yet been 
performecQ. Ruby Siddiqui and Karen Young screened the families firom Vishakapamam 
using markers in which the lod scores in both the first and second rounds had been 
greater than 1. They also screened flanking markers around D10S197 and D2S125.
The results of the first round genome screen on the South Indian families are shown 
in full in the appendix. Table 4.1 summarises the results of GAS™ and Sib-Fair™
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!•* round 2°  ^round
Marker p-value Lod score MMS score p-value Lod score
D1S229 0.041 0.653 0.525 0.5 0
D2S165 0.0009 2.103 1.279 0.274 0.079
IL-la 0.007 1.29 0.937 0.5 0
D2S125 0.028 0.788 1.217 0.155 0.224
D3S1279 0.028 0.793 1.306 0.39 0.017
D4S1565 0.051 0.581 0.633 0.069 0.476
D5S422 0.024 0.845 0.787 0.29 0.77
D5S408 0.03 0.766 0.864 0.5 0
D6S273 0.046 0.618 0.075 0.013 1.064
ESR 0.019 0.939 0.698 Failed
amplification
Failed
amplification
D7S692 0.025 0.837 1.233 Failed
amplification
Failed
amplification
CFTR 0.001 1.937 0.059 0.5 0
D7S550 0.01 1.197 0.757 0.3 0.06
D8S286 0.01 1.161 0.654 0.5 0
D8S257 0.046 0.619 0.787 0.357 0.029
D8S556 0.014 1.041 0.535 0.331 0.04
D9S257 0.007 1.319 1.124 0.5 0
D9S176 0.053 0.562 1.094 0.104 0.343
Tabk 4.1 Results from 1^  and 2nd rounds of the ^nome screen in Tamil Nadu analysed by Sib- 
P«r™ (chromosomes 1-9)
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round 2nd round
Marker p-value Lod score MMS score p-value Lod score
D10S197* 0.127 0.283 0.073 0.008 1.244
D12S43 0.016 0.992 1.215 0.5 0
D12S95 0.037 0.689 1.468 0.5 0
D12S366 0.037 0.692 0.461 0.354 0.03
D13S153 0.021 0.897 1.447 0.497 0
D15S117 0.048 0.601 0.49 0.06 0.525
D16S515 0.05 0.576 0.414 0.5 0
D16S516 0.007 1.312 1.98 0.5 0
D16S289 0.016 0.992 2.34 0.5 0
D16S422 0.004 1.541 1.357 0.5 0
HOX2B 0.017 0.985 0 0.099 0.361
DXS451 0.05 0.586 0.171 0.389 0.017
^repeated before sib-pair analysis complétée based on GAS result of p==0.091
and maximum lod score = 0.4
Tabk 4.1 (continued) Results from 1^  and 2nd rounds of the ^ mme screen in Tamil Nadu analysed ly 
Sib-Pair™ (chromosomes 10-X)
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analysis on first rounds markers that were rescreened in the second round, and Fig. 4.3 
shows two maps produced by Mapmaker Sibs™ on the results firom chromosomes 2 and 
10. There was n o  evidence o f  a tuajor gene, but the results that stood  out as particularly 
interesting were three consecutive markers on chromosome 16, where the lod score for 
one of the markers reached 2.34.
No markers stood out in the second screen, although 2 markers, D6S273 and 
D10S197, had lod scores over 1. Table 4.2 shows the combined results of the first two 
rounds of the South Indian study. The chromosome 16 results were now completely 
insignificant apart firom Mapmaker Sib™ analysis on D16S289 (lod score 1.419). The 
markers that now stood out were D2S165 (lod score of 1.47 by Sib Pair™), D6S273 (lod 
score of 1.75 by Sib Pair™), D10S197 (lod score of 1.25 by Sib Pair™) and HOX2B on 
chromosome 17 (1.39 by Sib Pair™). None of these scores are very remarkable even 
after multipoint analysis, but may point to the presence of m inor genes.
Table 4.3 shows the combined results of the South Indian screens with the 
Vishakapatnam study, which have recently become available (Ruby Siddiqui — personal 
communication). Flanking markers were used for D2S125 and D10S197. Mapmaker Sib 
analysis™ produced a lod score of 3.006 with D10S197. It is unlikely to represent a 
major gene effect since it required analysis of 288 families to see much of an effect (over 
316 alleles were available for analysis after allowing for non paternities and 
homozygous/intercross families). However, it stiU represents a very exciting result- 
espedally in view of a nearby candidate gene (see below).
4.4.1 OTHER COMMENTS ON THE SCREEN
There were 15 families in which non-parentage was present in the first round. These
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Fig.4.3 Mapmaker Sib™ Mcps of Chromâmes 2 and 10 results from the first round screen in Tamil 
Nadu
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Marker p-value Lod score
D2S165 0.005 1.47
D2S125 0.016 1.0
D4S1565 0.016 1.0
D6S273 0.002 1.75
D7S692* 0.025 0.84
D7S550 0.023 0.87
D9S176 0.019 0.93
D10S197 0.008 1.25
D15S117 0.022 0.87
HOX2B 0.006 1.39
* Failed amplification in round 2
Tabk 4.2 Combined Sib Pair™ Results of Rounds 1 and 2 of Genome Screen in Tamil Nadu uéere 
the results show one or more score of interest (courte  ^of R.Stddtqui)
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M arket p-value Lod score MMS
D2S165 0.011 1.14 0.609
D2S125 0.007 1.323 0.929
D4S1565 0.145 0.243 0.284
D6S273 0.079 0.939 0.671
D7S530 0.039 0.671 0.558
D10S1653 0.0004 2.44 1.646
D10S548 0.002 1.927 2.519
D10S197 0.002 1.87 3.006
HOX2B 0.006 1.392 0
Table 4.3 Combined Results of Genome Screen in South India (Tamil Nadu and Vishah^atnam) 
(courte  ^of R.Siddiqui)
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families were all replaced. In the second round 14 fiimilies were identified with non­
parentage. These fiunilies were excluded firom the final analysis. The overall non­
paternity rate in this population was 15.3%, corresponding well with previous data in 
South India (Fine et aL 1979). The rate was significandy higher in the families firom 
Vishakapatnam at 32% (R. Siddiqui — personal communication). There is a large degree 
of consanguinuity in South India (see table 3.4). As a result of this, the number of 
families that were informative was decreased. Intercross parents and cases of 
homozygosity were firequent, causing, on average, a 25% reduction in information.
4.4.2 POTENTIAL CANDIDATE GENES FOR FURTHER INVESTIGATION
The reason for performing a genome-wide search was to identify regions that
may be linked to disease susceptibility genes. We did not find any evidence for major
leprosy susceptibilty genes in this screen, although the recent result obtained by Ruby
Siddiqui using the families from Vishakapatnam is very exciting. It may be that there is a
gene of moderate effect in the region of D10S197. However, the finding o f a number of
low p-values and lod scores above 1 after combining the first and second screen round
results, some of these being further reinforced by the results in Vishakapatnam, may
indicate the presence of some minor genes in the vicinity of these markers.
There are two main approaches to identifying genes. These are fine mapping, 
including chromosome walking and jumping, and the identification of candidate genes 
followed by case-control studies. Fine mapping is a very e:q>ensive and labour intensive 
procedure, and therefore only worthwhile in cases where there is a strong su^estion of 
linkage and no candidate genes are available. Only a small percentage of the estimated
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65-80,000 genes in the human genome have been identified (Strachan and Read 1996). 
Despite this, there are frequently a large number of candidate genes in any given region. 
Best guess policies based on knowledge of the function of the given g ^e , together with 
information of currently identified polymorphisms are used to choose whether any of 
these are worth pursuing. Below I have outlined a few potential candidate genes that may 
be worth pursuing further based upon the results of our genome screen on leprosy. 
Table 4.4 summarises these.
CHROMOSOME 2
There are a number of candidate genes in the vicinity of D2S165 that may play a role 
in influencing susceptibility to infection. The T-lymphocyte activation gene on 2pl2 
encodes a protein that is expressed in T lymphocytes, the liver and mature neurons (Arai 
et aL 1992). It is related to the dual function ecotropic retrovirus receptor/cationic amino 
add transporter (CATl). The lymphocyte isoform, CAT2p, is a Na"*" independent basic 
amino add transporter with a relatively high affinity for arginine (Kavanaugh et al. 1994). 
The increased uptake of arginine may be related to its role as a precursor of nitric oxide, 
an important intermediary in mycobacterial killing.
Some other candidate genes of interest indude Catenin (cadherin associated protein). 
Calmodulin and the Ig kappa light chain gene duster. Catenin is a peripheral cytoplasmic 
protein that mediates the connection of cadherin to the actin filament network (Kemler 
1993). (See Chromosome 16 candidate genes for further details). It is possible thalt 
variations in this connection could affect phagocytic properties of the celL Calmodulin is 
involved in the regulation of nitric oxide biosynthesis, so a polymorphism in this gene
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Marker Position Nearby candidate genes (Name 
and position)
D2S165 2pl2
43.081Mb
T-lymphocyte activation gene, Catenin 
(CAP-R 97.5+/-13.3), Cahnodulin 
(CALMl), Ig kappa %bt chain gene 
cluster
D2S125 2q37
253.365Mb
NRAMPl (231.3+/-4.2Mb)
D6S273 6p21-22
37.344Mb
MHC (e.g. HLA-DMB 37.805Mb), 
TNF (37.805Mb), numerous others
D10S197 10pl3
20.312Mb
Macrophage Mannose Receptor 
(MRCl 25.9 +Z-3.5)
D16S516 16q22-24
92.615Mb
Cadherin (CDH13 96.1-97.8)
D16S289 16q22-24
94.067Mb
Cadherin (CDH13 96.1-97.8)
HOX2B 17q21-22
50.200Mb
Nerve Growth Factor Receptor 
(NGFR 53.9+Z-5.3)
Tabk 4.4 Candidate ÿnes of markers ideni^d from the lepro  ^genome screen that might be worth 
pursuingjurther
(Positions obtained using http:jjgdhwww.gdh.org and httpijjcedar.^ eücs.soton.ac.uklpuhtic- 
htmlf)
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could well influence host defence against mycobacteria (Bredt and Snyder 1990).
Variations in the Ig kappa light rhain would probably influence humoral immune 
responses rather than cellular ones, but could still play a crucial role in the control of 
infections.
Candidate genes in the vicinity of D2S125 include NRAMPl, which is dicussed 
further in chapter 6.
CHROMOSOME 6
D6S273 is right in the middle of the Major Histocompatibility Complex, close to 
numerous potential candidate genes including the Tumour Necrosis Factor gene 
(discussed in chapter 5).
CHROMOSOME 10
The candidate gene that stands out in the vicinity of D10S197 is the human 
macrophage mannose receptor. This is a C-type lectin involved in the recognition and 
binding of high mannose structures present on the surface of potentially pathogenic 
organisms. The receptors are present on macrophages and on the endothelial cells of the 
hver. They have been found to mediate phagocytosis of mycobacteria following 
recognition of Upoambinomannam on the cell surface (Kang and Schlesinger 1998). 
Interestingly, the receptor is upregulated by EL-4 and EL-13, which might explain the 
association of multibacdllary leprosy with a Th2 response (DeFife 1997). No 
polymorphisms have been identified to date.
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CHROMOSOME 16
Cadherin is a very strong candidate gene in the region of D16S516 and D16S289. 
The cadherins are a family of cell-cell adhesion molecules involved in calcium dependent 
intercellular interactions. Classically they comprise N-, R-, M-, P-, and E-cadherin, 
present in nervous, retinal and nervous, skeletal muscle, placenta and epithelial tissues, 
respectively. They are glycoproteins with highly conserved cytoplasmic domains, a 
transmembrane r^ o n  and an extracellular domain involved in homophilic calcium 
dependent adhesion. Recently it has been shown that E-cadherin is the receptor for 
intemalin, the surfrce protein used by T.igterift monocytog^es to ^ in  entry into 
epithelial cells (Mengaud et aL 1996). H- (heart) and T- (truncated) cadherin are present 
on 16q24, near to D16S516. T-cadherin is present on many tissues including many 
neuronal cells, frequently in dose association with N-cadherin. To date the only 
polymorhisms known in cadherin genes are in E-cadherin on 16q22.1. They affect 
codons 115, 133, 582 and 2797. The latter has a relatively high frequency and is situated 
54 nudeotides downstream of the TAG stop codon (Becker et aL 1995).
CHROMOSOME 17
HOX2B, a homeobox gene, is located near to the Nerve Growth Factor Receptor. 
This is a potential candidate gene in view of the neurotropism of M. kpnu. It is possible 
that the bacteria enter the Schwann cells using this receptor.
4.5 CONCLUSION
In condusion, no major susceptibility gene for leprosy has been identified in this 
population from South India. A study of this size, in which all the genotypes are
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informative, has a power of 99.9%, so the chance that we have missed a major gene is 
very small (Davies et aL 1994). It could be that there is a major gene causing 
susceptibility to lepromatous leprosy that we have missed since the vast majority of the 
cases we studied had tuberculoid leprosy. Alternatively, it may be that, despite the 
findings in segregation analyses, there is no major leprosy susceptibility gene. Instead, 
several minor genes may be controlling susceptibility, which may be detectable using 
association studies. In leprosy the X, has been calculated as 2.38 (Risch 1987). Some of 
this effect is already known to be due to the MHC, which does not leave a tremendous 
amount of room for a major gene. In fiict it seems unlikely that the X, of any infectious 
disease is going to be large. Hence, it nmy be that in future genome screens for infectious 
diseases may prove more useful as a means of identifying potential candidate genes 
rather than major genes.
The recent finding of a lod score of 3.006 at D10S197 when the results of 288 
families were merged and extza markers mapped suggests the possibility of a gene of 
moderate effect in this area (R.Siddiqui — personal communication). These results are 
particularly exciting in view of the presence of the macrophage mannose receptor in the 
close vicinity of this microsatellite. Case control studies will be performed if a 
polymorphism is identified in the gene or its promoter region. Transmission 
disequilibrium studies are also planned.
Richard Bellamy has recently completed a tuberculosis genome screen on sputum 
positive individuals fcom the Gambia and South Afdca (R. Bellamy — personal 
communication). Since both tuberculosis and leprosy are caused by mycobacteria that 
require intracellular growth, one might have expected the two studies to identify identical
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regions. Both screens were of similar sizes in terms of the number of sib-pairs and 
microsatellites studied. Neither identified a major gene, or evidence of strong linkage to 
the MHC. lu the TB study the regions identified with a potential minor effect were on 
chromosomes Xq and 15p. The former region had already been identified as an area of 
potential interest in leprosy in view of the raised male to female ratio of disease and an 
excess of red-green colour-blind individuals amongst leprosy patients (Shwe 1992). We 
found no evidence for linkage to either of the regions identified in the TB screen.
Some problems associated with genome screens may have affected our results to a 
degree. Genetic heterogeneity can cause problems in linkage studies. We made sure that 
all our patients were firom one region. Although they were of the same ethnic group 
(apart firom one family who were half Tamil and half Malay), there is evidence that caste 
group is a strong determinant of genetic profile (Pitchappan et aL 1997). Over 25% of 
our families were of the Padaychi caste groiq), but most were firom diverse groiq>s, so it 
is possible that we have missed a gene due to heterogeneity.
Infectious diseases can pose a special problem in this type of study. Not aU 
genotypically susceptible people will get disease. This incomplete penetrance is mainly 
due to lack of exposure, and the affected sib-pair method circumvents this by only 
including affected individuals. A large infecting dose in an individual may be sufficient to 
overcome host defences as may be seen in tuberculosis. Temporary immunosuppression^ 
due to factors such as famine, may allow individuals without the susceptibility gene to be 
included. This can result in a decrease in the power of the study. Another factor that is 
difficult to control for is environmental exposure to other mycobacteria, which may
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affect both susceptiblity and phenotype.
Because of these problems, and the fact that different genes may be playing a role in 
different ethnic groups, there are plans to repeat the genome screen in other populations. 
Sample collection from sibling pairs and their parents is well underway in a population 
fcom Malawi It will be interesting to see whether the findings with D10S197 are 
repeatable. This population wiU also be of interest as there are a greater proportion of 
multibadUary cases than in India. In due course new approaches to gene identification 
will become available that will make the process of searching for susceptibility genes a 
great deal more powerful, and may make sample collection more straightforward (Risch 
and Merikangas 1996).
Above I have discussed some candidate genes that might be worth investigating 
further based on the results of the genome screen. The association of late onset 
Alzheimer’s disease with ApoE4 provides an example of how evidence for linkage on 
family studies may be very weak, but allelic association may be very marked (Liu et aL 
1996). In the following two chapters I will discuss a few candidate genes that I looked at 
prior to the completion of the genome screen. These were chosen on the basis of 
knowledge of their function.
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CHAPTER 5
5 CANDIDATE GENE STUDIES PART l:CYTOKINES
5.1 INTRODUCTION
Cytokines ate soluble molecules that can be thought of as the hormones of the
immune system, the pattern of cytokine production determining the subsequent immune
response. Their production is aimed at protecting the host ftom toxic inflammatory
agents and microbial invasion, but at times there is overproduction of one type of
cytokine which may tip the balance in such a way that immunopathology is produced.
Cytokines are secreted by lymphocytes, monocytes and macrophages. They have
pleiotropic effects and act in both a paracrine and an autocrine fashion. Many of the
cytokine genes have now been identified and their actions clarified. Genetic differences
in the promoter sequences of cytokine genes may alter the binding of regulatory factors
and hence affect the level of transcription of cytokines (Jain et aL 1995). An example of
this is clearly demonstrated by woth on polymorphisms of tumour necrosis factor in
malaria (McGuire et al. 1994).
Leprosy has a diverse rliniral and immunnlngical spectrum with a number of 
complications that may be attributable to variations in cytokine production (see 1.5.1). 
The Thl/Th2 tespuusc plays a major role in determining the outcome of infection with 
M. leprae. Although a Thl response appears to protect the individual ftom widespread 
bacterial dissemination, the same response ran result in tissue damage causing both skin 
and nerve pathology. A Th2 type response allows bacterial growth to occur leading to
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lepromatous leprosy. Thl cells downregulate Th2 cells and vice versa, which tends to 
polarise the final response (Powtie 1993). In tuberculoid patients, interferon-y, 
interleukin-2, TNF and interleukin-12 predominate, whilst interleukins-4, 5, 6,10 and 13 
are seen in lepromatous leprosy patients (Ottenhoff 1994), (Yamamura et aL 1992) and 
(Misra et aL 1995). In Type 1 leprosy reactions there tends to be a predominantly Thl 
response. Despite the fiict that Type 2 leprosy reactions onfy occur in people with 
lepromatous or borderline lepromatous disease, it appears that during the acute phase of 
the reaction, Thl responses predominate (Rao and Rao 1987).
I have looked at three polymorphic cytokines to see if they are involved in 
determining the clinical manifestations of the disease. The cytokines studied were 
interleukin-4 (IL-4), interleukin-10 (EL-10) and tumour necrosis factor (INF). In the 
remainder of this chapter I will discuss the characteristics of these cytokines, their 
association with various diseases, and the results of case control studies performed on 
them using samples firom patients firom India and Mali Table 5.1 briefly summarises the 
candidate genes described in this chapter and Chapter 6, and Table 5.2 summarises the 
samples used in each study.
5.2 INTERLEUKIN-4
5.2.1 BACKGROUND
Interleukin-4 is an 18-20 kD glycoprotein produced by activated T lymphocytes,
basophils and mast cells (Seder et aL 1992). The gene is located in the cytokine cluster on
the long arm of chromosome 5. Its main immunoreguktory function is in induction of
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Gene Known associations with 
infectious diseases
Some immunological effects
IL-4 ? Schistosmiasis ^tensity of 
infection linked to 5q31-33)
Promotes TH2 response 
Inhibits macrophage activity
IL-10 Hepatitis B 
Cervidts
Cervical intraepithélial neoplasia 1
Promotes TH2 response 
Decreased reactive intermediates
T N F Cerebral malaria. 
Leishmaniasis, Leprosy, 
Fatal meningococcal disease
Promotes granuloma formation 
Activates macrophage killing
VDR TB, Hepatitis B, Leprosy Promotes TH2 response
NRAM Pl Salmonella, Leishmania & 
mycobacterial infections in mice. 
TB in humans
Early intramacrophage killing
candidate genes are worth studying in lepro^
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Gene Pofymoiphisms studied Population studied
IL ^ -590C/T Tam ila and Ben^dis
IL-10 -1082G/A
-592C/A
microsatellite
Mali
TN F -238G/A
-308G/A
T am ils
VDR Taq 1 site T am ils and Mali
NRAMPl 469+14G/C
1729+14del4
microsatellite
T am ils and Mali
Tahk 5.2 Summcny of Candidate ^ e s  studied in this thesis, with the population studied
(EL = intedeukin, TNF = turnout necrosis factor, VDR = vitamin D receptor, NRAMPl
= human natural resistance associated macrophage protein 1)
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immunoglobulin isotype switching to IgE expression and induction of Th2 cells, which 
regulate humoral immunity, eosinophilia and inflammatory macrophage deactivation 
(Song et al. 1996). Tt also has anti-tnmour activity in anim al models. Giving EL4 at the 
time of an infection causes a Th2 type response (Chatekin et aL 1992). Anti EL-4 
antibodies result in inhibition of EL-10 production, suggesting that EL-4 is necessary 
before EL-10 can be produced. Interleukin-4 is a B cell activating factor resulting in 
greatly increased expression of class II MHC on B cells, p rim ing them to respond to anti 
IgM and to express the FcSRII receptor, CD23 (Austyn and Wood 1993). By 
downregulation of EL-2, it blocks proliferation and interferon gamma production by 
mononuclear cells. A high affinity EL-4 receptor is present on nearly all types of cell. EL-4 
profoundly inhibits the activity of the TNFa promoter and protein production, 
dampening down the immune response (Rhoades et aL 1995). Macrophage function is 
markedly reduced, including the production of reactive oxygen intermediates.
5.2.2 PROMOTER POLYMORPHISMS OF THE IL-4 GENE
Rosenwasser found a C to T transition within the EL-4 promoter region at —590 base
pairs fcom the open reading fcame. This was associated with a significant increase in the
serum IgE levels in 44 Jewish asthmatic and atopic individuals fcom Colorado
(Rosenwasser et aL 1995). These findings were not replicated in Australian or British
subjects apart fcom a weak association of the polymorphism with specific IgE to
housedust mite in the Australians (Walley and Cookson 1996). Song et aL identified 8
other EL-4 polymorphisms between positions -306 and +55. Although some of these
may not be present at polymorphic fcequencies, at least two appear to be fiinctionaL An
A to G transition at —81 in an OAP40 site markedly enhanced trancriptional levels. It is
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thought that the transition makes the OAP40 element a higher affinity binding site for 
certain proteins. In humans the polymorphism may lead to overexpression of IL-4 which 
then biases cdls towards the Th2 end of the spectrum (Song et al. 1996).
5.2.3 IL-4 IN d is e a s e
BALB/c mice are intrinsically susceptible to infection, whereas B10.D2 mice are
intrinsically resistant to infection with Leishmania major. In vitro experiments have shown
that BALB/c T cells acquire a Th2 type phenotype whilst B10.D2 cells acquire a Thl
type response, and that the former is due to greater initial production of EL-4 (Guler et al
1996). Both IL-4 and EL-10 inhibit the IFNy mediated microbicidal effect of
macrophages against amastigotes of leishmaniasis in BALB/c mice. Administration of
EL-4 antibodies to susceptible mice within the first week of infection cured them of this
otherwise lethal infection, whereas recombinant EL-4 given to resistant mice made them
susceptible to leishmanisis, schistosomiasis, listeria and trichinella (Sadick et aL 1990).
The usual IgE response to Nippostrongyhis brasiliensis is ablated when anti EL-4
antibodies are administered to mice prior to challenge with the parasite (Pinkelman et aL
1990).
It has long been recognised that atopic conditions tend to run in fam ilies  and there is 
good evidence for heritability of IgE levels (Gerrard et aL 1978). Since EL-4 is the 
cytokine that mediates the switch firom IgM to IgE production, it is a good candidate 
gene for both atopic and parasitic conditions. There have been reports that the EL-4 gene 
is overexpressed in cells isolated firom atopic individuals ^ong et aL 1996). Quantitative 
trait analysis of asthmatic Anush families has shown that the EL-4 gene region on 5q31-
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q33 is tightly linked to serum IgE levels and susceptibility to asthma (Marsh et al. 1994). 
These findings would be consistent with the £act that the production of IgE by T cell 
clones is directly related to their ability to produce EL-4 (Splawski et aL 1993) and that 
cells fiom atopic individuals have high levels of expression of EL-4 (Kay et al. 1991). The 
same genetic r ^ o n  has been linked to IgE levels and bronchial hyperresponsiveness 
(Meyers et aL 1994) and (Postma et aL 1995). A genome screen on some Brazilian 
families demonstrated that this region is also important in determining the intensity of 
infection with Schistosoma mansonii (Marquet et aL 1996). Despite the above studies, 
neither a genome wide search for asthma susceptibility genes in Australians nor a study 
on asthmatic families firom Finland found evidence of linkage between chromosome 5q 
markers and serum IgE levels or asthma (Daniels et aL 199Q and (Laitinen et aL 1997).
As mentioned above, lepromatous leprosy patients have been found to lie at the Th2 
end of the immunological spectrum, with high levels of EL-4 in thé tissues. IgE specific 
for Beg antigen was significantly elevated in patients with tuberculosis and leprosy 
compared to controls firom East Java. The elevation of IgE in both diseases may be due 
to a shared antigen stimulating the response (Yong et aL 1989).
5.2.4 IL-4 RESULTS
The —590 EL-4 polymorphism was typed by oligonucleotide specific hybridisation in 
cases and controls collected by Di, S, Roy fiom Calcutta, and also in a selection of cases 
and controls fiom the samples collected by myself in South India. Results are shown in 
Tables 5.3 and 5.4. No significant association was found between the different 
polymorphisms and either susceptibility to leprosy per se, or to leprosy type. Nor was
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Genotype Total Controls MB cases ENL Cases LL Controls
11 59 (75.6%) 79 (79.0%) 38 (74.5%) 26 (86.7%)
12 18 (23%) 16 (16.0%) 10 (19.6%) 3 (10.0%)
22 1 (1.3%) 5 (5.0%) 3 (5.9%) 1 (3.3%)
Total 78 100 51 30
Tahk 5.3 Interkukin-4 -590pofynofpUsm and kproy in South India
(MB = multibadllajy cases, ENL = erythema nodosum leprosum cases. LL Controls = 
lepromatous leprosy controls who had not developed ENL after at least 1 year of 
therapy. 1 = wild type IL-4 -590 allele, 2 = mutant IL-4 -590 allele).
3x2 (2d.f.) =3.01 p=0.222 for total MB cases versus total controls
3x2 y} (2d.f.) =1.69 p=0.430 for ENT, cases versus Lepromatous leprosy controls
Controls are in Hardy-Weinberg equilibrium
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Genotype Controls Tuberculoid Lepromatous Total Cases
11 101 (60.8%) 63 (58.9%) 66 (54.5%) 129 (56.6%)
12 51 (30.7%) 37 (34.6%) 45 (37.2%) 82 (36.0%)
22 14 (8.4%) 7 (6.5%) 10 (8.3%) 17 (7.5%)
Total 166 107 121 228
Tahk 5.4 InUrkukitiA —590po^orphism and kpro^ in Bengal 
(1 = wild type IL-4-590 allele, 2 = mutant EL-4-590 allele)
3x2 y} (2d.f.) =0.52 p=0.770 for tuberculoid cases versus lepromatous leprosy cases 
3x2 y} (2d.f.) =1.20 p= 0.549 for total cases versus controls 
Controls are in Hardy-Weinberg equilibrium
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there an association in the South Indians with susceptibility to erythema nodosum 
Iqprosum. The mutant allele was less fiequent in the South Indian population than in the 
Bengalis.
5.2.5 DISCUSSION
By enhancing Th2 responses, the individual’s resistance to extracellular infections 
such as encapsulated bacteria and h elm inth infections is increased. A pay-off for this is 
that the individual becomes more susceptible to infections with intracellular organisms. 
Because of its role in the Thl/Th2 response, EL-4 may play an important role in 
determ ining susceptibility to infectious diseases, and it may even be that the high 
prevalence of atopy and asthma is a direct result of selective pressures driven by 
infectious diseases. It is possible that polymorphisms of EL-4 may promote greater 
fecundity by enhancing the Th2 response in pregnancy (Wegmann et a l 1993), which 
may also have shaped the distribution of various alleles and hence the observed disease 
patterns in different populations.
There is a strong association between Thl and Th2 responses and the two extreme 
clinical forms of leprosy. Based upon the role that EL-4 appears to play in shaping this 
response, one might have expected an excess of mutant alleles in the lepromatous 
comipared with the tuberculoid cases. A non significant trend in this direction was seen 
amongst the Bengali population with the —590 EL-4 polymorphism. Th2 responses 
predominate in lepromatous leprosy, but during acute erythema nodosum leprosum a 
transient increase in T cell activity occurs consistent with a Thl-type response. A 
comparison between lepromatous cases who went on to get ENL with those that had
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not done so after at least a year of treatment, failed to show a significant difference in EL- 
4 —590 genotypes between the two groups. If anything there was a trend towards an 
excess of mutant alleles amongst the ENL cases, the reverse of what might have been 
expected. Our study was performed in two distinct populations, the difference being 
clearly apparent in terms of allele frequencies between the two groups, but both failed to 
show any association with the polymorphism studied.
We only typed a single EL-4 polymorphism It may be that the polymorphism that we 
looked at is not responsible for variations in EL-4 expression after alL This may be 
because there is another unlinked polymorphism in the same region and it would be of 
interest to investigate these variants further. Interestingly, Blackwell et aL found that the 
Th2 cluster on chromosome 5 shows linkage to the ability to mount an immune response 
to mycobacterial antigens in Brazilian fam ilies. They found no evidence for linkage of 
two polymorphisms of EL-4 to leprosy per se (Blackwell et aL 1997).
Other genes may be responsible for the varied expression of EL-4. With the 
numerous cytokines involved in determining the immune response, there may be 
complex interactions occurring at both genetic and environmental levels that determine 
where a patient falls on the clinical spectrum An EL9 polymorphism was found to be 
associated with serum IgE in an English study (DouU et aL 1996), which could explain 
the findings of Marsh (Marsh et aL 1994). Another area of interest that might be worth 
investigating is the EL-4 receptor gene (EL-4Ra) on chromosome 16. Although studies 
have ruled out linkage of this r^ o n  with Job’s syndrome of hyper IgE production 
(Grimbacher et al. 1998), a human variant (He50) has been associated with susceptibility 
to atopic asthma and raised total serum IgE levels in a Japanese population. In anim al
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studies the IleSO variant was found to significantly upregulate receptor response to IL-4, 
and hence IgE production (Mitsyasu et aL 1998).
5.3 INTERLEUKIN-10
5.3.1 BACKGROUND
IL-10 is a 36kD covalent homodimeric protein that is secreted by T cells, B cells, and
activated macrophages and is coded for on chromosome 1 (Eskdale et al. 1997). It may
be expressed by some CD4 and CD8 Tcell clones and by monocytes, macrophages,
' activated B cells and kératinocytes. The production of Thl type cytokines ftom T cells,
macrophages and monocytes is reduced in the presence of IL-10, favouring a Th2-like
response that allows the survival of pathogens (Sher et aL 1991) and (Fiorentino et aL
1991). EL-10 also downregulates class II MHC expression by monocytes and
macrophages, thus inhibiting antigen presentation and resulting in suppression of chronic
granulomatous inflammatory responses (Herfarth et aL 1996). However, class II MHC
expression on B cells is upregulated, causing them to proliferate and differentiate into
plasma cells, hence increasing the production of IgM, IgG and IgA levels. Mast cell
proliferation and differentiation is promoted by EL-10. By blocking IFNy activation and
TNFa production EL-10 inhibits the synthesis of nitric oxide, resulting in decreased
resistance to intracellular parasites (Sher et aL 1991).
In the presence of lL-2, 4 or 7 it acts as a costimuiator of proliferation of thymocytes 
and T cells. Unlike EL-4 there is no class switching of lipopolysaccharide stimulated B 
cells. It has been implicated in autoimmune disease, malignancy, and transplant tolerance. 
Levels of EL-10 appear to be critical in detemtining the type of immune response that
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develops in response to parasitic infections (Sher et aL 1991) and (Mosmann and Moore
1991). The overall effect of IL-10 is decreased Thl-type T cell activity, decreased 
cytotoxic T lymphocyte mediated lysis, and S u p p r e s s i o n  o f  m a c r o p h a g e  a c t i v i t y .
5.3.2 IL-10 IN d is e a s e
EL-10 production is markedly increased in anim als with a Th2 type response as
occurs in nematode infections e.g. L.major, S.mansonii, T.cruzii, and N.braziliensis. EL­
IO deficient mice develop an enterocolitis, which may be due to failure to control normal 
immune responses against enteric, antigens. This would result in chronic inflammation 
secondary to continual overproduction of Thl type cytokines, enhanced class II 
expression, and increased exposure of lymphoid cells to luminal antigens and bacterial 
cell wall components (Kuhn et aL 1993).
Patients with cervicitis, CINl, and adenocarcinoma of the cervix have been found to 
have a higher incidence of the -1082 G allele (high producers of EL-10) and also a higher 
frequency of the TNFa -308 G allele (low producers of TNFa) compared to control 
patients (p=0.04). This results in a Th2 type response (Majeed et aL 1997). Infection with 
M.avium induces EL-10 production and it is possible that EL-10 enhances host 
susceptibility to mycobacteria (Bermudez and Champsi 1993). Several of the EL-10 
polymorphisms mentioned below have been associated with protection from hepatitis B 
carriage following acute infection (Zhang et al personal communication).
5.3.3 IL-10 POLYMORPHISMS
Turner et aL have confirmed the presence of 3 single base pair substitutions in the
EL-10 promoter region and investigated the correlation of the polymorphisms with
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protein production In vitro. The mutations are a G to A substitution at —1082, a C to T 
substitution at —892, and a C to A substitution at —592. Healthy kidney donors without 
the —1082 A allele had sjgmficandy higher l e v e l s  of IL-10 iha.ii t h o s e  w i t h  t h e  A a l l e l e  
(Turner et aL 1996). The polymorphism lies within an ETS-like recognition site, a 
transcription factor that has been shown to downregulate EL-2 production and may have 
the same effect on the binding of EL-10 (Kube et al. 1995) (Romano-Spica et al. 1995). 
The EL-10 microsatellite has been found to be in a region that decreases promoter 
function (Kube et aL 1995). Eskdale and Gallagher have speculated that this length 
polymorphism affects expression of EL-10 (Eskdale and Gallagher 1995).
5.3.4 IL-10 RESULTS
IL-10 typing was performed on the samples collected in Mali using oligospecific
typing for the —1082 and —592 polymorphisms, and fluorescently labelled microsatellite
typing for the microsatelUte. The —892 polymorphism was not studied because previous
findings have shown complete linkage disequilibrium between this and the —592
polymorphism in the Gambia. The results are shown in tables 5.5 to 5.13. No significant
association was found between the different polymorphisms and either susceptibility to
leprosy per se, or to leprosy type or form in this population. Mantel Haenszel tests
performed on the results for the four largest ethnic and the four largest regional groups
failed to show any association with either the —1082 or the —592 genotypes (GG vs. GA
+ AA and CC vs. CA + AA respectively).
Because of the potential role of EL-10 in determining differences in Thl and Th2 
responses, comparisons of the genotypes were made between those experiencing no
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IL-10-1082 Type MB PB Controls Total
GG 85(47.2%) 44(48.4%) 82(44.8%) 211
GA 73(40.6%) 42(46.2%) 78(42.6%) 193
AA 22(12.2%) 5(5.5%) 23(12.6%) 50
Total 180 91 183 454
cases and controls from MaH (G=ndld allele, A=  mutant allele)
3x2 y f (2d.fi) =0.86 p=0.651 for controls versus leprosy cases 
3x2 y f (2d.fi) =3.21 p=0.201 for PB vs. MB leprosy cases
Comparison of controls versus leprosy cases in the 4 largest regional groups (GG vs GA 
+ AA) 2x2 Mantel-Haenszel test =0.04, p=0.849, odds ratio = 1.07 (C.I. 0.68-1.69) 
Comparison of controls versus leprosy cases in the 4 largest ethnic groups (GG vs GA + 
AA) 2x2 Mantel-Haenszel test =0.00, p=0.980, odds ratio = 1.03 (C.I. 0.66-1.60) 
Comparison of MB versus PB cases in the 4 latgest regional groups (GG vs GA + AA) 
2x2 Mantel-Haenszel test y f =0.94, p=0.95, odds ratio = 0.89 (C.I. 0.51-1.75)
Comparison of MB versus PB cases in the 4 largest ethnic groups (GG vs GA + AA) 
2x2 Mantel-Haenszel test =0.06, p=0.799, odds ratio = 0.90 (C.I. 0.5 -1.60)
Controls are in Hardy-Weinberg equilibrium
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IL-10 -1082 Type LL TT
GG 61(45.2%) 28(48.3%)
GA 55(40.7%) 25(43.1%)
AA 19(14.1%) 5(8.6%)
Total 135 58
kpro^ cases from MaH (G=wiJd allele, mutant allele)
3x2 X^(2d.f.) =1.11 p=0.574 for LL vs. TT  cases
Comparison of LL versus TT cases in the 4 largest regional groups (GG vs GA + AA) 
2x2 Mantel-Haenszel test =0.07, p=0.794, odds ratio = 1.22 (C.I. 0.49 -  3.03) 
Comparison of LL versus TT  cases in the 4 largest ethnic groups (GG vs GA + AA) 2x2 
Mantel-Haenszel test =0.00, p=0.946, odds ratio = 0.91 (C.I. 0.4 - 2.07)
Controls are in Hardy-Weinberg equilibrium.
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IL-10-1082 Type No reaction Type 1 reaction Type 2 reaction
GG 59(47.2%) 21(51.2%) 49(46.7%)
GA 57(45.6%) 15(36.6%) 43(41%)
AA 9(7.2%) 5(12.2%) 13(12.4%)
Total 125 41 105
Tahk 5.7 lnterkukin-10 polymorphism types in cases of kproty reaction from MaH (G—ndld alkk, 
A=  mutant alkk)
3x2 y f (2d.fi) =1.6 (2d.fi) p=0.450 for no reaction vs. Type 1 reaction 
3x2 y f (2d.fi) =1.89 (2d.fi) p=0.389 for no reaction vs. Type 2 reaction 
3x2 (2d.fi) =2.33 (2d.fi) p=0.311 for Type 1 or Type 2 reaction vs. noreaction
Controls are in Hardy-Weinberg equilibrium
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IL-10 -592 Type MB PB Controls Total
CC 55(30.7%) 26(28.6%) 66(33.7%) 147
CA 79(44.1%) 43(47.3%) 85(43.4%) 207
AA 45(25.1%) 22(24.2%) 45(23%) 112
Total 179 91 196 466
Table 5.8 lnterieukin-10 -592potymorbism types in multibadllaiy (MB) andpaucibacillaiy(PB) cases 
and controls from Mali (allele types are A  and C)
3x2 y f (2d.f.) —0.73, p—0.693 comparing total cases (MB+PB) vs. controls 
3x2 y f (2d.fi) =0.25, p=0.884 comparing MB vs.PB cases
Comparison of total cases (MB+PB) vs. controls in the 4 largest regional groups (CC vs. 
CA + AA) 2x2 Mantel-Haenszel test y f =0.07, p=0.795, odds ratio = 0.92 (C.I. 0.56 - 
1.49)
Comparison of total cases (MB+PB) vs. controls in the 4 largest ethnic groups (CC vs. 
CA + AA) 2x2 Mantel-Haenszel test y f =0.14, p=0.704, odds ratio = 0.90 (C.I. 0.57 - 
1.42)
Comparison of MB versus PB cases in the 4 largest regional groups (CC vs. CA + AA) 
2x2 Mantel-Haenszel test y f =0.34, p=0.559, odds ratio = 1.27 (C.I. 0.64 —2.58) 
Comparison of MB versus PB cases in the 4 largest ethnic groups (CC vs. CA + AA) 2x2 
Mantel-Haenszel test y f =0.63, p=0.428, odds ratio = 1.34 (C.I. 0.70 - 2.57)
Controls are in Harcfy-Weinberg equilibrium.
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IL-10 -592 Type LL TT
CC 44(32.8%) 17(29.3%)
CA 58(43.3%) 25(43.1%)
AA 32(23.9%) 16(27.6%)
Total 134 58
leproty from MaU, (allek types an A  and C)
3x2 y f (2d.fi) = 0.38, p=0.827 comparing LL vs. TT cases
Comparison of LL vs. TT cases in the 4 largest regional groups (CC vs. CA + AA) 
Mantel-Haenszel test 2x2 =149, p=0.223, odds ratio = 2.06 (C.I. 0.71 -  6.42)
Comparison of LL vs. TT cases in the 4 largest ethnic groups (CC vs. CA + AA) Mantel- 
Haenszel test 2x2 y f =0.5, p=0.479, odds ratio = 1.48 (C.I. 0.60 - 3.73)
130
T h e  G e n e t i c s  o f  Su s c e p t ib il it y  t o  L e p r o s y
IL-10 -592 Type No reaction Type 1 reaction Type 2 reaction
CC 37(29.6%) 13(32.5%) 31(29.5%)
CA 58(46.4%) 13(32.5%) 51(48.6%)
AA 30(24%) 14(35%) 23(21.9%)
Total 125 40 105
Tabk 5.10 InteHeukin-10 -592pofymorpbim types in cases of lepro  ^reactions from Mali (allele types 
are A  and C)
3x2 =2.82 p=0.244 for no reaction vs. Type 1 reaction
3x2 (2d.f.)=0.17 p=0.921 for no reaction vs. Type 2 reaction
3x2 y} (2d.f.)=0.15 p=0.27 for Type 1 reaction phis Type 2 reaction vs. no reaction
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Mictosatellite
Allele
MB PB Controls Total
124 0 1 (0.6%) 1 (0.3%) 2
130 0 0 1 (0.3%) 1
132 23 (6.8%) 15 (8.9%) 23 (6%) 61
134 20 (6%) 11 (6.5%) 15 (3.9%) 46
136 113 (33.6%) 51 (30.4%) 116 (30.4%) 280
138 [50 (14.9%) 20 (11.9%) 61 (16%) 131
140 71 (21.1%) 35 (20.8%) 93 (24.3%) 199
142 31 (9.2%) 20 (11.9%) 35 (9.2%) 86
146 22 (6.5%) 9 (5.4%) 27 (7.1%) 58
148 6 (1.8%) 6 (3.6%) 10 (2.6%) 22
Total 336
-  — •--------- ------
168 382 886
paucibadllaty (PB) cases and controls from Mali
There ate no significant differences in the allele fiequendes between the different 
categories.
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Microsatellite
Allele
LL(allele frequency) TT(allele frequency)
124 0 1 (1.3%)
130 0 0
132 15 (6.4%) 3 (3.8%)
134 12 (5.1%) 4 (5.0%)
136 81 (34.3%) 27 (33.8%)
138 31 (13.1%) 12 (15.0%)
140 49 (20.8%) 15 (18.8%)
142 25 (10.6%) 13 (16.3%)
146 18 (7.6%) 5 (6.3%)
148 5 (2.1%) 1 (1.3%)
Total 236 80
Tuberculoid (IT) leprosy in Mali
There are no significant differences in the allele frequencies between the different 
categories.
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Mictosatellite Allele No reaction Type 1 reaction Type 2 reaction
124 1 (0.4%) 0 0
130 0 0 0
132 19 (8.2%) 6 (7.9%) 13 (6.6%)
134 14 (6.0%) 7 (9.2%) 10 (5.1%)
136 73 (31.5%) 20 (26.3%) 71 (35.9%)
138 32 (13.8%) 11 (14.5%) 28 (14.1%)
140 45 (19.4%) 17 (22.4%) 44 (22.2%)
142 27 (11.6%) 7 (9.2%) 17 (8.6%)
146 14 (6.0%) 6 (7.9%) 12 (6.1%)
148 7 (3.0%) 2 (2.6%) 3 (1.5%)
Total 232 76 198
Mali
There are no significant differences in the allele frequencies between the different 
categories
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reaction and those experiencing a type 1, type 2 and types 1 and 2 combined reaction. 
No significant differences were found between these groups although there was a trend 
towards those people experiencing both type 1 and type 2 reactions to have a greater 
number of mutant homozygotes (AA) in the IL-10 — 1082 Group. The IL-10 
microsatellite alleles showed no evidence of any particular allele predisposing individuals 
to, or protecting them from the different forms or types of leprosy, reactions or leprosy 
per se.
5.3.5 DISCUSSION
As with IL-4, IL-10 probably plays a major role in the T h l/ Th2 response and hence 
in determining the individual's response to intracellular and extracellular organisms. 
Despite evidence for functional polymorphisms of EL-10, and involvement in a number 
of diseases, we have not found any associations between leprosy and these 
polymorphisms. The trend towards an increase in the EL-10 —1082 AA homozygotes in 
people experiencing both type 1 and type 2 reactions is interesting. It is consistent with 
the findings of Turner et al. (see section 5.3.3), given that in those experiencing type 1 
reactions, and transiently in ENL patients, there is a marked Thl type response (Turner 
et al 1996) and (Rao and Rao 1987).
It would be interesting to repeat these studies in the samples collected in South India 
to see if the trend persists or becomes significant It may be that there are other unlinked 
functional polymorphisms of EL-10 that have not yet been identified that play a role in 
determining susceptibility to leprosy or leprosy type. Alternatively, other cytokines may
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exert a stronger influence in determining the immune response, and hence determining 
leprosy disease expression.
5.4 TUMOUR NECROSIS FACTOR
5.4.1 BACKGROUND
The tumour necrosis factors (INF) are multifiictorial cytokines that possess
numerous biological activities involving the acute phase response. It has been suggested 
that TNF may act as an important antigen independent host defence mechanism against 
infectious disease. Production of TNFOC is mainly stimulated by infection and tissue 
injury, TNpp by tissue injury.
TNFa (also known as cachectin) is a 157 amino add polypeptide with a molecular 
weight of 17kD. It is a trimeric molecule with an antiparallel P-pleated sheet ordered in a 
“P barrel jelly roll” (Jones et aL 1989). The gene is appprox. 3.6 kb, contains 3 introns 
and is coded for by genes in the class III region of MHC on the short arm of 
chromosome 6 between p21.1 and p21.3, approximately 250kb centromeric to HLA-B 
and 1Mb tdomeric to HLA-DR (Dunham et aL 1987). TNFOC is produced by activated 
macrophages in response to a wide range of stimuli such as bacteria and their products, 
viruses, and other cytokines. It is also secreted by activated T cells, natural killer cells 
(NK cells), B cells, smooth musde cells and kératinocytes. There are TNF receptors on 
all cells, hence TNF has numerous and varied biological effects.
TNFa stimulates leucocytes to adhere to other cells to a greater degree, and to
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release cytokines. The expression of class II and EL-2 receptors by T cells is upregulated. 
TNF, in synergy with EFNy tri^ers the activation of both the superoxide and nitric oxide 
dependent cytotoxic pathways. Macrophages have greater phagocytic activity, whilst NK 
and CTLs are more effective in their cytotoxic role. TNF in concert with EL-2 results in 
proliferation of activated B cells and increased antibody expression. TNFa results in 
increased adhesion of leucocytes to endothelial cells, release of EL-1, 6, 8 and GM-CSF 
from endothelial cells and increased permeability by loss of fibronectin from the 
basement membrane. Complement receptor expression is upregulated. All these actions 
result in increased inflammation and enhanced host antimicrobial activity (Tracey and 
Cerami 1993) and (Austyn and Wood 1993).
As well as tumotiddal activity and useful effects in viral, bacterial and parasitic 
infections, TNF plays a role in various forms of pathology. These include induction of 
tumorigenesis and metastasis, septic shock, cerebral malaria, the Jarisch-Herxheimer 
reaction and autonutnunity (Bcudcr and Cciami 1989) and (Vassalli 1992). TNF may 
contribute to anaemia by causing dyserythropoesis and erythrophagocytosis (Clark and 
Chaudhri 1988). As with many cytokines, there seems to be a fine line between the 
beneficial effects of TNF in infections, and pathological effects.
TNF P, also known as lymphotoxin, is a glycoprotein that is produced by activated T 
lymphocytes usudly as a residt of MHC restricted antigen presentation. It too is coded by 
genes in the class EH region of MHC in close proximity to TNFa, and is probably 
derived from a common ancestor. There is 28% homology at amino acid level, and 46% 
at nucleotide level to TNFa (Turetskaya et aL 1992). TNF P receptors are present on
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almost every cell and it has been implicated in a wide range of syndromes and diseases. It 
is involved in the killing of bystander cells in delayed type hypersensitivity reactions, the 
induction of necrosis in tumour cells, increased egression of MHC dass I and adhesion 
molecules on endothelial cells, increased activity of polymorphonucleocytes, and 
resorption by bone osteoclasts. It probably plays an important role in defense against 
viral, bacterial and parasitic infections (Austyn and Wood 1993).
5.4.2 POLYMORPHISM IN THE TNFa PROMOTER
The biosynthesis of TNF is controlled at many levels. Beutler et al. found that
stimulation of monocytes and macrophages with LPS resulted in a 3 fold increase in 
TNF transcription levels, 100 fold increase in mRNA content and 10,000 fold increase in 
TNFa protein secretion (Beutler and Cerami 1989). There are numerous r^;ulatory 
sequences in the 5* region of the gene. These include NFkB elements, GC and TATA 
boxes that confer a high degree of inducibility on TNF and are all areas where critical 
nucleotide changes could have significant effects upon transcription (Tracey and Cerami 
1993) and (Emery et aL 1993).
Several polymorphisms have been identified in the TNFa promoter region. A G to 
A substitution within the consensus sequence for the transcription factor AP-2 at 
position -308 has been associated with higher constitutive and inducible levels of TNF 
(Wilson et al. 1994). It may function by inhibiting a transcriptional repressor. 
Homozygotes for this mutation have been found to be at increased risk of cerebral 
malaria in the Gambia (McGuire et aL 1994). There is an increased frequency of the 
mutant allele amon^t lepromatous compared to tuberculoid leprosy patients in Bengal,
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and mucocutaneous leishmaniasis patients have a higher frequency of this allele than 
controls (Roy et aL 1997) and (Cabrera et aL 1995). Death from meningococcal disease 
has also been associated with this allele (Nadel et al 1996).
Another polymorphism has been identified at —238 in the Y box regulatory element 
of the promoter region. This is a G to A substitution which may alter the curvature of a 
specific nuclear factor binding site (D'Alfonso and Richiardi 1994). Despite this, there is 
no evidence that it results in reduced transcription (Pociot et aL 1995). This variant has 
been associated with an increased risk of severe malarial anaemia in Kenya and the 
Gambia (D’Alfonso and Richiardi 1994) and (Kwiatkowski, personal communication). 
Heterozygosity for the -238 mutation has been weakly associated with protection from 
HIV infection in Uganda (SAli, personal communication).
5.4.3 TNF IN MYCOBACTERIAL DISEASE
TNF plays an important antigen independent role in host defense against infectious
diseases. This may be mediated by stimulation of effector mechanisms that kill
mycobacteria and promote granuloma formation. However high levels can lead to
immunopathology including direct damage to myelin and to oligodendrocytes (Selmaj
and Raine 1988). TNF plays an important role in mycobacteriocidal and -static
mechanisms in macrophages, resulting in the killing of M.avium and restricted growth of
M. tuberculosis (Bermudez 1988) and (Denis et al. 1990). In mice TNFa enhances the
bacteriostatic potential by triggering NO production in IFNy activated macrophages.
Mice that are given anti-TNFa and are infected with M. tuberculosis rapidly succumb to
disseminated disease (Flynn et aL 1995).
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TNF is involved in  the formation of granulomas, which control the spread of 
mycobacterial infections (Vassalli 1992). This appears to be a local phenomenon and has 
b een  d etu on slta led  in TB pleutltis (B atncs c l aL 1990). M onocytes and m acrophages 
from active TB patients produce higher levels of TNFa than healthy controls and 
chronic TB patients (Kim et aL 1991). On a more general level, TNF contributes to the 
cachexia seen in tuberculosis and also to the fever, weight loss and nig)it sweats (VassaUi 
1992) and (Tramontana et aL 1995).
5.4.4 TNF AND LEPROSY
TNF probably mediates host defense against mycobacterial diseases by the
promotion of granuloma formation and the stimulation of effector mechanisms that kill 
mycobacteria. Unfortunately these mechanisms may also produce immunopathology 
including direct damage to myelin and to oligodendrocytes (Selmaj and Raine 1988). 
Barnes et aL demonstrated that stimulation of cells with M. leprae or lipoarabinomsmnam 
(the dominant lipopolysaccharide o f  M. leprai) resulted in high levels of T N F  production 
by cells from tuberculoid leprosy patients, and lower levels from lepromatous patients' 
cells. However cells from patients with erythema nodosum leprosum produced extremely 
high levels during the acute phase of the reaction though these levels fell to the 
lepromatous range once the episode had abated (Samo et al. 1991). It seems likely that 
the levels of TNF produced in tuberculoid patients have a useful effect in controlling the 
disease. However, in patients with type 2 reactions the levels of TNF production are 
sufficient to produce pathology such as the nerve damage and tissue necrosis (Barnes et 
aL 1992). .
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In type 1 leprosy reactions there is an increase in cell mediated immunity towards M. 
leprae that may result in severe pathology in the nerves and skin. Khanolkar-Young et aL 
have demonstrated high levels of TNFa mRNA and protein in the skin and nerve 
macrophages of people with reactions (Khanolkar-Young et aL 1995).
Roy et aL have investigated the association of TNF polymorphisms in a population 
of leprosy patients from Calcutta. They found that the mutant allele of the —308 
promoter polymorphism was associated with lepromatous but not tuberculoid leprosy 
(0.R  3.0 p=0.02) (Roy et aL 1997).
5.4.5 RESULTS FOR TNF
The results are shown in tables 5.14-5.18. No significant difference was found
between - 308 polymorphism frequencies in cases or controls, or between different 
forms of leprosy. In particular, there was no difference between the patients who 
developed ENL compared with those lepromatous leprosy cases that had never 
developed ENL, despite the fact that these individuals are known to have markedly 
elevated TNF levels during reactions (Samo et aL 1991). There was, however, a 
marginally significant difference between cases and controls (p=0.042), with an excess of 
people homozygous for the common form of the —238 allele amongst the cases. When 
the largest ethnic groiq>, the Padayachis, were examined, the trend persisted but was no 
longer significant A non significant trend in the same direction occurred when allele 
frequencies alone were looked ati
Disappointingly, there was no evidence of any difference in allele frequencies
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T N F -238 Controls ENLs LL
controls
Total
MBs
PBs Total
cases
11 145 (81.5) 80 (88.9) 32 (82.1) 132 (88.6) 156 (87.6) 288 (88.1)
12 31 (17.4) 8 (8.9) 6 (15.4) 14 (9.4) 21 (11.8) 35 (10.7)
22 2 (1.1) 2 (2.2) 1 (2.6) 3 (2) 1 (0.6) 4 (1.2)
Total 178 90 39 149 178 327
Table 5.14 T7VF -238 fftiotypes (% in brackets) (1 represents the mid type allele, 2 the mutant allele)
(MB = multibadllaty cases, ENL = erythema nodosum leprosum cases. LL Controls = 
lepromatous leprosy controls who had not developed ENL after at least 1 year of 
therapy. Total MB cases include some cases where it was uncertain whether or not they 
had suffered from or were going to suffer from ENL, hence the discrepancy between 
ENLs phis LL controls and Total MBs).
2x2x^ = 4.12, p=0.042 OR=1.68 {CI= 0.98-2.87} comparing Cases vs. Controls (11 vs. 
12+22)
2x2%2 =1.11, p=0.292 comparing LL Controls vs. ENLs (11 vs. 12+22)
3x2%^  (2d.f.)= 1.84 p=0.398 comparing MB vs. PB cases 
Mantel Haenszel test for 2 laigest castes = 2.55 p=0.110
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T N F -238 
allele
Controls ENLs LL
controls
Total
MBs
PBs Total
cases
1 321 (90.2) 168 (93.3) 70 (89.7) 278 (93.3) 333 (93.5) 611 (93.4)
2 35 (9.8) 12 (6.7) 8 (10.3) 20 (6.7) 23 (6.5) 43 (6.6)
Total 356 180 78 298 356 654
Table 5.15 TNF -238 allele frequencies (% in brackets)
(MB = multibadllaiy cases, ^ 4 L  = erythema nodosum leprosum cases. LL Controls = 
lepromatous leprosy controls who had not developed ENL after at least 1 year of 
therapy. Total MB cases include some cases where it was uncertain whether or not they 
had suffered ftom or were going to suffer from ENL, hence the discrepancy between 
ENLs plus LL controls and Total MBs).
Cases vs. Controls 2x2%^  = 3.43, p=0.064 
LL Controls vs. ENLs 2x2%^  =0.98, p=0.322 
MB vs. PB cases 2x2%^  = 0.02 p=0.897
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T N F -238 
genotype
Controls ENLs LL
controls
Total
MBs
PBs Total
cases
11 49 (77.8) 16 (84.2) 1 23 (85.2) 56 (86.2) 79 (85.9)
12 13 (20.6) 2 (10.5) 1 3 (11.1) 9 (13.8) 12 (13.0)
22 1 (1.6) 1 (5.3) 0 1 (3.7) 0 1 (1.1)
Total 63 19 2 27 65 92
Tabk 5.16 TNF -238genotypes in Padayachis alone (aUeks are 1 and 2)
(MB = multibacillaiy cases, ENL = erythema nodosum leprosum cases. LL Controls = 
lepromatous leprosy controls who had not developed ENL after at least 1 year of 
therapy. Total MB cases include some cases where it was uncertain whether or not they 
had suffered ftom or were going to suffer ftom ENL, hence the discrepancy between 
ENLs plus LL controls and Total MBs).
Cases vs. controls (11 vs. 12+22) 2x2%^  = 1.70 p=0.192 
MB cases vs. PB cases (11 vs. 12+22) 2x2%^  = 0.01 p=0.903
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T N F -308 
genotype
Controls ENLs LL
controls
Total
MBs
PBs Total
cases
11 164 (88.6) 82 (88.2) 39 (92.9) 130 (89.7) 163 (88.1) 293 (88.8)
12 21 (11.4) 11 (11.8) 3 (7.1) 15 (10.3) 21 (11.4) 36 (10.9)
22 0 0 0 0 1 (0.5) 1 (0.3)
Total 185 93 42 145 185 330
Tahk 5.17 TNF -308^notypes in South Indian subjects (Vo in brackets) (alkks are 1 and 2)
(MB = multibacillaiy cases, ENL = erythema nodosum leprosum cases. LL Controls = 
lepromatous leprosy controls who had not developed ENL after at least 1 year of 
therapy. Total MB cases include some cases where it was uncertain whether or not they 
had suffered from or were going to suffer from ENL, hence the discrepancy between 
ENLs plus LL controls and Total MBs).
Cases vs. Controls (11 vs. 12+22) 2x2%^  = 0.00, p=0.962 
LL Controls vs. ENLs (11 vs. 12+22) 2x2%^  =0.68, p=0.408 
MB vs. PB cases 2x2%^  = 0.20 p=0.658
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TNF
-308
alleles
Controls ENLs LL
controls
Total
MBs
PBs Total
cases
1 349 (94.3) 175 (94.1) 81 (96.4) 275 (94.8) 347 (93.8) 622 (94.2)
2 21 (5.7) 11 (5,9) 3 (3.6) 15 (5.2) 23 (6.2) 38 (5.8)
Total 370 186 84 290 370 660
Tabk 5.18 TNF -308 alkk frequencies in South Indian suljects(/o in brochets)
(MB = tn i i l t ih a r i l l a iy  cases, ENL = erythema nodosum leprosum cases. LL Controls = 
lepromatous leprosy controls who had not developed ENL after at least 1 year of 
therapy. Total MB cases include some cases where it was uncertain whether or not they 
had suffered from or were going to suffer from ENL, hence the discrepancy between 
ENLs plus LL controls and Total MBs).
Cases vs. Controls 2x2%^  = 0.00, p = 0.957 
LL Controls vs. ENLs 2x2%^  = 0.65, p = 0.422 
MB vs. PB cases 2x2%^  = 0.33 p = 0.568
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between the different types of leprosy or between the cases of lepromatous leprosy that 
went on to get ENL and those that did not However, the number of uncomplicated LL 
cases was very small, and the ovemll frequency of the 238 mutant allele was also low.
5.4.6 d i s c u s s i o n
It now seems very likely that the certain genotypes of TNF may be beneficial in 
protection from various infectious diseases. Unfortunately these beneficial effects may
have serious pathological side-effects. Apart from an increased predisposition to various 
chronic inflammatory conditions such as rheumatoid arthritis, patients may also have life- 
threatening complications from the excessive amounts of TNF produced (Tracey and 
Cerami 1993). In leprosy these complications manifest themselves as erythema nodosum 
leprosum, a destructive inflammatory reaction that can result in severe and permanent 
nerve damage.
The results obtained in this study of a South Indian population are su^ estive of a 
possible association between polymorphisms of the TNF — 238 region and susceptibility 
to leprosy per se. The significance level is borderline and c o nfirm ation  of these results is 
needed in other populations. The -238 polymorphism is not thought to be functional, so 
these findings may relate to chance alone, although another nearby linked polymorphism 
could produce the same results. Alternatively, it may be functional after all, possibly 
affecting the speed and magnitude of the response such that individuals with the —238 
wild type allele produce greater tissue damage. If the association were c o n firm ed , further 
investigations into the biological m e ch an ism  would be necessary, but it could lead to new 
therapeutic approaches. We did not replicate Roy et als.’ findings of an excess of mutant
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—308 alleles amongst lepromatous cases in our study population (Roy et aL 1997).
It is interesting to note that there was no evidence of linkage with the TNFa 
microsatellite in the genome screen. This does not exclude a role for TNF though. In the 
first instance the power of genome screening to detect genes with a sm all effect is low. 
Secondly, the role of TNF may be related to specific fo rm s or reactions of leprosy rather 
than to susceptibility to leprosy per se and would therefore be missed due to the study 
design. Finally, D6S273 showed some evidence of linkage with leprosy per se in the 
genome screen. This marker maps closely to TNF. It may be that there are other 
polymorphisms of TNF that are not in linkage disequilibrium with any of the TNFa 
microsatellite alleles, but are linked  to one of the alleles of D6S273. Alternatively the data 
may have been skewed by chance or as a result of failure of certain microsatellite markers 
amplifying better in some families than in others.
5.5 CONCLUDING REMARKS
We have identified a minor association of susceptibility to leprosy per se with the —
238 TNF polymorphism which has not been replicated in Roy's population of leprosy 
patients ftom Calcutta. Apart ftom this, the cytokine polymorphisms that we have 
studied have not provided any clues into the determinants of susceptibility to leprosy, but 
more polymorphisms will become available m due course and may be worth investigating 
further. Numerous other cytokines are involved in leprosy. Decisions will need to be 
made to rationalise the investigation of these as more and more functional 
polymorphisms are recognised.
We still have a great deal to learn about the complex interactions of the cytokines
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and the fine balance that they determine between health and disease. Although leprosy is 
now curable, there is still a great deal of morbidity attributable to reversal reactions. If we 
knew who was at high risk of going on to develop leprosy reactions because of genotypic 
features, efforts could be concentrated on early detection and treatment of these 
individuals. Understanding the mechanisms involved in the development of reactions 
might help us to evolve treatments could be to prevent them happening. With its 
immunological spectrum, leprosy may help provide some more insight into the Thl/Th2 
paradigm. This may help us to understand more about infectious, autoimmune and 
allergic conditions and give dues as to the optimal methods of e^loiting this T-cell 
diversity in the prevention or treatment of disease.
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CHAPTER 6
6 CANDIDATE GENE STUDIES PART 2: NRAMP AND VDR
6.1 NRAMP
6.1.1 BACKGROUND
One gene that is a particularly strong candidate for susceptibility to mycobacterial
infections in humans is NRAMPl, the human homologue of the mouse gene, Nrampl, 
the natural resistance associated macrophage protein 1 (also known as Beg, Ity or Lsh) 
(Skamene et aL 1982). Nrampl is situated on mouse chromosome 1 and controls natural 
resistance to infection with several unrelated intracellular parasites, which include 
Salmonella, Leishmania and several mycobacterial species (M. bovis, M.avium and M. 
lepraemuriurd). In 1993 Nrampl was positionally cloned (Vidal et aL 1993). The gene 
encodes a 548 amino acid integral membrane protein with 12 transmembrane domains, a 
glycosylated extracytoplasmic loop, and an intracytoplasmic consensus transport 
signature that is expressed on macrophages (Bairoch 1993) (fig. 6.1). Susceptibility to 
mycobacterial infections was associated with a non-conservative glycine to aspartic add 
substitution in the fourth ttansmembrane domain in mice (Vidal et aL 1993) and (Malo et 
aL 1994). The structure of this protein is shared with ion channels and transporters that 
are found in a number of prokaryotic and eukaryotic membranes.
It has been found that Nrampl is specifically located in the late endocytic 
compartment of macrophages and in the phagosomal membrane after phagocytosis
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Extracellular
Cell Membrane
NH; COOH
Intracellular
Fig.6.1 The structure ofNramp (based on structure proposed ly Vidal et aL Cell 1993)
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(Gnmheid et aL 1997). Nramp appears to control the replication of intracellular para - 
sites during the early phase of infection in reticuloendothelial organs. Recently, Hackam 
et aL dctuoUsLnitcd that there w as a slgn lfiean t d ifféren ce  in  th e  acidity o f  p h a g o so m e s  
containing live mycobacteria in mice with and without the Nrampl mutation. This was 
partially due to enhanced pumping of hydrogen ions across the phagosomal membrane 
and partially to an increased ability of the phagosomes to fuse with endosomes and 
lysosomes following ingestion of live mycobacteria (Hackam et aL 1998). These fin d in gs 
are consistent with the structure of Nrampl, the actions of sim ilar proteins in other 
organisms, and the recent findings of the iron transporting function of NRAMP2 
(Fleming et aL 1997). NRAMPl has been mapped to chromosome 2q35.
6.1.2 NRAMPl POLYMORPHISMS
Nine sequence variants have been identified in the h um an homologue of Nrampl,
NRAMPl (Liu et aL 1995). White et al have identified a further polymorphic 
microsatellite m exon 2 (White et al. 1994).
6.1.3 NRAMP AND DISEASE
Several people have speculated that NRAMPl might be a good candidate for
susceptibility to mycobacterial disease in h u m an s (Skamene et al. 1982). It has been 
implicated in autoimmune disease (ComaU et aL 1991), which may reflect evolutionary 
influences if it plays a protective role against infectious diseases in man as it does in 
animals. Shaw et aL looked at 149 individuals with leprosy ftom 35 multicase families and 
found no convincing evidence for either a disease susceptibility allele for leprosy per se, 
or for one controlling the form of disease or response to M. leprae soluble antigen. In fact
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LOD scores were less than -2, consistently against the possibility of a gene of this type in 
the region. The families were from two distinct geographical regions and were relatively 
small in number so these results could have been due to low power and/or ethnic 
genetic differences. They also looked at NRAMPl polymorphisms in some tuberculosis 
families, and these did show some evidence that it might be playing a role in mberculosis 
susceptibiUty (Shaw et aL 1993). In some more recent work Roger et al. looked at the 
mutations of NRAMPl found by Liu et al., as well as 3 microsatellite markers in the 
region, in 7 multicase pedigrees from Polynesia. These included 39 leprosy cases. Their 
results were again strongly against NRAMPl being linked to leprosy susceptibility in 
these pedigrees (Roger et aL 1997). Abel et aL looked at 20 multiplex leprosy families 
from Vietnana and found that there was segregation of NRAMPl haplotypes with 
leprosy though the lod scores were relatively low (Abel et al. 1998).
The most convincing evidence that NRAMPl does play a significant role in human 
mycobacterial disease comes fcom a large case-control study by Bellamy et aL They 
looked at 4 NRAMP polymorphisms in smear positive mberculosis cases and controls 
from Africa. They found that a single nucleotide transversion in intron 4 (469+14G/C) 
and a TGTG deletion in the 3* untranslated region (55 nucleotides 3* to exon 15), 
referred to as 1729+55del4, were significantly associated with susceptibihty to 
mberculosis and were not in linkage disequilibrium Heterozygotes for both these alleles 
had a risk of 4.07 (C.I. 1.86-9.12) of developing mberculosis. In addition a microsatellite 
polymorphism at -150 base pairs from the start codon was weakly associated with 
mberculosis (p=0.03) (Bellamy et aL 1998).
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6.1.4 r e s u l t s
The results are shown in tables 6.1 — 6.19. There was no association between the 
intron 4 polymorphism and either leprosy type or form, or susceptibility to leprosy per se 
(tables 6.1 and 6.2). There was trend towards an excess of mutant homozygotes in the 
controls compared with total cases, but this was not significant Risk of developing a 
leprosy reaction was unaffected by intron 4 genotype (table 6.3). NRAMPl microsatellite 
alleles were present at sim ilar frequencies in multibadllary and paudbadllary cases, and in 
controls (tables 6.4 and 6.5). When broken down into pure lepromatous (LL) and pure 
tuberculoid (IT) cases, there appeared  to  b e  an  ex cess  o f  in d ividuals w ith  the rater 201 
and 203 alleles amongst the LL cases, but these findings were not significant (table 6.6). 
Similar findings were seen when risk of leprosy reaction was examined, people 
experiencing type 1 reactions (those with polar and borderline lepromatous disease) 
having a non significant excess of the rarer alleles whereas those experiencing type 2 
reactions had an excess of the common 199 allele (table 6.7).
There was a significant association between the NRAMPl 1729+55del4 
polymorphism and leprosy type in this population (table 6.8). A significant excess of 
heterozygotes were found amongst the multibadllary cases, and an excess of mutant 
homozygotes amongst the tuberculoid cases (x^ = 8.88, p = 0.003, O.R= 5.79 with 
confidence intervals of 1.46 — 24.61). This result persisted after logistic regression was 
performed to take account of regional, ethnic and sex differences. Mantel Haenszel tests 
were also performed using the four largest ethnic, and the four largest regional groups to 
ensure that population stratification was not confounding the results. The p-value 
remained significant at 0.012 when stratifying for ethnic group, but rose to 0.056 when
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Intron 4 
Type
MB PB Total Cases Controls Total
WW 121(84.0%) 64(82.1%) 185(83.3%) 134(80.2%) 319
WM 23(16.0%) 13(16.7%) 36(16.2%) 27(16.2%) 63
MM 0 1(1.3%) 1(0.05%) 6(3.6%) 7
Total 144 78 222 167 389
Tabk 6.1 NRAMP Intron 4 ÿmotypes in muttibadUarji (MB) and paudbadllmy (PB) cases, and 
controls from Mali
(HF = wild allele, M  — mutant allele)
2x3 =1.88 (2d.f.), p=0.390 for MB versus PB leprosy cases
2x3 =5.34 (2d.f.), p=0.069 for controls versus all leprosy cases
2x2 y f =4.64 (ld.f.), p=0.031 for controls versus leprosy cases when comparing 
heterozygotes with mutant homozygotes. By Fisher’s exact test (2-tailed) p=0.046. 
Mantel Haenszel test controlling for 4 largest ethnic groups y} =1.24 p=0.266. Mantel 
Haenszel test controlling for 4 largest regional groups y} =1.05 p=0.307. The results 
were not significant after logistic regression taking into account ethnic group, region and 
sex.
Controls are in Hardy-Weinberg equilibrium
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Intron 4 Type LL TT
WW 83(83.0%) 33(84.6%)
WM 17(17.0%) 5(12.8%)
MM 0 1(2.6%)
Total 100 39
Table 6.2 NRAMP1 Intron 4 genotypes in cases of lepromatous (LL) and tuberculoid (TT) leproty in 
Mali
— wild allele, M  = mutant allele)
2x3 =2.88 (2d.£), p=0.237 for LL vs. TT cases
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Intron 4 Type Type 1 reaction Type 2 reaction No reaction
WW 25(83.3%) 67(81.7%) 93(84.5%)
WM 5(16.7%) 15(18.3%) 16(14.5%)
MM 0 0 1(0.9%)
Total 30 82 110
Tahk 6.3 NRAMP1 Intron 4 ^ otypes in cases with reactions 
(IP' = wild allele, Af = mutant allele)
3x2 5^2=0.35 (2d-£), p=0,840 comparing leprosy cases with Type 1 reaction vs. cases 
without reaction
3x2 %2=i 20 (2d.f.), p=0.549 comparing leprosy cases with Type 2 reaction vs. cases 
without reaction
3x2 L43 (2d.£), p=0.489 comparing leprosy cases with reaction vs. cases without
reaction
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Microsatellite
Allele
MB PB Total Cases 
(MB + PB)
Controls
199/199 117 (64.6%) 62 (66.7%) 179 (65.3%) 119 (61.0%)
199/201 48 (26.5%) 27 (29.0%) 75 (27.4%) 63 (32.3%)
199/203 5 (2.8%) 3 (3.2%) 8 (2.9%) 1 (0.5%)
201/201 7 (3.9%) 1 (1.1%) 8 (2.9%) 9 (4.6%)
201/203 4 (2.2%) 0 4 (1.5%) 2 (1.0%)
203/203 0 0 0 1 (0.5%)
Total 181 93 274 195
Table 6.4 NRAMP microsatellite g^otypes in multibacilUay (MB) andpaucibaciUofy (PB) cases, and 
controls in Maü
Microsatellite
Allele
MB PB Total Cases Controls
199 287 (79.3%) 154 (82.8%) 441 (80.5%) 302 (77.4%)
201 66 (18.2%) 29 (15.6%) 95 (17.3%) 83 (21.3%)
203 9 (2.5%) 3 (1.6%) 12 (2.2%) 5 (1.3%)
Total 362 186 548 390
Table 6.5 NRAM P microsatellite allele frequencies in multibacillaiy (MB) and paucibaàllaiy (PB)
cases and controls from Mali 
(Alleles are 199, 201 and 203 base pairs long)
2x3 %2 —3.17 (2d.£), p=0.205 comparing total cases (MB+PB) vs. controls 
2x3 —1-11 (2d.£), p=0.574 comparing MB vs. PB cases
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Microsatellite
Alkie
LL TT
199 198 (77.3%) 74 (82.2%)
201 50 (19.5%) 15 (16.7%)
203 8 (3.1%) 1 (1.1%)
Total 256 90
Table 6.6 NRAMP1 mimsatellite alkie jrequendes in cases of lepromatous (LL) and Tuberculoid 
(TT)kprvsy
(Alleles are 199,201 and 203 base pairs lon^
2x3x^ =1.53 (2d.f.) p=0.465 for LL vs. TT cases
2x2x^ =0.94 (ld.f.) p=0.332 for LL vs. TT cases comparing allele 199 with others
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NRAMP
micfosatellite
allele
Type 1 reaction Type 2 reaction No reaction
199 70 (85.4%) 161 (76.7%) 210 (82.0%)
201 11 (13.4%) 42 (20.0%) 42 (16.4%)
203 1 (1.2%) 7 (3.3%) 4 (1.6%)
Total 82 210 256
Table 6.7 NRAMP1 mimsatellite alkie jrequendes in cases of leproy reactions in MaB 
(Alleles are 199,201 and 203 base pairs long)
Cases of leprosy with Type 1 reaction vs. cases without reaction 3x2 %2=o.49 (2d.f), 
p=0.784
Cases of leprosy with Type 2 reaction vs. cases without reaction 3x2 %^=2.78 (2<Lf), 
p=0.250
Cases of leprosy with reaction vs. cases without reaction 3x2 .25 (2d.f), p=0.536
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NRAMPTGTG
Type
MB PB Controls Total
TGTG/TGTG 105 (58.0%) 55 (59.8%) 118 (58.7%) 278
TGTG/Del 72 (39.8%) 28 (30.4%) 71 (35.3%) 171
Del/Del 4 (2.2%) 9 (9.8%) 12 (6.0%) 25
Total 181 92 201 474
Table 6.8 NRAMiP/ 1729+5Sdel4 ( 'SfRAMPTGTG) allele types in multibadllary (MB) and
paucibacillaiy (PB) cases, and controls in Mali 
(Alleles ate TGTG {wild type} and Del {mutant allele with TGTG deletion})
Overall comparison of multibadllary cases versus paucibacdllary cases 3x2 = 8.83
(2df), p=0.012
2x2 table of leprosy type vs. heterozygotes/homozygous mutant status, =8.88 (ld.f), 
p=0.003 Odds ratio = 5.79 (Cl 1.46-24.61). 2-tailed Fisher’s exact test p=0.009 
Comparison of leprosy type vs. heterozygotes/homozygous mutant status cases 2x2 
Mantel - Haenszel for the 4 largest ethnic groups:X^= 6.29, p=0.012 Odds ratio=6.87 
(C.1.1.44-39.41).
Comparison of leprosy type vs. heterozygotes/homozygous mutant status cases 2x2 
Mantel - Haenszel for the 4 largest regional groups:%^= 3.64, p=0.056 Odds ratio=4.62 
(C.I. 0.99-29.91).
The effect of NRAMP TGTG genotype on leprosy type remained after logistic 
regression accounting for sex, region and ethnic group (p=0.005).
Controls are in Hardy Weinberg equilibrium
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stratifying for regional group. A similar trend was seen when the population was broken 
down into polar lepromatous and polar tuberculoid cases, with an excess of mutant 
homozygotes in the tuberculoid group and excess heterozygotes amongst the 
lepromatous cases (tables 6.9 and 6.10). When a 2x2 y  ^was performed the p-vahie was 
0.0304, but this disappeared after the Mantel Haenszel test was performed to account for 
the four largest regional and ethnic groups. A similar study in a South Indian population 
showed no evidence of an association between the NRAMPl 1729+55del4 
polymorphism and leprosy form (table 6.18 and 6.19).
An excess of TGTG del alleles were present in people experiencing a type 1 leprosy 
reaction, the majority of these being accounted for by those with paucibadllary leprosy. 
The number of lepromatous leprosy patients who experienced type 1 leprosy reactions 
was low, but the percentage of homozygotes for the mutant allele was much lower in this 
group than in those with tuberculoid leprosy. This reflects the original association of 
leprosy form with NRAMPl 1729+55del4 genotype (tables 6.10 and 6.12). All people 
experiencing type 2 reactions were, by definition, multibacillary cases so it was no 
surprise that there were a greater percentage of heterozygotes amongst this group (table 
6.11). Despite the above trends, there was no significant difference between cases 
experiencing reactions (type 1 or type 2) and cases that had no reactions.
Table 6.13 shows the breakdown of MB vs. PB cases by ethnic group, with 
percentages of cases shown for the four largest groups. There were more Bambara cases 
than controls and fewer Malinke cases than controls, hence the requirement to perform
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NRAMP TGTG Type LL TT
TGTG/TGTG 70 (54.3%) 26 (57.8%)
TGTG/Del 56 (43.4%) 15 (33.3%)
D el/D el 3 (2.3%) 4 (8.9%)
Total 129 45
Tahk 6.9 NRAM Pl 1729+55del4 (NRAMPTGTG) gén o is in cases of lepromatous (LL) and 
tuberculoid (FT) leproy
(Alleles are TGTG {wild type} and Del {mutant allele with TGTG deletion})
3x2 X^=4.48 (2d.fi), p=0.107 comparing leprosy type with genotype
2x2 X^-4.49 (ld.fi), p=0.034 Odds ratio = 4.98 (C.I. 0.81-32.38) 2-tailed p-value (Fisher’s
exact test) = 0.056 comparing leprosy type with heterozygous and homozygous mutant
genotypes
2x2 Mantel - Haenszel ^eterozygotes vs. homozygous mutants in LL vs. TT cases) 
accounting for the 2 largest ethnic groups =5.13, p=0.113 Odds ratio=5.13 (0.8-48.27) 
2x2 Mantel - Haenszel%  ^(heterozygotes vs. homozygous mutants in LL vs. TT cases) 
accounting for the 4 largest regional groups%  ^ =1.22, p=0.269 Odds ratio=3.8 (0.52- 
38.94).
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NRAMP TGTG Type No reaction Type 1 reaction Type 2 reaction
TGTG/TGTG 74 (59.7%) 27 (64.3%) 59 (55.1%)
TGTG/Del 44 (35.5%) 11 (26.2%) 45 (42.1%)
Del/Del 6 (4.8%) 4 (9.5%) 3 (2.8%)
Total 124 42 107
T M  6.10 NRAM Pl 1729+55deM- (NRAMPTGTG) genotypes in cases of leproy reactions in 
Mali
(Alleles are TGTG {wild type} and Del {mutant allele with TGTG deletion})
Cases of leprosy with Type 1 reaction vs. cases without reaction 3x2 %^=2.07 (2d.fi), 
p=0.355
Cases of leprosy with Type 2 reaction vs. cases without reaction 3x2 X^=1.46 (2d.fi), 
p=0.482
Cases of leprosy with reaction vs. cases without reaction 3x2 X^=0.13 (2d.fi), p=0.938
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NRAMP 
TGTG Type
No reaction & 
MB leprosy
Type 1 reaction & 
MB leprosy
Type 2 reaction & 
MB leprosy
TGTG/TGTG 31 (60.8%) 15 (65.2%) 59 (55.1%)
TGTG/Del 20 (39.2%) 7 (30.4%) 45 (42.1%)
D el/D el 0 1 (4.3%) 3 (2.8%)
Total 51 23 107
Tabk 6.11 NRAM Pl 1729+55del4 (NRA 
broken down into multibadllary cases in Mali
MPTGTG) genotypes in cases of type 1 leprosy reach
NRAMP 
TGTG Type
No reaction & PB 
leprosy
Type 1 reaction & 
PB leprosy
TGTG/TGTG 43 (58.9%) 12 (63.2%)
TGTG/Del 24 (32.9%) 4 (21.1%)
D el/D el 6 (8.2%) 3 (15.8%)
Total 73 19
Tahk 6.12 NRAM Pl 1729+55del4 (NRAMPTGTG) genotypes in cases of type 1 kproy nacHons 
broken down into paucibadllary cases in Mali
(Alleles are TGTG {wild type} and Del {mutant allele with TGTG deletion})
Cases of MB leprosy with Type 1 reaction vs, cases of MB leprosy without reaction 3x2 
%2=2.60(2d.f.), p=0.272
Cases of MB leprosy with Type 2 reaction vs. cases of MB leprosy without reaction 3x2 
X2=1.69(2d.f.),p=0.429
Cases of PB leprosy with Type 1 reaction vs. cases of PB leprosy without reaction 3x2 
X2=1.62 (2d.f.), p=0.445.
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ETHNIC
GROUP
Frequency
of
NRAMPTG 
TG wild 
type allele
MB
(% cases)
PB
(% cases)
TOTAL 
NO. OF 
CASES
CONTROLS
Bambara 0.75 79(44%) 39(42%) 118(43%) 71(35%)
Bobo 0.5 1 1 2 1
Bozo/Somono 0.77 5 1 6 3
Dogon 0.82 7 2 9 2
Forgeron 1.00 1 0 1 3
Kassouke 0.8 2 1 3 2
Kissie 1.00 0 0 0 1
Malinke 0.79 16(9%) 11(12%) 27(10%) 37(18%)
Minianka 0.7 0 0 0 5
Moor 0.75 3 0 3 1
Ouolof 1.00 1 0 1 1
Penlh/Foulah 0.73 36(20%) 25(27%) 61(22%) 35(17%)
Sarakole 0.84 18(10%) 7(8%) 25(9%) 24(12%)
Senoufo 0.75 0 1 1 5
Song/rhai 0.77 9 4 13 9
Sonike 0.83 3 0 3 0
Touareg 0.5 0 0 0 1
(NRAMPTGTG) allele amongst them
(Alleles are TGTG {wild type} and Del {mutant allele willi TGTG deletion})
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the Mantel — Haenszel test to eliminate this potential confounding effect The frequency 
of the NRAMP TGTG allele is shown for each group and is not markedly different 
bcLwccu the groups. Combined analysis of NRAMPl haplotypes for NRAMP TGTG 
and the Intron 4 alleles show no evidence of an association between NRAMPl and 
leprosy (table 6.14). Tables 6.15 to 6.17 show the relationship between possession of the 
different alleles of the 3 polymorphism that I looked a t There was evidence of strong 
linkage disequilibrium between the 199 microsatelhte and both the TGTG wild type 
allele and the Intron4 G allele. It is therefore rather surprising that there was no evidence 
of linkage between the NRAMP TGTG wild type allele and the Intron4 G allele, since 
the Intron4 region is midway between the microsatellite and NRAMP TGTG. These 
findings are consistent with those of Bellamy et aL in a closely related Gambian 
population although they do not comment on any association of the microsatellite with 
the NRAMP TGTG polymorphism. The association of leprosy form with the NRAMP 
TGTG polymorphism but not with, the 199 microsatellite may indicate that the actual 
causative polymorphism is not NRAMP TGTG itselfi but another polymorphism 3’ to it.
In view of the findings with the NRAMP TGTG polymorphism in Mali, we 
performed similar studies in Tamil subjects (tables 6.18 and 6.19). Paucibadllary (PB) 
cases comprised of the affected sibling pairs used in the first round of the genome 
screen. Using the haplotype relative risk method ‘Virtual” controls were derived ftom the 
non-inherited parental alleles of these PB cases (see section 1.7.1). Caste matched 
controls were used in the smdy of lepromatous and ENL cases. No significant 
association was found between any of the groiq>s and alleles or genotypes of NRAMP 
TGTG. The del allele was markedly less common in this population, so numbers were
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NRAMPTGTG
/Intton4
Type
MB PB Leprosy
Case
Leprosy
Control
test
Yates
corrected
p value
Yates
corrected
TGTG/TGTG
/GG
72
(55%)
38
(55%)
110
(53%)
85
(56%)
TG TG /D el/
GG
44
(34%)
21
(30%)
65
(31%)
41
(27%)
0.49 0.48
TGTG/TGTG
/GC
10
(8%)
7
(10%)
17
(8%)
14
(9%)
0 0.98
TG TG /D el/
GC
13
(10%)
4
(6%)
17
(8%)
11
(7%)
0.05 0.82
Tahk 6.14 NRAM Pl hcpktypes in multihadUary (MB) andpaucihadlkay(PB) cases, and controls 
fromMak
(Alleles are TGTG {wild type} and Del {mutant allele with TGTG deletion} for the 
NRAMPl 1729+55del4 (NRAMPTGTG) polymorphism, and G and C for the intron4 
polymorphism)
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lntton4 GG Intton4 GC Intcon4 CC Total
TGTG/TGTG 195 31 3 229
TGTG/Del 106 28 3 137
Del/Del 13 3 1 17
Total 314 62 7 383
Table 6.15 Intron 4 genotype versus NRAMP TGTG ffnotype in Mali
(Alleles are TGTG {wild type} and Del {mutant allele with TGTG deletion} for the
NRAMPl 1729+55dcl4 (NRAMPTGTG) polymorphism, and G and C for the intron4
polymorphism)
2x3%^= 5.207 (2d.fi), p=0.267 comparing GG and GC Intron 4 genotypes with TGTG 
genotype, su^esting no evidence of linkage between the 2 markers
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199/199 199/201 199/203 201/201 201/20
3
203/20
3
Total
TGTG/
TGTG
209(71%) 53 (39%) 4 4 0 0 270
TGTG/
Del
76 (26%) 72 (53%) 5 5 6 1 165
D el/D el 7 (2%) 10 (7%) 0 7 0 0 24
Total 293 136 9 16 6 1 459
1 abie 6.16 Microsateltite ÿmotype versus NRAMP TGTG genotype in Mad 
(Alleles are TGTG {wild type} and Dei {mutant allele with TGTG deletion} for the 
NRAMPl 1729+55del4 (NRAMPTGTG) polymorphism, and 199, 201 and 203 for the 
microsatellite polymorphism)
3x2%^  of 199/199 homozygote and 199/201 heterozygotes against NRAMP TGTG 
genotype: 2x3 41.39 (2d.fi), p=0.000
3x2 of 199/199 homozygote compared to all other microsatellite genotypes against 
NRAMP TGTG genotype: 2x3 X^  — 56.46 (2d.fi), p=0.000. These findings suggest 
strong linkage between the 199 microsatellite allele and the TGTG wild type allele.
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199/199 199/201 199/203 201/201 201/203 203/203 Total
Intron4 GG 239
(99.6%)
64 (56%) 1 6 1 0 311
Introii4 GC 1 44 (39%) 8 6 3 1 63
Intton4 CC 0 6
(5%)
0 0 1 0 7
Total 240 114 9 12 5 1 381
Table 6.17 Microsatelhte genotype versus Intron 4 ^ otype in Mah
(Alleles are G and C for the Intron4 polymorphism, and 199, 201 and 203 for the 
microsatellite polymorphism)
3x2%^  of 199/199 homozygote and 199/201 heterozygotes against NRAMP Intron4 
genotype: = 118.3 (2d.f.), p=0.000
3x2%^  of 199/199 homozygote compared to all other microsatelhte genotypes against 
NRAMP Intron 4 genotype: 139.43 (2d.f.), p=0.000 su^esting strong linkage
between the 199 microsatelhte aUele and the Intron 4 G aUele
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NRAMPTGTG
Type
PB “Virtual
Controls**
TGTG/TGTG 145 (84.3%) 146 (84.9%)
TGTG/Del 24 (14.0%) 25 (14.5%)
D el/D el 3 (1.7%) 1 (0.6%)
Total 172 172
Tahk 6.18 NRAM Pl 1729-¥55deI4 (NRAMPTGTG) genomes in Tamil subjects paudbacillary 
(PB) cases versus controls (Haplotype relative risk method)
(Alleles are TGTG {wild type} and Del {mutant allele widi TGTG deletion})
Comparison of paucibadllary cases versus “virtual” controls 3x2 —1.02 (2d.fi),
p=0.599
Controls are in Hardy-Weinberg equilibrium
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NRAMPTGTG
Type
ENL Cases Lepromatous
leprosy
controls
TotalMB
cases
Controls
TGTG/TGTG 68 (81.0%) 29 (80.6%) 123 (82.0%) 83 (78.3%)
TGTG/Del 14 (16.7%) 6 (16.7%) 24 (16.0%) 21 (19.8%)
D el/D el 2 (2.4%) 1 (2.8%) 3 (2.0%) 2 (1.9%)
Total 84 36 150 106
Table 6.19 NRAMPI 1729+S5del4 ( •^TRAMPTGTG) genotypes in Tamil subjects muMbacilkny
(MB) cases versus mntrols 
(Alleles are TGTG {wild type} and Del {mutant allele with TGTG deletion})
(N.B. Total MB cases are greater than ENL plus LL controls because other subjects in 
whom the ENL status was unknown are also included. LL controls are cases of 
lepromatous leprosy who had not developed ENL after at least 1 year’s treatment) 
Comparison of multibacillary cases versus controls 3x2 = 0.62 (2d.fi), p=0.732
Controls are in Hardy-Weinberg equilibrium
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too small to draw any conclusions regarding trends in the same direction as the Mali 
subjects.
6.1.5 DISCUSSION
NRAMPl is a very strong candidate for an infectious disease susceptibility gene. The 
association of the NRAMP TGTG polymorphism with leprosy form is of particular 
interest in the light of the recent findings of Bellamy et aL They studied a Gambian 
population (ethnically very similar to Mal^, and found that heterozygosity for the 
NRAMP TGTG polymorphism was associated with sputum positive tuberculosis 
(Bellamy et aL 1998). Since this form of tuberculosis may be thought of as being 
analogous to lepromatous leprosy, our findings complement theirs. This contrasts with 
the findings in mice where only homozygotes of the Nrampl polymorphism are 
susceptible to disease. It is of interest that D2S125, which is situated relatively close to 
the human NRAMPl gene, was one of the markers in the South Indian leprosy genome 
screen that was mildly su^estive of linkage. The low lod score would be in keeping with 
a minor gene effect
The results were not replicated in the South Indian population (Tables 6.18 and 
6.19). One reason for this would be low power in view of the lower frequency of the del 
allele firequency in the Indian population. An alternative explanation is that the causative 
polymorphism may be in linkage disequilibrium with NRAMP TGTG in Mali but not in 
all other populations. Finally, the findings in Mali may have been due to chance alone 
and there may be no association at alL The NRAMP TGTG polymorphism was not 
found to be linked with leprosy in either Polynesia or Pakistan (Roger et aL 1997) and
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(Shaw et aL 1993), although weak evidence for linkage was found in Vietnamese families 
(Abel et al. 1998).
In mice Nrampl controls the replication of intracellular parasites during the early 
phase of infection in reticuloendothelial organs. Possible mechanisms for this are ion 
transportation or modulation of the intraphagolysosomal pH (Seade et aL 1998) and 
(Hackam et aL 1998). Heterozygosity for NRAMP TGTG may correlate with optimal 
intraphagolysosomal conditions for the growth of M.leprae. It has recently been found 
that immunisation of mice with recombinant salmonella raises a predominantly Thl type 
response in those with the Nrampl resistance allele, and a Th2 type response in Nrampl 
mutant homozygotes (Soo et aL 1998). The mechanism for this is unknown, but the 
parallel with NRAMPl and the different forms of leprosy (which are associated with 
different immune responses) is intriguing. However, the role that the NRAMP TGTG 
allele plays is still unknown, and the possibility remains that it is in linkage disequihbrium 
with another functional polymorphism within NRAMPl, or even in another gene, 
remains.
Further studies need to be performed to clarify the role of NRAMPl in determining 
leprosy form. If a role is su^ested by future results, the cellular mechanisms for this will 
need to be determined. Gene therapy or alternative approaches to treatment may then 
become possible. Studies on infected human cells of different genotypes could give 
further insights as will continuation of the already vast amount of animal work.
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6.2 VITAMIN D AND LEPROSY
6.2.1 INTRODUCTION
Classically, lOC - 25 dihydroxy vitamin D3 (1,25 (OH) 2  D3), the active metabolite of
vitamin D, is known to be involved in calcium and phosphate homeostasis and in bone 
mineralisation. Over the last 15 years or so, it has become apparent that vitamin D also 
has an immunomodulatory role, being involved in the control of both cellular and 
humoral immunity. Monocytes and macrophages are upregulated by dihydroxy- 
cholecaldferol, whereas lymphocyte function is depressed. Immunoglobulin production 
falls, THl-type helper cell function is reduced with decreased production of IL-2, IL-12 
and IFNy, and there is reduced Class II antigen expression by lymphocytes and 
monocytes (Lemire et al 1995), (Rigby et al 1990), (D'Ambrosio et al 1998) and 
(Hustmyer et al 1992). Cell mediated immunity is enhanced (Hemandez-Frontera and 
McMurray 1993) and (McMurray et al 1990). Macrophages and other cells of the 
immune system can produce l,25(OH)2D3, which acts in a paracrine manner, controlling 
cellular and humoral immunity locally. This has the effect of enhancing adherence, 
chemotaxis, and phagocytosis as well as increasing the levels of H2O2, oxygen radicals 
and heat shock proteins (Casteels et al. 1995) and (Yamamoto and Naraparaju 1996).
The vitamin D receptor (VDR) is required for normal calcium absorption from the 
gut It forms homo or hetero dimers with other members of the steroid hormone 
receptor superfrmily and is encoded by a gene on 12ql3-14 (Cariberg et al 1993). 
Vitamin D receptors are present on cells of the immune system (monocytes and 
activated T and B lymphocytes) as well as the classical tissues, kidney, gut and hver 
(Prowedini et al 1983). The immunoregulatory effects described above are mediated
176
T h e  G e n e t ic s  o f  Su s c e p t ib il it y  t o  L e p r o s y  
through the VDR.
6.2.2 VDR po ly m o rph ism s
Morrison et al defined a number of polymorphisms in the 3’ untranslated region of
the VDR gene. A Taql RFLP polymorphism (T to C substitution conservative for 
isoleucine) at codon 352 of the vitamin D receptor gene has been associated with bone 
density and susceptibility to osteoporosis (p=0.0008) (Morrison et al 1994). (The alleles 
at this site are designated T and t). The other polymorphisms are in linkage 
disequilibflvun with the Taql site such that people either have the baT or Bat haplotypes. 
There is evidence fix>m transfection studies that the Bat haplotype is associated with 
increased e3q>ression of VDR mRNA (Morrison et al 1994). This could lead to greater 
monocyte activation in people with the Bat haplotype. Several further studies 
investigating the association of the Taq polymorphism with osteoporosis have produced 
variable results, about half of them confirming Morrison’s findings^  the others showing 
no evidence of an association. It is likely that this reflects differences in other genetic and 
environmetal factors (Ferrari et al 1998).
6.2.3 VITAMIN D AND DISEASE
Apart ftom the association with bone mineral density in some populations, vitamin
D has been implicated in a variety of diseases. These include autoimmune diseases in 
eq>erimental animals e.g. prevention of SLE, insulitis, diabetes and experimental allergic 
encephalitis in mice (Lemire et al 1995) (Casteels et al 1995) and (Mathieu et al. 1995). 
More recently the Taql polymorphism has been associated with risk of developing 
prostate cancer in humans. Men homozygous for the t allele have 1/3 of the risk of
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developing prostate cancer compared with men who are heterozygous or homozygous 
for the T allele (Taylor et al 1996). l,25(OH)2D3 has been implicated in defence against 
infectious diseases and in particular against tuberculosis, details of which are described 
below. Children with rickets were noted to be at increased risk of infections and 6 weeks 
of supplementary fish oil resulted in decreased susceptibihty to infection with Klebsiella 
pneumonia and cerebral malaria in C57B1/6 mice (Yener et al. 1995) and (Blok et al 
1992). Prostimtes ftom Uganda who were homozygous for the tt allele of VDR were 
more susceptible to HIV, the effect being greater in females (SAli, personal 
communication).
Denis found that l,25(OH)2D3 resulted in decreased intramacrophage growth of 
mycobacterium tuberculosis and that there was evidence for significant mycobacterial 
killing when monocytes were pulsed with l,25(OH)2D3, IFNy and TNFa (Denis 1991). 
There have been numerous reports suggesting further possible links between vitamin D 
and tuberculosis. These included the diintial effect uf calciferol on lupus vulgans, the fiict 
that tuberculosis is 2.8 times more common in strict vegetarians, and the increased rate 
of tuberculosis in new immigrants from the Indian subcontinent (Dowling and Prosser- 
Thomas 1946) and (Strachan et aL 1995). These lead Bellamy et al. to look at vitamin D 
receptor polymorphisms in tuberculosis. They found that there was a significantly lower 
risk of developing tuberculosis (O.R.= 0.31 95% C.I. 0.14 - 0.67) in those who were 
homozygous for the lower bone mineral density allele (tt) compared with other 
genotypes (Tt and i 'i)  in a Gambian population. In the same study, Bellamy et al were 
able to examine susceptibility to clinical malaria and hepatitis B carriage rates with VDR 
genotypes in the Gatubiaus. Clinical m alana was not associated with VDR. However, for
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those individuals with evidence of previous hepatitis B infection, possession of the tt 
genotype protected them from becoming persistent hepatitis B carriers. Despite linkage 
disequihbdum between t and A, the AA VDR genotype was independently associated 
with an increased risk of carrier status in this population (Bellamy et al in press).
In contrast to mycobacterium mberculosis, there is scanty literature on the effects of 
vitamin D on leprosy. In 35 villages studied in South India the prevalence of leprosy 
correlated with malnutrition in children aged l-4years of age but not in adults 
(Sommerfelt et al. 1985). Cappuro and Guillot used intramuscular injections of vitamin 
D in tuberculoid leprosy patients with reactions and found an improvement in the 
reactional state within 7-21 days. Unfortunately they had no control group (Cappuro and 
Guillot 1948). Underhill et aL found that leprosy patients retained supplemental calcium 
whilst normal patients secreted it, although others have found that serum calcium levels 
were significantly lower in lepromatous leprosy patients than normal controls (Underhill 
et aL 1920) and (Nigan et aL 1979). There do not appear to be any animal studies looking 
directly at vitamin D in leprosy but rats fed on a calcium deficient diet had a greater rate 
of growth of M. lepramurium than controls rats (Badger et aL 1940).
6.2.4 RESULTS
The results of the studies of the Taq 1 polymorphism of the vitamin D receptor in 
leprosy cases and controls from Mali and from South India are shown in tables 6.20 to 
6.23. There was a minor excess of tt homozygotes and slightly fewer heterozygotes 
amongst the controls when compared with the cases in Mali. No significant difference in 
the distribution of the different genotypes was found between cases and controls, or
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Genotype Controls Cases MB PB Total
TT 86 (45.0%) 122 (46.0%) 81 (47.1%) 41 (44.1%) 208 (45.6%)
Tt 71 (37.2%) 104 (39.2%) 67 (39.0%) 37 (39.8%) 175 (38.4%)
tt 34 (17.8%) 39 (14.7%) 24 (14.0%) 15 (16.1%) 73 (16.0%)
Total 191 265 172 93 456
Table 6.20 Taq 1 VD R genotypes in MMÜibacillary (MB) and Pauàbaàüary (PB) cases and controls 
from Mali
(T = wild type allele and t = mutant allele of Taq 1 polymorphism of Vitamin D)
2x3 comparison of cases vs. controls %^=0.81 (2d^, p=0.667 
2x3 comparison of MB vs. PB X^=0.32 (2df), p=0.851 (2df)
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Genotype LL TT
TT 54 (44.3%) 22 (48.9%)
Tt 51 (41.8%) 18 (40.0%)
tt 17 (13.9%) 5 (11.1%)
Total 122 45
Tahk 6.21 Taq 1 VDKÿsnotypes in lepromaious (UL) and tuberculoid (TT) cases from Mali 
(T = wild type allele and t = mutant allele of Taq 1 polymorphism of Vitamin D)
2x3 comparison of LL vs. TT %^=0.38 (2df), p=0.827
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Genotype Type 1 
reaction
Type 2 
reaction
No reaction
11 22 (56.4%) 46 (44.7%) 54 (43.9%)
12 10 (25.6%) 41 (39.8%) 53 (43.1%)
22 7 (17.9%) 16 (15.5%) 16 (13.0%)
Total 39 103 123
(T wild type allele and t — mutant allele of Taq 1 polymorphism of Vitamin D)
2x3 comparison of Type 1 reactions vs. no reaction X^=3.81 (2d^, p=0.148 
2x3 comparison of Type 2 reactions vs. no reaction %=0.41 (2df), p=0.817 
2x3 comparison of controls vs. Type 1 and Type 2 reactions %=1.55 (2df), p=0.461
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Genotype “Virtual” 
Controls for 
TT patients
TT Cases Controls LL Cases
TT 76(41.3%) 89(48.4%) 30(39.5%) 43(46.7%)
Tt 87(47.3%) 78(42.4%) 34(44.7%) 35(38.0%)
tt 21(11.4%) 17(9.2%) 12(15.8%) 14(15.2%)
Total 184 184 76 92
Tabb6.23 Taq 1 VDRgenotypesfbr South Indian ijspro^ patients
Hapbtype 'Relative Risk Method used to derive “Virtual Controls” of Tuberculoid (TT) leprosy Cases 
(see section 1.8.1).
Standard Case - Control Method usedforljpromatous Lepro^ Cases (LL)
(T = wild type allele and t = mutant allele of Taq 1 polymorphism of Vitamin D)
2x3 comparison of TT Cases vs. Controls %^=1.94 (2df), p=0.380
2x3 comparison of LL Cases vs. Controls %^=0.97 (2df), p—0.616
2x3 con^arison of LL vs. TT Cases yf=2.21 (2df), p=0.322
2x3 comparison of Controls forTT cases vs. Controls for LL cases %^=0.93 (2d^,
p=0.628
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between the different forms or types of leprosy in the Malian subjects. The different 
types of leprosy reactions were studied. Numbers were relatively small, especially 
amongst the p e o p le  w ith  type 1 reaction s. H e n c e , a lth ou gh  there ap peared  to  b e  au  
excess of both TT and tt homozygotes amongst those experiencing type 1 reactions over 
both those experiencing type 2 reactions and those who did not experience a reaction, 
this finding was not significant It would be hard to find a biologically plausible 
explanation for this phenomenon.
A similar study was performed in the South Indian patients. Tuberculoid cases 
comprised of patients being used in the genome screen. Controls for these cases were 
derived from the parents using the haplotype relative risk method (see section 1.7.1). 
Lepromatous cases were made up of the ENL cases, the LL controls who had not gone 
on to develop ENL, and miscellaneous extras. Their controls were matched for caste. 
Amongst the tuberculoid cases there was a trend towards an excess of individuals 
posessing the TT genotype, but the findings were not significant These findings are in 
the reverse direction to those of Roy et aL In conclusion, no association was found 
between the Taql polymorphism of VDR and leprosy in either the South Indian or the 
Malian population.
62.5 DISCUSSION
At the same time that I performed his study, my colleague, Sushismita Roy 
performed an identical study on her leprosy cases and controls ftom Calcutta and found 
very different results. The tt genotype was over-represented in the tuberculoid leprosy 
cases (odds ratio 3.22 95%C.I. 1.47-7.13) and the TT genotype was over-represented
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amongst lepromatous leprosy cases (odds ratio 1.67 95%C.I. 1.02-2.75) compared to 
controls (Roy et al 1999).
I did not replicate the results found by Roy et al in either the S.Indian or the Malian 
patients. This may be due to either genetic or environmental differences between the two 
groups (e.g. differences in exposure to sunlight, dietary factors such as calcium intake), or 
may reflect the fact that the results in the Calcutta population were a chance occurrence. 
Alternatively, one of these findings may be spurious or there may be alternative genes 
that control susceptibility that are in linkage disequilibrium with this gene in one 
population, but not in the other. Because of the known functions of VDR, and the 
results found in both the Gambian tuberculosis patients, it would be interesting to 
investigate the In ntm function of macrophages of the different genotypes.
The present pattern of VDR genotypes, and consequent prevalence of osteoporosis 
may well reflect evolutionary processes. The newly discovered role of the VDR in 
susceptibility to various infectious diseases lends support to this theory.
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CHAPTER 7
CO N CLU D IN G  REMARKS
Unravelling the complex factors involved in determining susceptibility to leprosy 
per se, and to its different forms, is no simple task. In the past people have mainly 
concentrated on looking at the HLA genes, but evidence exists that these genes do not 
account for aU the differences in susc^tibihty between individuals (Risch 1987). With 
recent advances in the field of genetics, including the Human Genome Project and more 
sophisticated technology, the possibility of solving this seemingly Herculean problem is 
becoming a reality.
We have tackled the question with a two-pronged approach. We looked at some 
candidate genes with known polymorphisms that are potentially functional using a case- 
control methods. Although more powerful in detecting genes than genome screening, 
and thus useful for the detection of minor genes, this method relies on a degree of 
educated guess-work combined with luck as to which polymorphisms have been 
identified at the time of the study. If associations are identified and subsequently 
confirmed, our understanding of the mechanisms involved in determining susceptibility 
to infection may be increased leading to novel therapeutic approaches.
We found an association between leprosy type and an NRAMPl polymorphism, and 
a su^estion of an association between susceptibility to leprosy per se and a TNF 
promoter polymorphism. The NRAMPl result was found in a population ftom Mali but 
was not observed in South India. In view of very convincing findings in tuberculosis
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patients (Bellamy et al 1998), it would be worthwhile investigating the relationship of 
this polymorphism to leprosy in further populations. The TNF finding was a very 
borderline association with a polymorphism that has not yet been demonstrated to be 
functional Previous studies in a population of leprosy patients ftom Calcutta had not 
shown an association between this polymorphism and leprosy form (Roy et al 1997). 
TNF remains an interesting candidate gene especially as a determinant of leprosy 
reactions, and it may be that the — 238 polymorphism is in linkage, disequilibrium with 
another more important polymorphism
Based upon results of complex segregation analysis which su rest a major gene effect 
in susceptibility to leprosy (Abel and Demenais 1988), we decided to perform a genome- 
wide search for leprosy susceptibility lo d  This is the largest genome screen to be 
performed to date in an infectious disease. The potential advantage of this method is that 
new genes may be identified that might have been overlooked in a candidate gene 
approach. Simulation studies s u r e s t  that the power of a study of this size to detect a 
major gene is greater than 99% (Davies et al 1994).
Until just now we had no clear-cut evidence for a major gene effect in susceptibility 
to leprosy in South India. No marker stood out prominently after the first round screen, 
and even after the second screen there were no lod scores over 1.47 using either single or 
multi point analysis. However, D2S125 and DIOS 197 looked interesting and Ruby 
Siddiqui has just performed further genotyping on these two microsatelhtes using 
flanking markers. 100 families from Vishakapatnam were used in addition to the 188 
Tamil families and there was strong evidence for a genetic effect in the region of 
D10S197 when the results ftom all the families were pooled ^od score = 3.006 using
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Mapmaker Sibs™). Whether this constitutes a “major gene** effect is debatable, as the 
effect was only prominent once 288 families had been analysed. Interestingly enough, 
DIOS 197 only just scraped through into the second screen. These results are particularly 
exciting in view of the presence of the macrophage mannose receptor in the close 
vicinily of this microsatellite. Transmission disequilibrium studies are planned in the near 
future.
The possibility that there is no “major gene** in leprosy in this South Indian 
population may be explained in a number of ways. The original complex segregation 
analyses were performed in the Caribbean. None have been performed in Tndia^  and it 
may be that the two populations have different susceptibility genes. Population 
heterogeneity within the Tamils, possibly due to caste differences, is another explanation. 
It is possible that the original results in Desirade were wrong. Segregation analysis relies 
upon making a number of assumptions. The technique works well for simple Mendelian 
tiaits, but in the case of infectious diseases a particular problem arises in modelling for 
environmental transmission. The finding of a recessive gene for attendance at medical 
school provides a delightful example of the fact that a degree of scepticism should be 
exercised in the interpretation of segregation analyses (McGufEn and Huckle 1990).
The leprosy genome screen was originally designed to detect major genes for 
“leprosy per se**, but it turned out that the majority of our sibling pairs had tuberculoid 
leprosy. It may be that there are different genes that control susceptibility to lepromatous 
leprosy. In order to be rpftain that there are no major gene effects in different 
populations, studies are underway to examine a large cohort of patients from Malawi for 
leprosy susceptibility genes using an identical approach. It will be interesting to see
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whether the findings with DIOS 197 are repeatable, and whether it is possible to sub­
divide the sibling pairs for leprosy type.
No major gene has been mapped for any common infectious disease to date and it 
may be that evolution has simply selected a large number of minor genes. Several 
markers on chromosomes 2, 6, 7, 16 and 17 stood out as potential minor genes in 
different stages of the leprosy genome screen in Tamil Nadu. There was evidence of a 
minor effect at D6S273, which is in the MHC. This was most prominent on combining 
the results of the first and second screens. This was a smaller effect than might have been 
anticçated ftom the work of Risch et aL (Risch 1987). They calculated that the X« 
attributable to the MHC in tuberculoid leprosy in South India was 1.485 out of a total 
of 2.38. It is noteworthy that the results of association studies on the MHC have 
produced such a varied picture and it is likely that population heterogeneity contributes 
significantly towards this (Todd et al. 1990) and (Serjeantson 1983).
The X chromosome is another area that we thought might play a role in susceptibility 
to leprosy. It has long been noted that there are an excess number of men who contract 
the disease that does not seem to be attributable to ascertainment bias. This pattern is 
also seen in other infectious diseases and it was interesting that Bellamy et al found 
evidence of a genetic effect on the X chromosome in a genome screen of sputum 
positive tuberculosis cases from The Gambia and South Africa (R Bellamy - personal 
communication). Another interesting finding has been the excess of red-green colour­
blind individuals amongst leprosy patients, which could again point towards an X-linked 
gene being involved in leprosy susceptibility (Shwe 1992). There is a red-green colour­
blindness gene on Xq28, about 25cM terminal to the X marker identified by Bellamy et
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aL The lack of evidence for linkage to this region in our genome screen may be a result 
of uneven spread of the markers with a largish gap in the region of the colour - blindness 
gene on Xq28. We did identify a marker that was closer to this region, DXS1766, but 
found that the microsatellite was non-polymorphic in our population. It may be 
worthwhile keeping an eye out for other microsatelhtes in this region and performing 
further analyses in the future. If there were a major gene on the X chromosome one 
might have anticipated finding it on a genome screen of this size, but the power of 
studies on the X chromosome are lower than those on autosomes because full 
information can only be gleaned when there are sister-sister pairs.
Apart ftom potential candidate genes identified in the genome screen, there are 
numerous others that might be worth investigating for more minor effects. Although it’s 
unlikely that the gross defects seen in the IFNy receptor of the children studied by 
Newport et al are also involved in patients with leprosy, it may be that minor defects of 
this gene are involved (Newport et al 1996). The fact that IFNy has been clearly 
demonstrated to be essential for effective macrophage activity and granuloma formation 
raises the possibility that mutations within the gene might be involved in lepromatous 
leprosy where granuloma formation does not occur. Inducible nitric oxide synthase 
(ENOS) is another gene that would be worth investigating further because of the 
important role that nitric oxide plays in the control of mycobacterial infections. There are 
numerous cytokine genes that are involved in the complex interaction of the host 
response to infection, many of which may have polymorphisms and would be worth 
considering studying. New, less labour intensive, approaches to gene identification are on 
the horizon. Genome scanning by association should be possible. By present methods it
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would involve a lot of work, but has much greater power than linkage methods (Risch 
and Menkangas 1996). Sibling pairs are not required for this method, which makes 
collection of cases a great deal more straightforward.
In summary, by using two methods in a search for leprosy susceptibility genes, we 
have identified a region on chromosome 10 that looks very promising in terms of playing 
at least a moderate role in leprosy susceptibility in a South Indian population. Several 
other regions with potential minor genes have also been identified. The samples collected 
during my two visits to India provide a vast resource that ran be used for further studies 
on susceptibility to leprosy per se, leprosy type and form, and leprosy reactions. The 
samples from Mah and Calcutta provide us with the opportunity of seeing whether genes 
identified in South India are responsible for susceptibility to leprosy in other ethnic 
groups.
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A P P E N D I C E S
APPENDIX 1- BREAKDOWN OF WORKLOAD IN THIS THESIS
1) SAMPLES FROM TAMIL NADU
Collection of blood samples and DNA extraction: SJM and KB 
Database preparation & examination of rliniral notes: SJM 
Measurement of DNA concentrations: SJM 
Preparation of DNA plates for 1®* and 2^ round of genome screen: SJM 
Decision of which primers to include in sets 15-20: RS 
Genome Screen:
Set Optiinisfl-tions Large-scale
PCR
Gcl-loading Genotyping
1 S]M SIM SIM SIM
2 RS RS RS RS
3 SJM SIM SIM SIM
4 RS RS RS RS
5 SEF SEF/SIM SIM SIM
6 SEF SEF/SIM SEF/SIM SEF
7 SEF/SIM SEF/SIM SEF/SIM SEF/SIM
8 SEF SEF SIM SIM
9 SIM SJM SIM SIM
10 SIM SIM SIM SIM
U SEF SEF SEF SEF
12 RS RS RS RS
13 SIM/RS SIM/RS SIM/RS SIM/RS
14 SJM SIM SIM SIM
15 SIM SIM SIM SIM
16 RS RS RS RS
17 SIM SIM SIM SIM
18 RS RS RS RS
19 SIM SIM SIM SIM
20 SIM SIM SIM SIM
A RS RS SIM RS
B RS RS RS/SIM SIM
Global binning and sib-pair analysis was mainly done by chromosome rather than 
sets. SJM globally binned markers in sets 15, 17, 19, 20 and B, and markers in 
chromosomes 1, 3, 5 and 7 ^5 markets). RS binned the rem ^der of die markers w d
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pooled the results £com die first and second screens.
2) sam ples fr o m  v isha ka pa tn am
Collection of blood samples and DNA extraction: SG and team £tom Agra (minimal help 
from SJh^
Screening of key markers: RS and KY
3)CANDIDATE g e n e  w o r k  o n  INDIAN SAMPLES
a)IL4:SJM andSR
b) TNF: SJM (using some samples collected by RMP)
c) VDR: SJM
d) NRAMP: SJM
4)CANDIDATE GENE WORK ON MALI SAMPLES 
Collection of blood samples: SM and GW
Database preparation & examination of clinical notes: Sh^ GW & SS 
DNA extraction: SJM, GW and SM 
Candidate gene work:
a) VDR: GW and SJM
b) NRAMP: SJM
c) IL-10: SJM 
Abbreviations
GW= Giles Warner, KB = K. Balakrishnan, KY — Karen Young, RMP= Prof. R.M. 
Pitchappan, RS = Ruby Siddiqui, SEF= Simon Fisher, SG — Satish Ghei, SM= Stuart 
Mucklow, SJM= Sarah Meisner, SR= Suschismita Roy, SS= Samba Sow
II
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APPENDIX 2 - TABLE OF MICROSATELLITE PRIMERS USED
Table shows microsatellite name, primer sequences, fluorescent label and PCR 
conditions (see Table 2.6 for explanation of PCR conditions)
MaAcr Set Primer sequence (labelled) Primer sequence (unlabcllcd) Label ConditioDS
dls228 1,15 ACT GCA ACA TTG AAA TGG CA TAG TAT ITT ACA GGG ACC 
ATA G
HEX 53/2
dls470 6 AAA TGG GGC TAA TAA ATC 
TCCTGG
CTA CAC CAT AGG CAT AGG 
TGCAA
TET 53/2
dls255 1 TTA GCA AAT CCC AAG CAA TA GTG ATG GTG GTA AAG GCA 
GA
HEX 53/2
dlsl97 1 TCA TGT CCC TCC TCC CAA AG GAG CAA GCA TCC AAA AAC GA FAM 53/25
dls209 1 AAA CAT CAG TGT TCC ATC 
ATA GAC
AGC TTT GGG GGA CAT AAC 
AT
HEX 53/2
dlc216 1,17 ACC TTC CAO ACA CCC TAT TC TCA CAT AiVr CCT TCT AAT 
GTGCT
HEX 51XL/2
dls207 1 CAC TTC TCC TTG AAT CGC TT GCA AGT CCT GTT CCA AGT CT FAM 58/2
dls252 1,17 AGC TIT  TTA CTC TTA ACC TAT 
TCAT
GCA GAG AAC ATG TGT ATT 
AATGA
HEX 51/3
dlsl96 1,17 ACC AGC AGC CAA CAT ATG TTT ACA TTC TCA CAG ACT 
GTC A
HEX 49XL/2
dls238 1 GAT CTG CAT TCC AAG ACT 
CAT G
CAT GGA GGC AGT TTA GAT 
TGT G
FAM 53L/2
dls249 15 AAT AAC TCC CCC ATT ATT CAG 
G
AAT ATG GTT GTA GAT GAG 
ACT GGC
FAM 58/3
E^IO 17 GAA GTC CTG ATG TCA CTG CC CAG GAT TCC ATG GAG GCT 
GG
FAM 53/1
'dls229 1 GCT TGT TTC CAT TTA TGG TG ACT CTA GTT GTG TGT GAA 
TGT ATG
HEX 53/25
dlsl03 1 ACG AAC ATT CTA CAA GTT AC TTT CAG AGA AAC TGA CCT GT FAM 55/3
d2s291 14 TCC ATC TGT GTT TGT ATA 
TGT ATT A
CAT CGT CTT GCA TTA GAC AG FAM 55/2
d2sl31 14 CAA TTG TAC CCC ATT TAC 
TGC
GGG TCC AAG GAA CTC TCC HEX 58/3
d2sl65 2 GTA ATG CTG TCT CTG AAT 
CAG G
AGC TTC AAC NCC TTT GAG AT FAM 51/3
d28l77 2,16 CTTTTTTGAAGG GAAGTG G TTA CAG GTG TGA GCC ACC FAM 58/3
d2sl34 2 CGT CTG CTC GTC AGA GTC AGC TCT CCA CGT TTG CTT FAM 58/2
d2sl39 2 ATG TAC CCC ACC CTC AAC AAC AAG GTT TTC TAA AGT 
TTCC
FAM 58/3
H^la 17 GCC TAG TGA GTG TGG AAG 
ACA TIG
CAG CAC TGG TTG GTC TTC 
ATC TTG
FAM 55/3
d2sl60 2 TGT ACC TAA GCC CAC CCT 
TTA GAG C
TGG CCT CCA GAA ACC TCC AA FAM 53/3
d2sll4 2 TFT TTC ATG AAC TGG TAC 
ACT G
TAG TAC ATT AAC TTG GGT 
TCC A
HEX 58/1.5
d2sl42 2 GGA GAC ACT GAA CGG GTA 
GA
AGA TTA TCC TAG ATT ACC 
CAGGG
HEX 58/2
d2s326 2 CAC TTG CTT TTG GAA AAG G ACC AAG TCA TTG TGT GGA 
AG
HEX 51/25
d2sl52 2 CCA AAA ATG TCA TTA TTG 
TGA
CTC CTT AAG ANC TTG TTT TG FAM 45/25
dSsll 10 CAA ACT TTC CAC AGT ATC 
GTTC
GTT TCC TTG AGA AGA ATG 
GAGC
FAM 53/2
d2s72 2 AGC TAT AAT TGC ATC ATT 
GCA
TGG TCT ATA ACT GGT CTA TG HEX 53/25
d2sl57 2 CTG NTA CCC AAA ACT TGG C GCC TAN TTG ATC GTA GTG 
AATT
FAM 58/3
III
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Marker Set Primer sequence (labelled) Primer sequence (unkbcUcd) Label Conditions
NRAMP 19 TTC CGC ATT AGG GCA ACG 
AG
TIC TGT GCC TCC CAA GTT 
AGC
TET 55/2
d2sl471 16 Unavall^lc Unavailable FAM 48/3
d2sl26 2 AGC ACA GAG CCT ACT TAA 
TAGC
GTA GCA CAA TCT TAC TAT 
GCC A
HEX 58/2
d28l59 14 AGG GATTGG GGACTG G GCA GTT TGA GTT TAG GAT 
GA
FAM 53/3
d2s206 2 TTA AAA ATT AAG TAG GCT 
TTTGGTT
GTC CTC ATG TGT TTA TGC 
TGT
HEX 51/2
d2sl25 2 GGA GGA TCA CTT GAG CCT AGC GTT AGA TAC ATT TCA 
AAATG
HEX 53/2
d3sl297 3 TTT TTA AGA AGC CCT TCC 
TGG
GGA AAC ACC TAA TGG GCA 
AG
FAM 53/2
d3sl560 14 GCA TCT ACA GGG GGT GTC T AGG CTG ATT TTC AGC ACA A HEX 55XL/3
d3sl263 3 CTG TTG ACC CAT TGA TAC CC TAA AAT CAC AGC AGG GGT 
TC
HEX 58/2.5
d38l289 17 AAAGCAACTTGTAAGAGAGCA CTCCTAGATATAATCACTGGCA TET 51XL/2
d3sl300 3 AGC TCA CAT TCT AGT CAG CC GAT TGT GCT CAA ATG TCA CA HEX 53/2
d38l261 3,19 GAG GTG ATG TGA GAG TGG 
AT
CTC AGC ACC ACA GTA TGT GT HEX 55/3
d3sl271 3 AAG GTC CAA GAG TGT GGG 
G
GCA GAG AGA GGG AGG AAA 
CA
FAM 53/2
d3sl303 3 CAG ACA ATG GCT TCC AAA 
AGT A
CAA ACT TAG GGT TGTTCC 
TCAC
HEX 53/2
d3sl576 14 GCT TTG GAC GCA GGA AGA 
TA
AGA ACA AAA AGG GAA GAA 
CCC
HEX 58/2
d3*1279 3 CAC CAT CTG TGT GGT ATT 
GG
GAC CTA TTT TGG TTA ACA 
ATTTAGA
HEX 53/25
d3sl282 3 CTG AGA TTA AGT TTA TTG 
GGG
AAT ATA ATC ATG CTA TCT 
CCA A
FAM 53/2
d3sl262 3 CGG CCC TAG GAT ATT TTC AA CCA GTT TIT  ATG GAC GGG 
GT
FAM 53/2
d3*1314 14 GAC TCT GCT TCA GGG AAA 
ACC
CTT CCA GCC CTG AAA AAC AT HEX 58/2
d3sl265 3 TTC TAT AAG GGC AGG GAC 
AC
GCT CGC AAT TTC TCC TTA AT LIEX 53/25
d4s412 4 ACT ACC GCC AGG CAC T CTA AGA TAT GAA AAC CTA 
AGG GA
HEX 53/2
d4s403 4 CAC ACC CAG CAC ACA TCT TT CCT CTG AAA CAC TAG TAA 
TTCG
HEX 53/2
d4s418 4 TTG GAG GTG GGG TCT AAT G ATC ACA GAG TGA AGN AGG 
ATG
FAM 53/2
d4s405 4 ATC AGG AGA TGT TGC CTT 
GC
CAG GGC TAT GAT TGG ATG 
TC
HEX 55/3
d4s398 4 CAT GAA ATG CTG ACT GGG 
TA
TCA ATT TAT GTG CAG CCA AT HEX 53/2
d4s231 4,16 AGA TGA GTA TGT TAT TAT 
ACC
TGC TAG AGT TCC CTA GTG HEX 48/3
d4s250 4 TGG ACT TGA ACT AGT TCT 
CCAGC
AGG TTC TCC AGA GAA ACA 
AAACC
HEX 53/3
d4s4% 4 CTG GTT TTA AGG CAT GTG 
TG
TCC TCA CGG AGG TCT AAT 
CA
FAM 53/3
d4«430 4 TAA CCC TGT ATA TGT TAA 
TGTGC
TAA CCC TGT ATA TGT TAA 
TGTGC
FAM couldn't
optimise
d4sl565 14 TGC AAA CTG TCA CTC AAA AG GCC AAG GCT GAT CCT C HEX 58/3
d4«413 4.17 GAA TAT AGT GCT CCA GAA 
ACA
GCT ATG GAA TAA TAC CGA 
GA
FAM 55/2
d4s415 4 GGG CTA AGG CAA CTC C GGT TAG ATT AAC TGC AAA 
ACG
FAM 53/2
d4e408 4 CAT GAA AAT TTG AGG GGT 
CTG
TCC TCA GGG AGG TCT AAT 
CA
FAM 53/2
d4s426 4.16 ATA CAC TGC ATC CAT ATA 
TAC AAG G
ACA TTG TGA AAT GAC CAC 
AG
HEX 49/3
IV
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Marlfer | Sct | Ppmcr gcqucncc Qabdlcd) PriiMf sequence (unlabcllcd) label Conditions55/3
d5s432 15 GCT TAG TTA CCA CGA AGG 
T G A ____________________
GAC CAG ATT CCC AGT T FAM
dsS ïë T ü  I CTG GGG c m  T IT  GTC A AGT GAA ACT CGG NCC CTA HEX 53/253/2
d5s268 CAA TCA GGC CAT T IT  TAA 
c r r c A ____________________
AAG GTG AGG CAA AAT GAG 
TGT A ____________________
FAM
d5s419 ATC TTT TAT TGT GGG GTG 
C T _____________________
TGC CCA GAC TTC TCA CCT HEX 53/2
d5s426 GAT CAG GTT TCT GAA AAG 
TGG G ____________________
GTT CTC TIT  CCA TGG TGG 
ATG _______________
HEX 53/2
d5s407 5,15 GCC CCG TCT GCA ATA ACT
AG _______________
TGT TGT TCA TTG GAA GTC 
AAG A _______________
FAM 58/2
d5s428 AAC ATC TTA GGG CATCCTG AAT GAT TTA AAA TAG ATT AGG AGC A__________________
HEX 53/2
d5s409 GGG ATG AAG TGT GGA TAA
A C _________________
TAG GAT GGC AGT GCT CTT 
AG _________________
FAM 53/2
TTT ACA CCA GGT GGC CTC TC AGA CAT GAG CCA CTG GGC FAM 60/1.5
55/2
irfl I s  I GGC CTC AAC TTC ATA ATC AA GAG TGT ATC AGT CAG TCA GGG TGC____________________
FAM
Ü9 17 GGT GGT TGA CCT CAA ATT 
G G ______________________
AGG CTT TCT CTA ATG CAG 
A G _________________
TET 51L/2
d5s399 18 GAG TGGT ATC AGT CAG GGT 
G C ____________________
GGC CTC AAC TTC ATA ATC AA HEX 53/25
d5s210 CTT TAA CAT CCT TTA ACA GC ATG CAG AAT CTA CAA GGA 
CC _________________
FAM 55/2
d5s410 TGC TAG TTT ATC CCA CTG 
TGA A _________________
AAG GAG AAA ATC ATA TTT 
GGGC
FAM 53/1.5
d5s422 14 CCT TGC CTT TCT TCC TTT ATT
T _________________
GCT CTC ACT CAC TGA ACT 
CCA _________________
TET 58/3
d5s400 ATG ATC ATG CCA CTG CAC TC TCC TAA TTT GCT GGC TTC CCTGG___________________
FAM 60/1.5
d5s408 CAA CCA AGA CAA AGG AAT 
CAT G _________________
GAA CTC CTG GCC TCA AGT 
GA _________________
FAM 61L/2
D6s470 15 AAG CGA TCT CAC CAT ATA 
C A C _________________
ACA CTG CAA AAC GAT TAC CA TET 55/2
d6s260
d6s276
TTT TCA CTA TCA ATG GCA GC TTC ATT TTC AGC AGC AAT TT FAM
TCA ATC AAA TCA TCC CCA 
GAA G _______________
GGG TGC AAC TTG TTC CTC CT FAM
53L/2
53/2
GCA ACT TTT CTG TCA ATC CA ACC AAA CTT CAA ATT TTC GG HEX
HEX
53/2
53/2
tnfa CCG GCT GTC CAG GCT TGT 
C C ___________________
GAT GTG GCG TCT GAG GGT 
TGT TTT _______________
d6s291 CTC AGA GGA TGC CAT GTC 
TAA AAT A ____________
GGG GAT GAC GAA TTA TTC 
ACT AAC T _______________
HEX 53/2
CCC AGC ATC ACC CCT AAT AC TGC ATA TGT TGA ACC AAT CG HEX
TET
53/2
55/3
D6s268 15 CTA GGT GGC AGA GCA ACA T AAA AGG AGG CA TTT TAA 
TCG _______________
d6s262 ATT CTT ACT GCT GGA AAA 
CCAT _________________
GGA GCA TAG TTA CCC TTA 
A A A T C _______________
HEX 53/2
d6s308 CCT TGG AGA GAA TTC ACG 
TAC A _______________
TCT GCT GAG GGC CTA GTT 
TC _________________
FAM 53/2
d6s314 ATG ACT TCT TTG GGT GGGC GTG GGT AGC AAC ACT GTG 
GC _____________ _____
FAM 53/2
D6S279.3 6.19 AGC TTC AAG TGT AGG GCA 
A G _________________
GAC ATT ATT GGG TCA GCT 
GA _________________
TÈT 5 3 /2
6,19 ATT AGG CTG CAG CAA AGG 
A A ____________
TAC ATT GTC GGT CTG GTC 
CA ___________________
FAM 58/2
GTT TGC TGG ATG AGT GG GAT TTG GTG AAT GCT CTG HEX
FAM
53/2
53/2TGT TAT GTT TCG CCC TCC TC GGA AGA GCA AGC AGC ACA C
d6s264 6.17 AGC TGA CTT TAT GCT GT 
C C T _____________________
TTT TCC ATG CCC TTC TAT CA FAM r 51XL/2
d6s281 CAT CCC TGC AAT ATC AAA AA GTT TCA GGC AAA GGC CAT 
A C ____________
FAM
~WX
53/2
58/2
d7s531 AAA CTG TGG TCC TGG CTG AAA CTA GAG TCC TGG CCT 
GA ________________
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Marker Set Primer sequence (labelled) Primer sequence (unkbeDed) Label Conditions
d7s513 7 ATG CAT TGC TAC AAC TAG 
CCA
GGG AGC AGG AAA GAT AGA 
CAG
HEX 56/1.5
d7s493 7,16 CCA GCC ATA GTT AAC TGC 
ACG
AGG AGA TGT ACT GTG GAA 
AGC A
HE 58/2
d7s629 7 AGA AGT AAA TCC TCA GTT 
CTCCA
CAA GGA TTT CTG TGG GAA 
AG
FAM 54/25
d7s484 7 TGC GTT TGA TCG AAG CAG A GCT GAG CAA GGC ATT GTTT FAM 56/16
d78519 7 ACA GCC AAG CAT TTC TGC TG ACA GAC CAG GAC TCA GCC 
AG
FAM 61/1.5
d7s502 7 GGA AGG TAT GTT GCG G TAA GCC ACC AAG AAC ACC HEX 57/2
d7s669 7 ATG CAA. CCT ACC CTC AAA TG TTT GAA TTT ACA GAA AAA 
ATG TGC
HEX 56/3
d7s524 7 AAG TAA TGC AAA ACA GCC 
TTG A
ACC CAC TGA AAA GAT TTG 
TGTC
FAM 56/25
d7s527 7.16 CTC CGC ATT GCA AAC TCA CAT TTG AGG ATG CGC AAG HEX 48/3
d7s486 7 AAA GGC CAA TGG TAT ATC 
CC
GCC CAG GTG ATT GAT AGT 
GC
FAM 56/1
cftr 7,16 CTG AGC GAC AGC AAA ATC 
AG
CTG TAG CTT TGC ATT AAA 
GCC A
FAM 55/3
d7s530 7 TGC ATT TTA GTG GAG CAC 
AG
CAG GCA TTG GGA ACT TTG HEX 57/2
d7s684 7,16 CAG TGA GCC GAC ATT GTG TAA TTA AGA GTA AAT GAG 
GCTGG
HEX 61/3
d7s483 13 CTG ACC ATN CTG GCA TAT 
GT
TTT TCA AAA ATT GGC AAA GA FAM 53/3
d7s550 7,15 GCT ACG TCA ACT GAA AAG 
CA
ATT TGC TGC ACC AGT CAG TA FAM 58/3
d8s504 8 GGC CAT ATG GGA ACT GTN T AAG ACT CAG GTG GTT GAG 
TG
FAM 58/2
d8s503 14 TGT CTC TAA TGG TTC TTT 
GACCA
TCC CTT ACA CAT CGC TCA GA TET 58/25
d8s552 8 AAN GGA GAA AGG ATT GTA A TCT CAG TGG GAA GGA AAA A HEX 53L/2
d8s261 8 GGG AAG GTT TCA CAA AAA 
TTG
TTA TGG CCC AGC AAT GTG 
TA
FAM 53/2
d8s258 8.19 CTG CCA CCA ATC AAC TCA C TTG ACA GGG ACC C \C  G HEX 53/3
d8s283 8 ATT CAT GTC TAG GCC ATT GC AGA TAC AGA TGT AGA TCT 
CTCCG
HEX 53/2
d8s285 8 CTT ATA TGA CCT AGG CAT 
CAC A
CTG TTT TCC CTC CAA ACT CT HEX 53/2
d8s260 8 AGG CTT GCC AGA TAA GGT 
TG
GCT GAA GGC TGT TCT ATG 
GA
FAM 53/2
d8s286 8 AGC TGT TTA T Tf GCC CAT G TGC TCA GTA AAT GTT TGT 
GAA
HEX 53/2
d8s273 8 AGT CCT TTA AAC AAC AAA 
ATC
AGG AAA ATG TAA ATT GCC 
AG
FAM 53L/2
d8s88 8 TCC AGC AGA GAA AGG GTT 
AT
GGC AAA GAG AAC TCA TCA 
GA
FAM 53L/2
d8»257 8 AAA GCC AGT GTT CTC TAA 
GG
CAA GCC TCT CCC TAA CAC CA FAM 55/2
d8s556 8,19 TCT TCC ATA CAC ATG NAC G TGC GTA GGA GTT AGA TAC 
ACT G
HEX 53L/3
d8s281 8 AGT ATT TTG TGC TGG GTG 
TGC
GGA GCG CAA TGG CAT AAT 
TA
FAM 53/1.5
d8sl98 8 AAC CAG ATT AGG GAC AAA 
GA
TAG GGA CTA CAC ATG ATG 
GA
FAM 53/2
d8s284 8 TCT CTG TGC CTC CAT TTC CT AGG GTT TAG GCC ACA TAG 
CA
HEX 53/2
d8s272 8 GCA CAC ACT CTT ACA CAC 
AAC G
TGG AAA ATA TGT GTT TTT' 
GTG G
HEX 53/2
d9tl44 9 AAA TAT TAT AGC AAG TTA 
ATT ACT GAA
GGA TAA ATA CAC TGG AAA 
AGA GAT
HEX 50L/2
d9»156 9 AAT CTC ACC TCC TCC ACG G ATG GTG GTG AAT AGA GGG 
AAG
HEX 53/2
VI
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Marker Sct Primer sequence (labelled) Primer sequence (unlabcllcd) Label Conditions
IFNa 16 Unavailable Unavailable TET 65/3
d9»171 2 AGC TAA GTG AAC CTC ATC 
TCTGTCT
ACC CTA GCA CTG ATG GTA 
TAG TCT
TET 58/25
d9sl47c 2 CTC CCT GCA CCC TTC CAT AA AGT GTT CAC CCT AAT AAG 
CC
TET 58/2
d9s43 9,16 ATC AAG GAT ATT GTC CTG 
AGG A
GCT CAT TCT ATG AGG CCA 
GC
HEX 58/3
d9sl5 9 TAA AGA TTG GGA GTC AAG 
TA
TTC ACT TGA TGG TGG TAA 
TC
HEX 53/2
d9al75 2 CCA GAG TTG AAA GAT GTT 
CTGA
GGC TTG TAG ACA GAG ACC 
CG
TET 58/2
d9«257 15 ACA GGT AAA TAC ATT CTA 
CCC TAC A
GTT TGA AGT GCT CTC CAG 
TG
FAM 55/2
d9sl76 9,16 TTT CTC TTC CCC CAC ATC AC GCT GCA TAA AAA GGG CAC 
AT
HEX 53/3
d9sl54 15 GGG GAA AAA CAA TGG TGT 
TG
ATG TGA ATA TCN ACC ACG 
GG
TET 55/2
d9sll8 9,15 TTG CTC CTC AAA GCC CGC A GTG GCC TAG GAT TGT GGG 
Â
HEX 58/3
d9sl59 2 CTT TCT GAC GGC AGC CAG 
GT
AGC TGG AAT GAG TGC TGG 
GC
TET 58/2
d9sl58 2 TCT CAA GCG ACA ACA ATC AC GAT TTG GCT AAA ATA GGC 
TCA
TET 58/2
dl0sl89 3 CAA AAG TAA CCA TTG AGC 
CC
TTG ATA GAA GAA GCG ATA 
GATCG
TET 53/2
dl08l91 2.19 CTT TAA TTG CCC TGT CTT C TTA ATT CGA CCA CTT CCC TET 53/2
dl0*197 3 ACC ACT GCA CTT CAG GTG 
AC
GTG ATA CTG TCC TCA GGT 
CTCC
TET 53/2
dl0s220 3 TGT TGA CTG GAA GCC TTA 
CT
GCA AGA CTG CAT CTC AAA 
AT
TET 53/25
dl0s537 14 CTA CTG TGC CTG GCT AGA 
AAAT
TAT GAT TAT GAG AGA GAC 
TTA CCT G
FAM 53/25
dl0s201 3 AGC TCA TGG GAT GGA AGC 
AT
AGC TAA AAG GCT GCT GGA 
GA
TET 53/25
dl0sl92 3 GAA ACA AGG CTT ACC TAG 
ACC
TGT ATT TTA TGT GTG GCC
TG
TET 53/25
dl0sl90 3,19 GTG TTT GGG TCA TGG AGA 
TG
AGG CAA AGC AGG AGC A TET 61/1.5
dl0s217 3,17 TTT GAA ACT ATT CAG TGC 
CACC
GCT CAC TGA ATG CAG GCA 
G
TET 51XL/1
dl0s212 10 GAA GTA AAG CAA GTT CTA 
TCC ACG
TCT GTG TAC GTT GAA AAT 
CCC
TET 53/2
dlls922 9,17 TCT TTG GCT ACA CTG GG TCC AGC CAG ATG CTN AGA GGG 
T
FAM 51XL/1
TH2 16 CAG CTG CCC TAG TCA GCA C GCT TCC GAG TGC AGG TCA 
CA
FAM 51/3
dlls569.
2
8,17 GTG TAT TAG TCA GGG TTC TGT CAG CCT CCA TAA TTC TET 53/3
dlls899 9 CAG GAG GCA GAC ACA AGG 
AC
GAA TTG GAT TCT CTG GGG 
AG
FAM 53/1
dlls904 9 ATG ACA AGC AAT CCT TGA 
CC
CTG TGT TAT ATC CCT AAA 
CTC CTC A
FAM 58/2
dlls907 9 GCT TAT TGT CCA TAC CCA AA AAA GNA CCT TAA TTT CAG 
GC
FAM 58/2
dlls903 1,19 AAC ACT TCG ATG TTC CTT CC AGC TGA GAG CGC ATG TAT 
AA
TET 53/2
INT2 9 CTA AAG GTG CAT TTC AGT 
TCCC
ACA CAG CTT CCA GAG GGA 
GA
FAM 53/2
dlls916 1 GCT AGC CAA CGC CAT AGA 
TC
ATT TTG GGA CTT CTA AGC 
CTCC
TET 53/2
dlls901 9 ATT ACT GGC CTC TTT CTT 
CTGG
TGA GTG CAT TCA ACT TTG 
AAG G
FAM 58/2
dlls35 1 GAG ACT GGG GAC AGA AGT 
G
TTG TAT CGA TTA ACC AAC 
TTC
TET 53/2
VII
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Marker
dlls927
Set
1
Primer sequence (labelled) _ 
CCC ATA ATC CCA GTT ACT 
CAG G
primer sequence (unlabcllcd)
CTT GAA ACC AAA AGC CTG 
GA
Label
TET
Conditions
57/2
dl 18925 9 AAT TCT GTC CAG ACC ACC CA TTA GAC CAT TAT GGG GGC 
AA
FAM 53/2
dllB934 1 CCA GTC ACT CTG GGG TTG 
TA
AGG AAC CAC CGA GAA CAC 
AG
TET 53/2
dll«910 1 AGC TTT GCA GAC AAG GCA 
AG
TCC CTG CTC ATA AGT CAG 
CC
TET 58/2
dlls968 9 GGC TCT TGT AGT TTC TTA 
TCT CCT
AAG GCG GAT GCT GGA C FAM 53/2
dl2s99
dl2s77
10
10
TAG GGC AGA AGT GCC TGG 
GAA GGG CAA CAA CAG TGA A
ACA TGA ACT TCT CAG AGC 
CAC A
ACA TAC TTT TTT TTC TCC CC 
n r  A r \ n  ATfî AfîA TCC CGT
HEX
FAM
FAM
58XL/3
53/2
53/2dl2s358
dl2s364
dl2s62
3
10
10
UCC TTi GGG AAA Cl 1 ICC 
CCA GTC CTG AAC AGG C 
ATC TTG AAG CCC TGT GCA 
AG
CAA ATC CCC TGG AAG TC 
CAG AGA TTT CTT AAA TGC 
CT
FAM
HEX
53/2
58/3
dl2s87 10 CTC CAG GCA TCA CAG GCT AGC TCC TGG ACC TCC TCA 
Cl
HEX 53/2
dl2s368 3 GCA ACA CCT TTG TGA TGA 
AAAT
AGT CTG CAC AGC CTG TCC FAM 58/1.5
dl2s83 10 TTT TTG GAA GTC TAT CAA 
TTTGA
TAG CAG AGA AAG CCA ATT 
CA
HEX 53L/3
dl2s43 10 AAT GTC CTT GTA CTT AGG AT CAC TTA ATA TCT CAA TGT 
ATAC
FAM 53L/3
dl2s92 10,19 TCC CAG TTT CCA TCA TTG TAT AGT GTA TTG GTC AGG 
ATTCC
HEX 58XL/2
dl2s95 10 AAG GTG CAA TGG GCT A CAA CTG TGT GTG TIT  ATA 
TGT G
HEX 53/3
sl2s338 14 CTG TTG GCT GGA GAC ATC 
AG
AAA TTC AGC AGG CAA AAT 
GG
TET 58/3
ifhg 20 TCTVTAC AAC ACA AAA TCA 
AA
GCC TTC CTG TAG GGT ATT 
AT
HEX 53/3
dl2s366 10 GCT ACG ATC TTG CCA CTG AAA ACC CAA ACA TTT CTC 
AG
FAM 53/2
dl2s342 10 CGC TCT CAC AGT TCT GGA 
GG
GCC AAG GCA GAG TTT TGG 
AC
FAM 53/2
dl2s97 10 GCT CGA ACT CCT CAG TGA 
AG
AGA CTC CTC ATC GTG GAA 
AA
HEX 53/2
dl3sl92 4 GGG TAA CAT AGC AAG ACC 
CC
GTC CGG CCT CTG TCG TGT TET 58/1.5
dl3sl20 4 TGA CCT AGA AAT GAT ACT 
GGCA
TAA GGA GGA GGG ATT TAA 
ACCT
TET 58/2
dl3sl53 4 AGC ATT GTT TCA TGT TGG 
TG
CAG CAG TGA AGG TCT AAG 
CC
TET 58/3
dl3s279 14 CGG AGG GTT CTT GTA GCA 
AG
GGG CCT TGT CAA CCT TCA 
TA
TET 58/1.5
dl3sl70 4 TTG CAC TGT GGA GAT AAA 
CAC A
TAG AAC TGG CTT TTC TTC 
CCC
TET 53/2
dl3sl22 4 TTG CAA TGA AGA ACA CAA 
TA
TGA ACC TAG ACT GGA ATA 
AAT
TET 53/3
dl3sl58 4 AGC TTT GAA ATG CCT AGG 
TA
GCT TTG ACA ATT TAG CAG 
CA
TET 53/2
dl3s285 15 ATA TAT GCA CAT CCA TCC 
ATGC
AGA TAT TGA GGA AAG GCC 
AAA
HEX 58/3
dl4«72 10 TCC TAA CAT TCT GCT ACC CA TGT AAA GTT TTG TAC ATG GTG TAA T
TET 53/3
dl4«50 10,19 AAC ACC CCT AAT TCA CCA CT ATG ATT CCA CAA GAT GGC 
AG
TET 53/1
dl4«80 10.20 CAT CTA CCT GCC GCA A TAG CCA ATT TAT GGA TAC AACTT
TET 53XL/3
dl4s49 11 CAC TTT GTG CAG CTT AAA GA CTT CAC TAG CTT TTT AAA 
GAC A
FAM 53/3
VIII
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Marker Set Primer sequence (labelled) Primer sequence (unlabellcd) Label Conditions
dl4«70 10 ATC AAT TTG CTA GTT TGG CA AGC TAA TGA CTT AGA CAC 
GTT GTA G
TET 53/2
dl4375 11 TAC CCA CAT ATC CCA CAC 
TG
TTT TAA CAC CCA ACT CCC FAM 53/2
dl4«63 3 TGA CAA TCG GAA AGT GTA 
CA
CCA CAC TGT ATG CAT AGG 
G
FAM 53/25
dl4«74 11 CCT GTA CCA CTA CCT GAG 
TTG AGT
CTT TGG CTG CCC GAA A FAM 53/2
dl4c68 10 AAG AAA TTG GAC TAA TAT 
TGT G
AGC TTT GGA AAT AAG ACC 
AG
TET 53/3
dl4«51 11 GCC TGA TTT TGA GAT TCC TA CCA CCA CCT CCT TAT ACA 
CA
FAM 53/2
dl4g267 11 TTA ATG CCC ACT GAA TGC T AAG GCA GCC CTG GTTT FAM 55/2
dl5sl28 6 GCT GTG TGT AAG TGT GTT 
TTA TAT C
GCA AGC CAG TGG AGA G TET 58/3
dl5sll8 7 GCT TCT AGC ACC ATG CTG G TCC CCA ATA AAG AAG ACT 
GGG
TET 58/2
dl5sll7 7,16 AAT TCC CAG TTT GAG GAC 
TGA
CCC AAT GCA GCC CCT AAG TET 49/2
dl5sl25 14 CTG TAG CAC CCC TGT GAG 
GT
TGA AGA CCG TGA TNC ACG FAM 53/2
dl5sll4 6.17 CCA TGC TTG CGT GCA CTC TGA CAG TGG ACA TTT CTC 
TG
TET 58/2
dl5sl27 6.16 CCA ACC ACA CTG GGA A AAC AGT TGC CCA CGG T TET 53/2
dl5s207 14 ACT TCC TCA ATT CCC AAG AA TTT TGA ACT GAG AAT GGA 
GC
TET 53/2
dl6s423 11 TAC AAA ACA GGC TTG AAA 
GTC TCT
TTT GCC TGC CTA TTT GAT 
AATGC
HEX 51/25
dl6s407 5 GTG CGG CTG AAG AAT CAA 
TT
AAG GAA GCA TGT GGG AAA 
TG
HEX 53L/1.5
dl6s405 12,20 CGT GGC CAG TTC TCT GCT TGA AGG CAT TAC CCC ATT 
TC
FAM 53/25
dl6s287 11 CAC CTC CAT TTT AGC ACT 
ATT TGG
GAG CCA AGT CCT TAT AGT 
GGA TAC
HEX 53/2
dl6s420 12 GGT CTA AAG CAC CCA ACA 
TIA T
TTG GAA GAC CCA TTC TTC 
TU
FAM 58/1.5
dl6s261 12 AAG CTT GTA TCT TTC TCA GG ATC TAC CTT GGC TGT CAT 
TG
FAM 53/3
dl6s411 12 GCT CTC ATC TCC AAA GGA 
GTT
CCT GTG TTG GTG CAT GTG 
TT
FAM 58/2
dl6s415 11 TTA AAA AGA GAA CCA TAG 
GGTAA
CTG AGA AGG GAA GAT TAC 
TTGA
HEX 53/2
dl6s320 12 AGT CTG AGA GAC ATC CAG 
GT
GTG ATA TCA GTC AGT CCT 
GTG
FAM 55/2
dl6s503 11 AGT GCT CTG GAA TGA TGT 
GGA AG
TAA CTG GTA AAC AAG GTG 
AAATTTG
HEX 53/2
dl6s265 11 CCA GAC ATG GCA GTC TCT A AGT CCT CTG TGC ACT TTG T HEX 51/3
dl6a515 12 GCA TCC GGG TCT ATA CAC AT GTG TCT TTA ACC TGA AAC 
ACACA
FAM 58/3
dl6s516 12 CCT CCA GAA ACC GTG AGA 
TA
CTG TNT CTT TGA AGT TTT 
ATG ACC
FAM 55/3
dl6s289 11 CAC 0 \C  TTA TCA TTT CTT CC AGT TGG AGG AAG AGA AGC 
AG
HEX 53/3
dl6s422 12 CCA GTG TAA CCT GGG GGC ACT TTC GAT TAG TTT AGC 
AGA ATG AG
FAM 53/2
dl7s513 5 TTC ACT TGT GGG CTG CTG 
TC
TAA GAA AGG CTC CCA CAA 
GCA
TET 59/1.5
dl7s786 5,20 TGA AAG TGA CAT GTT TTC CA TTG GGC TCT TTT GTA AAG 
AA
TET 51XL/3
dl7s799 12 ATT GCC AGC CGT CAG TT GAC CAG CAT ATC ATT ATA 
UAL AAU L
HEX 53/2
inos 20 TGG TGC ATG CCT GTA GTC C GAG GCC TCT GAG ATG TTG 
GTC
FAM 55XL/2
IX
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Maikci Set Pâmer sequence (labelled) Primer sequence (unkbcllcd) Label Condidons
dl7s798 12 CTG CTA CCC TCC CTC AAT 
ACA
TAA CCA TGG GAC AGA TTC 
TGTT
HEX 55/1
dl78250 5 GGA AGA ATC AAA TAG ACA 
AT
GCT GGC CAT ATA TAT ATT 
TAA ACC
TET 53L/2
dl7s934 12 AAG CAT GCA TAC ACA CAC AT ACT CCT GTT TCC TAT CTG 
AGG
HEX 53/25
hox2b 5 ACT TCG GGA GTA AAA TTC 
TT
TGG GAG TGA TCA CTC AGT 
AC
TET 53/3
dl7s787 5 TCC TTA GTC CCC e r r  GGT G GAT TGA TAC CTT TFT GAA 
GGGG
TET 53/2
dl7s807 12 TCC ACC TGT AGA CCT GGT 
AAA
AGT GCT GCG TCT TAC AAC 
CT
HEX 53/2
dl7s789 12 ACT CCA AAT CAA GTT TGT 
ACT GAG A
CTG CAT ACG AAG GGT AGG 
AC
HEX 58/2
dl7s939 5 AGC TAT AAG TAA CCA TGT 
TTNTGG
ATT TGT GTT ACA GTT TAC 
TCGTG
TET 53/2
dl7s784 5 GAG TCT CCT AAA TGC TGG 
GG
AGC TCC TGC ACA GTT CTT 
AAA TA
TET 53L/2
dl8s59 12 AGC TTC TAT CCA ACA GGG 
GC
CTA CCA GAA TGT GAA CGA 
CCC
TET 58/1.5
dl8s52 11 TFN CAA CAT AGG TTA TAC 
GCG
CCG GCC CAG TTC ATT TTC 
TA
TET 53/2
dl8s62 12 GTG TTC TGT TAG ATT CTT 
TTGC
TGT GAA GGG TIG  AGA ACA 
GA
TET 53/2
dl8s53 12 AGG TCA CCT ACA ACT TFG 
GA
TTA CTG AAT AGC TAT CTG 
CAT G
TET 53/3
dl8s71 1 2 ^ ACC CGC TCA AAA GCC T TTA ATG GAT TAT CAA GAG 
TGGTTCT
TET 55/1
dl8s57 12 TTC AGG GTC T IT  TGA AGA 
GG
AGA AGG CAT TAA ATT TIG  
CA
TET 53/2
dl8s470 15 AGC TTA CCA CAA GGC ATA 
ACT
AGG GTA GAC TGT TAA CTG 
CNTTAGA
HEX 55/2
dl8s64 12 AAT GAA AAG TTC TGG AAA 
TGGA
TIT TGA AAG CAT TIT  GGA 
TGC
TET 53/25
dl8s61 12J0 AAC CAA CAT AAT ATA GCA 
ATGG
TTC GAA CTT CGA ACC ACC C TET 58/3
dl9s221 9,16 GCA AGA CTC TGA CTC AAC 
AAAA
CAT AGA GAT CAA TGG CAT 
GAA A
TET 53/2
dl9s49 9 ACT CAT GAA GGT GAC AGT 
TC
GTG TIG  T IG  ACC TAT TGC 
AT
TET 53/2
dl9s225 9,18 ATG TAT GTT TGG TGT CCC C GTA CAG TCG TGT GTG TGT 
GG
TET 53/1
dl9s220 9 ATG TTC AGA AAG GCC ATG 
TCA TIT
TCC CTA ACG GAT ACA CAG 
CAA CAC
TET 53/2
dl9sl80 14 CTA AAT ATC CAT CAA GGA 
ATG
TAC TCC ATT TTC ATT CAG 
GT
TET 53/2
dl98210 9.17 TCA CAC TCA CTG GTC TCT 
CAC A
AGG CTC CGT GAG AGG GTG TET 49/2
d20sl86 13 AAC TTA GGC GTA CAG CAG 
CC
AAG TCA GAG ACA GGA AGC 
GG
FAM 57/3
d20sll2 7 ATG GGT GTG CCA AAT CTC TTC TTG TAA GTC AGA CAG 
CATCA
TET 57/lA
d20s200 7 AAC ACA GTC AAA GGC TGG AGC TAC CTG GGC TCA AAT TET 55/2
d20sl06 13 TGA AAA CCC TCC ACC TGA AC ACT GAG GTC ATG CAA GAG 
GC
FAM 58/25
d20sl07 11 CTA CAT GAT GCC TCT TGG 
GA
TCA GAC AAT GGC AAA TTC 
CT
FAM 53/2
d20sl20 13 TIT  TAC TAA GGA GAC TCA 
ACA GGG
TIG  CAC AAT GCC TGG AA FAM 52/25
d20sl71 7 TAT AGG TGA GGA CCC TGA
GG
ACA CCA AGC CAT GTA ACC
TO
TET 57/1.5
d20s93 6 TTC CTG ATC AGT CAC CAT 
GTA
CAG CCT GGG TGA CAG AGA 
A -
TET 53/2
T h e  G e n e t i c s  o f  Su s c e p t ib il it y  t o  L e p r o s y
Maikci
d21s258
Set
11
Primcf sequence QabclkxD___________
AGG CAT CTC CAA GAT TIC 
TAG G
Pnmcr sequence (unkbellcd)
CCA CGG GAC AGT GTT CAC 
TA
o o r i  tTC TGT GAA TAT GGG
Label
TET
TET
Conditions
55/2
53/2
j21»265
d21s219
11
11
11A AAG CAA 1CA A 1C A lC  C 
CAA AAG AAA TGG CAA ACA 
TCT G
TGC CTC TTG ACT TIT TGG 
CT
TET
TET
55/2
53/15
d21s65
d21sl67
3
11,16
iTA AAG CAA TCA ATC ATG G 
TTC CAT GTA CTC TGC ATT 
CAC A
ACA TGC CTT GCC CTG AAG TET 53/1.5
d21s270 11 GAA ATG TIT TAA TAA ATG 
GTG GTT A
ACA AAG TTA TGG TCA AGG 
GG
TET 53/2
d21s268 13 CTA CCC GGG AGG CTG AAG CTA CAC TGT T’lT  CCA AAT 
TGGC
TET 56/15
d2l8l259 16 GGG ACT GTA ATA AAT ATT 
CTG TTGC
CAC TGG CTC TCC TGA CC TET 58/3
(1228264 8 ATT AAC TCA TAA AGG AGC CC CAC CCC ACC AGA GGT ATT 
CC
TET 53/2
(1228156 8 AGC CTG GGA GTC AGA GTG A AGC TCC AAA TCC AAA GAC 
GT
TET 55/1
cyp2d 8 CCC CAC T IT  TTA CTA CAC 
AGGC
TGA GGC AGT CAG ATG ACC 
TG
TET 53/2
(1228274 8 GGA GGA CTG CTT GAG TCC 
AG
GCT TGC TAA ATC GCT CTC 
TAA A
TET 53/2
dx8996 13,15 AAA TTC TTG CTT AGG CCA 
CTC TAG G
ACG TTG TTC TGG ATC GTA 
TGC TAG G
HEX 58/2
dx8999 13 GCT AAC AAC CTA GAC TTC 
AACC
CAG IT T  CAC AAT CTC TGC C HEX 51/15
dz8451 13,15 CTT GAT CTT CTG AGG AGT 
GG
TTA TTC CTA GGC TTA GGA 
TTC
A AT AfiT fîTT TTC CTA AGG G
HEX
TET
58/3
49/3
dmd
dxs538
13.16
13,15
TAG Cl A AAA TGT ATG AGT A 
CTG ATT CAC TGT ACA ATG GT ATG GAT AAT AAA CAG ACA 
GGA
TET 55/2
(1x81068 13 CCT CTA AAG CAT AGG GTC 
CA
CCC ATC TGA GAA CAC GCT G TET 53/3
dxs993 13,15 AAG GAC ATT ATT TGG GTT 
TG
TTC ACT GGG GCC TCC TCT 
TC
HEX 55/2
maob 13,15 CTT CAC AGC CTC TCT CCC AG CTT CCT ATT TCT CTC TCI 
GTC
TET 58/3
(1x8991 11 CAC TTC AAC CAC AGA AGC CT ATC ATT TGA GCC AAT TCT 
CC
TET 53/2
ÂR2 19 ACA GCC GAA GAA GGC CAG 
TTG TAT
CAG GTG CGG TGA AGT CGC 
ITT CCT
FAM 51/3
dx8990 13 ATA TGA CCA GTA CAA ACA 
TAC ACA CA
ATT CTG GAT GAT TCA CTC 
ATGC
TET 55/15
dx8l047 6 CCGGCTACAAGTGATGTCTA CCTAGGTAACATAGTGAGACC
TTG
HEX 53/2
dx8984 13 ATT TAA TGG CAG CGT ACA 
TGC
GGC CCC ITT ACA CCA AGC HEX 57/15
dxs998 13,15 CAG CAA TIT  TTC AAA GGC AA TGT AAG AAA AAT CTT TTG 
TAG G
TET 55/3
XI
T h e  G e n e t i c s  o f  Su s c e p t ib il it y  t o  L e p r o s y
APPENDIX 3 -  TABLES SHOWING 1ST ROUND GENOME SCREEN RESULTS
Tables shoxdng the results £com the 1st round of the genome screen from Tamil 
Nadu are summarised in the tables on the following pages.
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